false	These agents, including norfloxacin, ciprofloxacin, ofloxacin,  <e1> enoxacin </e1> , and  <e2> lomefloxacin </e2> , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 
false	The  <e1> fluoroquinolones </e1>  are a rapidly growing class of  <e2> antibiotics </e2>  with a broad spectrum of activity against gram-negative and some gram-positive aerobic bacteria. 
false	These agents, including norfloxacin, ciprofloxacin,  <e1> ofloxacin </e1> , enoxacin, and  <e2> lomefloxacin </e2> , have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 
false	These agents, including norfloxacin,  <e1> ciprofloxacin </e1> ,  <e2> ofloxacin </e2> , enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 
false	These agents, including  <e1> norfloxacin </e1> ,  <e2> ciprofloxacin </e2> , ofloxacin, enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 
false	Advantages offered by this class of  <e1> antibiotics </e1>  include optimal pharmacokinetics, effectiveness against multidrug-resistant organisms, and oral administration even when parenteral  <e2> antibiotics </e2>  are generally used. 
false	These agents, including  <e1> norfloxacin </e1> , ciprofloxacin,  <e2> ofloxacin </e2> , enoxacin, and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 
false	In order to provide information for the appropriate package insert labeling of  <e1> progestin-only oral contraceptives </e1>  ( <e2> POC </e2> ) in the US, a comprehensive review was made of norgestrel (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  
false	In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives ( <e1> POC </e1> ) in the US, a comprehensive review was made of  <e2> norgestrel </e2>  (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  
false	In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives ( <e1> POC </e1> ) in the US, a comprehensive review was made of norgestrel (0.075 mg) and  <e2> norethindrone </e2>  (0.35 mg), with the clinical differences indicated where applicable.  
false	In order to provide information for the appropriate package insert labeling of progestin-only oral contraceptives (POC) in the US, a comprehensive review was made of  <e1> norgestrel </e1>  (0.075 mg) and  <e2> norethindrone </e2>  (0.35 mg), with the clinical differences indicated where applicable.  
false	These agents, including norfloxacin, ciprofloxacin,  <e1> ofloxacin </e1> ,  <e2> enoxacin </e2> , and lomefloxacin, have been extensively studied and have demonstrated efficacy and safety profiles comparable to those of other traditional agents for the treatment of complicated or uncomplicated urinary tract infections and prostatitis. 
false	To investigate the effects of antimicrobial combinations of GL with four kinds of  <e1> antibiotics </e1>  (ampicillin,  <e2> cefazolin </e2> , oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	To investigate the effects of antimicrobial combinations of  <e1> GL </e1>  with four kinds of antibiotics (ampicillin, cefazolin,  <e2> oxytetracycline </e2>  and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	To investigate the effects of antimicrobial combinations of GL with four kinds of  <e1> antibiotics </e1>  (ampicillin, cefazolin, oxytetracycline and  <e2> chloramphenicol </e2> ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin, cefazolin,  <e1> oxytetracycline </e1>  and  <e2> chloramphenicol </e2> ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics ( <e1> ampicillin </e1> ,  <e2> cefazolin </e2> , oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	To investigate the effects of antimicrobial combinations of GL with four kinds of  <e1> antibiotics </e1>  (ampicillin, cefazolin,  <e2> oxytetracycline </e2>  and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	Antimicrobial activity of  <e1> Ganoderma lucidum extract </e1>  alone and in combination with some  <e2> antibiotics </e2> .
false	In order to provide information for the appropriate package insert labeling of  <e1> progestin-only oral contraceptives </e1>  (POC) in the US, a comprehensive review was made of norgestrel (0.075 mg) and  <e2> norethindrone </e2>  (0.35 mg), with the clinical differences indicated where applicable.  
effect	The antimicrobial combinations of  <e1> GL </e1>  with four  <e2> antibiotics </e2>  resulted in additive effect in most instances, synergism in two instances, and antagonism in two instances. 
false	To investigate the effects of antimicrobial combinations of  <e1> GL </e1>  with four kinds of antibiotics (ampicillin, cefazolin, oxytetracycline and  <e2> chloramphenicol </e2> ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	In order to provide information for the appropriate package insert labeling of  <e1> progestin-only oral contraceptives </e1>  (POC) in the US, a comprehensive review was made of  <e2> norgestrel </e2>  (0.075 mg) and norethindrone (0.35 mg), with the clinical differences indicated where applicable.  
false	To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics ( <e1> ampicillin </e1> , cefazolin, oxytetracycline and  <e2> chloramphenicol </e2> ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	To investigate the effects of antimicrobial combinations of  <e1> GL </e1>  with four kinds of antibiotics (ampicillin,  <e2> cefazolin </e2> , oxytetracycline and chloramphenicol), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
false	However, the absolute number of alcohol-related deaths is far greater than the number of deaths in  <e1> amphetamine </e1>  or  <e2> heroin </e2>  users.
false	On the basis of the estimated number of regular users of intravenous  <e1> amphetamine </e1>  in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and  <e2> heroin </e2>  addicts. 
false	To investigate the effects of antimicrobial combinations of GL with four kinds of antibiotics (ampicillin,  <e1> cefazolin </e1> , oxytetracycline and  <e2> chloramphenicol </e2> ), the fractional inhibitory concentration index (FICI) was determined by checkerboard assay for each strain. 
effect	Synergism was observed when  <e1> GL </e1>  was combined with  <e2> cefazolin </e2>  against Bacillus subtilis and Klebsiella oxytoca.
false	However, the absolute number of  <e1> alcohol </e1> -related deaths is far greater than the number of deaths in  <e2> amphetamine </e2>  or heroin users.
false	However, the absolute number of  <e1> alcohol </e1> -related deaths is far greater than the number of deaths in amphetamine or  <e2> heroin </e2>  users.
false	The homodimeric disintegrin  <e1> contortrostatin </e1>  was compared directly to the monomeric disintegrins  <e2> echistatin </e2>  and flavoridin for the ability to affect protein tyrosine phosphorylation in tumor cells. 
false	Differential regulation of tyrosine phosphorylation in tumor cells by contortrostatin, a homodimeric disintegrin, and monomeric disintegrins  <e1> echistatin </e1>  and  <e2> flavoridin </e2> .
false	Differential regulation of tyrosine phosphorylation in tumor cells by  <e1> contortrostatin </e1> , a homodimeric disintegrin, and monomeric disintegrins echistatin and  <e2> flavoridin </e2> .
false	The homodimeric disintegrin contortrostatin was compared directly to the monomeric disintegrins  <e1> echistatin </e1>  and  <e2> flavoridin </e2>  for the ability to affect protein tyrosine phosphorylation in tumor cells. 
effect	 <e1> Flavoridin </e1>  alone was found to have no effect on CAS, but can completely block  <e2> contortrostatin </e2> -induced phosphorylation of this protein in MDA-MB-435 cells. 
false	The effects of  <e1> diethyl pyrocarbonate </e1>  could be reversed by  <e2> hydroxylamine </e2>  treatment. 
false	The homodimeric disintegrin  <e1> contortrostatin </e1>  was compared directly to the monomeric disintegrins echistatin and  <e2> flavoridin </e2>  for the ability to affect protein tyrosine phosphorylation in tumor cells. 
false	 <e1> Diethyl pyrocarbonate </e1> , at pH 7.0, was used to chemically modify exposed histidine residues on  <e2> toxin A </e2> . 
false	Exposed histidines on  <e1> toxin A </e1>  are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for  <e2> toxin A </e2>  using zinc-chelating chromatography.
false	Exposed histidines on toxin A are available for  <e1> zinc </e1>  chelation, and these have been exploited in the development of a novel purification protocol for toxin A using  <e2> zinc </e2> -chelating chromatography.
false	Exposed histidines on toxin A are available for  <e1> zinc </e1>  chelation, and these have been exploited in the development of a novel purification protocol for  <e2> toxin A </e2>  using zinc-chelating chromatography.
effect	 <e1> Echistatin </e1>  alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of  <e2> contortrostatin </e2>  when both are added simultaneously. 
false	Treatment of  <e1> toxin A </e1>  with [(14)C]- <e2> diethyl pyrocarbonate </e2>  revealed concentration dependent labelling of histidine residues on the toxin molecules. 
false	The effect of a  <e1> pulmonary surfactant </e1>  extract from bovine lung, Survanta, on the dissolution rate of aerosol particles of  <e2> budesonide </e2>  was determined. 
false	Aerosol particles of  <e1> budesonide </e1>  were generated from an  <e2> ethanol </e2>  solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments. 
false	 <e1> Survanta </e1>  also increased rate of dissolution, in a manner similar to  <e2> sodium dodecyl sulfate </e2> . 
false	Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of  <e1> budesonide </e1>  between the  <e2> Survanta </e2>  and aqueous phase. 
false	Modification of  <e1> toxin A </e1>  with  <e2> diethyl pyrocarbonate </e2>  abolished both its cytotoxic activity and the ability of the toxin to bind Zn-Sepharose gel. 
false	Analysis of the concentration of  <e1> budesonide </e1>  following ultracentrifugation indicated that there is rapid equilibration of  <e2> budesonide </e2>  between the Survanta and aqueous phase. 
false	The effect of a pulmonary surfactant extract from bovine lung,  <e1> Survanta </e1> , on the dissolution rate of aerosol particles of  <e2> budesonide </e2>  was determined. 
false	Note: dissolution of aerosol particles of  <e1> budesonide </e1>  in  <e2> Survanta </e2> , a model lung surfactant.
effect	Using in situ hybridization, we observed that  <e1> METH </e1>  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  <e2> SCH-23390 </e2>  but not by an atypical neuroleptic clozapine. 
false	Exposed histidines on  <e1> toxin A </e1>  are available for zinc chelation, and these have been exploited in the development of a novel purification protocol for toxin A using  <e2> zinc </e2> -chelating chromatography.
false	As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by  <e1> methamphetamine </e1>  ( <e2> METH </e2> ) has been characterized to define the changes in gene expression that may underlie its long-lasting behavioral effects. 
false	Using in situ hybridization, we observed that  <e1> METH </e1>  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an  <e2> atypical neuroleptic </e2>  clozapine. 
false	Using in situ hybridization, we observed that  <e1> METH </e1>  caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an atypical neuroleptic  <e2> clozapine </e2> . 
false	 <e1> Survanta </e1>  increased the extent of dissolution of  <e2> budesonide </e2>  in proportion to the added concentration, which was also verified by equilibrium solubilization studies. 
false	The effects of DCG-IV and L-CCG-1 upon  <e1> phencyclidine </e1>  ( <e2> PCP </e2> )-induced locomotion and behavioral changes in mice.
false	In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with  <e1> PCP </e1> ,  <e2> DCG-IV </e2> , and L-CCG-1 was carried out.
false	Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist  <e1> SCH-23390 </e1>  but not by an atypical neuroleptic  <e2> clozapine </e2> . 
false	In order to examine some molecular mechanisms of PCP-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP,  <e1> DCG-IV </e1> , and  <e2> L-CCG-1 </e2>  was carried out.
false	The effects of  <e1> DCG-IV </e1>  and L-CCG-1 upon phencyclidine ( <e2> PCP </e2> )-induced locomotion and behavioral changes in mice.
false	The effects of DCG-IV and  <e1> L-CCG-1 </e1>  upon  <e2> phencyclidine </e2>  (PCP)-induced locomotion and behavioral changes in mice.
false	In order to examine some molecular mechanisms of  <e1> PCP </e1> -induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with PCP, DCG-IV, and  <e2> L-CCG-1 </e2>  was carried out.
false	injection of  <e1> phencyclidine </e1>  ( <e2> PCP </e2> ) were observed by measuring locomotor activity and stereotyped behavior. 
effect	The effects of  <e1> DCG-IV </e1>  were very strong and completely depressed the  <e2> PCP </e2> -induced hyperlocomotion. 
false	Then, the effects of metabotropic glutamate receptor (mGluR) agonists,  <e1> DCG-IV </e1>  and L-CCG-1, on the above behavioral changes induced by  <e2> PCP </e2>  were found. 
false	In order to examine some molecular mechanisms of  <e1> PCP </e1> -induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with  <e2> PCP </e2> , DCG-IV, and L-CCG-1 was carried out.
false	Using in situ hybridization, we observed that METH caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist SCH-23390 but not by an  <e1> atypical neuroleptic </e1>   <e2> clozapine </e2> . 
false	Behavioral responses to repeated  <e1> cocaine </e1>  exposure in mice selectively bred for differential sensitivity to  <e2> pentobarbital </e2> .
false	Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and  <e1> L-CCG-1 </e1> , on the above behavioral changes induced by  <e2> PCP </e2>  were found. 
false	Mice from the 20th generation of three lines divergently selected for response to  <e1> pentobarbital </e1> -induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study  <e2> cocaine </e2> -induced behavioral sensitization. 
false	Like  <e1> ibogaine </e1>  (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and  <e2> nicotine </e2>  in rats; 
false	Both  <e1> ibogaine </e1>  and  <e2> 18-MC </e2>  enhance the locomotor and/or stereotypic effects of stimulants. 
false	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of  <e1> morphine </e1>  and cocaine and the oral self-administration of  <e2> ethanol </e2>  and nicotine in rats; 
false	Like  <e1> ibogaine </e1>  (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of  <e2> morphine </e2>  and cocaine and the oral self-administration of ethanol and nicotine in rats; 
effect	only  <e1> ibogaine </e1>  enhances  <e2> cocaine </e2> -induced increases in accumbal dopamine. 
false	 <e1> Ibogaine </e1>  attenuates, but  <e2> 18-MC </e2>  potentiates, the acute locomotor effects of morphine; 
false	Both  <e1> ibogaine </e1>  and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only  <e2> ibogaine </e2>  increases extracellular levels of serotonin in the nucleus accumbens. 
false	Both 18-MC and  <e1> ibogaine </e1>  are sequestered in fat and, like ibogaine,  <e2> 18-MC </e2>  probably has an active metabolite. 
false	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of  <e1> morphine </e1>  and cocaine and the oral self-administration of ethanol and  <e2> nicotine </e2>  in rats; 
false	Both  <e1> 18-MC </e1>  and ibogaine are sequestered in fat and, like ibogaine,  <e2> 18-MC </e2>  probably has an active metabolite. 
effect	Both ibogaine and  <e1> 18-MC </e1>  block morphine-induced and  <e2> nicotine </e2> -induced dopamine release in the nucleus accumbens; 
false	The effects of  <e1> DCG-IV </e1>  and  <e2> L-CCG-1 </e2>  upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.
false	 <e1> 18-Methoxycoronaridine </e1>  ( <e2> 18-MC </e2> ) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
false	While  <e1> 18-MC </e1>  and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than  <e2> ibogaine </e2>  for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 
false	Like  <e1> ibogaine </e1>  (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of  <e2> ethanol </e2>  and nicotine in rats; 
false	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of  <e1> morphine </e1>  and  <e2> cocaine </e2>  and the oral self-administration of ethanol and nicotine in rats; 
false	Like ibogaine (40 mg/kg),  <e1> 18-MC </e1>  (40 mg/kg) decreases the intravenous self-administration of morphine and  <e2> cocaine </e2>  and the oral self-administration of ethanol and nicotine in rats; 
false	The data suggest that  <e1> 18-MC </e1>  has a narrower spectrum of actions and will have a substantially greater therapeutic index than  <e2> ibogaine </e2> .
effect	Ibogaine attenuates, but  <e1> 18-MC </e1>  potentiates, the acute locomotor effects of  <e2> morphine </e2> ; 
false	Like ibogaine (40 mg/kg),  <e1> 18-MC </e1>  (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of  <e2> ethanol </e2>  and nicotine in rats; 
false	Both  <e1> ibogaine </e1>  and  <e2> 18-MC </e2>  ameliorate opioid withdrawal signs. 
false	18-Methoxycoronaridine ( <e1> 18-MC </e1> ) and  <e2> ibogaine </e2> : comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
false	Both  <e1> 18-MC </e1>  and  <e2> ibogaine </e2>  are sequestered in fat and, like ibogaine, 18-MC probably has an active metabolite. 
false	Both ibogaine and 18-MC block  <e1> morphine </e1> -induced and  <e2> nicotine </e2> -induced dopamine release in the nucleus accumbens; 
false	While  <e1> 18-MC </e1>  and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors,  <e2> 18-MC </e2>  has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 
false	Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of  <e1> ethanol </e1>  and  <e2> nicotine </e2>  in rats; 
false	Like ibogaine (40 mg/kg),  <e1> 18-MC </e1>  (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and  <e2> nicotine </e2>  in rats; 
false	Like ibogaine (40 mg/kg),  <e1> 18-MC </e1>  (40 mg/kg) decreases the intravenous self-administration of  <e2> morphine </e2>  and cocaine and the oral self-administration of ethanol and nicotine in rats; 
effect	Both  <e1> ibogaine </e1>  and 18-MC block morphine-induced and  <e2> nicotine </e2> -induced dopamine release in the nucleus accumbens; 
false	 <e1> 18-Methoxycoronaridine </e1>  (18-MC) and  <e2> ibogaine </e2> : comparison of antiaddictive efficacy, toxicity, and mechanisms of action.
false	Like  <e1> ibogaine </e1>  (40 mg/kg),  <e2> 18-MC </e2>  (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats; 
false	While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors,  <e1> 18-MC </e1>  has much lower affinities than  <e2> ibogaine </e2>  for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 
false	The intensity, uniformity and time course of  <e1> anticoagulant </e1>  interference by phenobarbital, secobarbital,  <e2> glutethimide </e2> , chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 
false	The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide,  <e1> chloral hydrate </e1>  and methaqualone were systematically investigated in 16 patients receiving  <e2> coumarin </e2>  therapy. 
false	unlike  <e1> ibogaine </e1> ,  <e2> 18-MC </e2>  does not affect responding for a nondrug reinforcer (water). 
int	 <e1> Chloral hydrate </e1>  and methaqualone interact pharmacologically with orally administered  <e2> anticoagulant agents </e2> , but the effect is not clinically significant. 
false	The intensity, uniformity and time course of  <e1> anticoagulant </e1>  interference by phenobarbital,  <e2> secobarbital </e2> , glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 
false	Anticoagulant inhibition was observed during the administration of  <e1> phenobarbital </e1> ,  <e2> secobarbital </e2>  and glutethimide; 
false	The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital,  <e1> glutethimide </e1> , chloral hydrate and methaqualone were systematically investigated in 16 patients receiving  <e2> coumarin </e2>  therapy. 
false	It is concluded that  <e1> chloral hydrate </e1>  and  <e2> methaqualone </e2>  may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.
false	there was no significant change in prothrombin test results during the trials of  <e1> chloral hydrate </e1>  and  <e2> methaqualone </e2> . 
false	 <e1> Barbiturates </e1>  and  <e2> glutethimide </e2>  should not be administered to patients receiving coumarin drugs. 
false	Both  <e1> ibogaine </e1>  and 18-MC ameliorate  <e2> opioid </e2>  withdrawal signs. 
false	The intensity, uniformity and time course of  <e1> anticoagulant </e1>  interference by  <e2> phenobarbital </e2> , secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 
false	The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide,  <e1> chloral hydrate </e1>  and  <e2> methaqualone </e2>  were systematically investigated in 16 patients receiving coumarin therapy. 
false	The intensity, uniformity and time course of anticoagulant interference by  <e1> phenobarbital </e1> , secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving  <e2> coumarin </e2>  therapy. 
effect	 <e1> Ibogaine </e1>  attenuates, but 18-MC potentiates, the acute locomotor effects of  <e2> morphine </e2> ; 
advise	Barbiturates and  <e1> glutethimide </e1>  should not be administered to patients receiving  <e2> coumarin drugs </e2> . 
false	It is concluded that  <e1> chloral hydrate </e1>  and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral  <e2> anticoagulant </e2>  therapy.
false	The intensity, uniformity and time course of anticoagulant interference by  <e1> phenobarbital </e1> , secobarbital,  <e2> glutethimide </e2> , chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 
false	both compounds attenuate  <e1> morphine </e1> -induced locomotion in  <e2> morphine </e2> -experienced rats. 
int	Chloral hydrate and  <e1> methaqualone </e1>  interact pharmacologically with orally administered  <e2> anticoagulant agents </e2> , but the effect is not clinically significant. 
false	It is concluded that chloral hydrate and  <e1> methaqualone </e1>  may be administered safely without additional caution in prothrombin test monitoring during oral  <e2> anticoagulant </e2>  therapy.
false	While 18-MC and  <e1> ibogaine </e1>  have similar affinities for kappa opioid and possibly nicotinic receptors,  <e2> 18-MC </e2>  has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 
false	The intensity, uniformity and time course of anticoagulant interference by  <e1> phenobarbital </e1> ,  <e2> secobarbital </e2> , glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 
false	The intensity, uniformity and time course of  <e1> anticoagulant </e1>  interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and  <e2> methaqualone </e2>  were systematically investigated in 16 patients receiving coumarin therapy. 
false	The intensity, uniformity and time course of  <e1> anticoagulant </e1>  interference by phenobarbital, secobarbital, glutethimide,  <e2> chloral hydrate </e2>  and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 
false	 <e1> Ibogaine </e1> , but not  <e2> 18-MC </e2> , decreases heart rate at high doses. 
false	The intensity, uniformity and time course of anticoagulant interference by phenobarbital,  <e1> secobarbital </e1> , glutethimide,  <e2> chloral hydrate </e2>  and methaqualone were systematically investigated in 16 patients receiving coumarin therapy. 
effect	Both ibogaine and  <e1> 18-MC </e1>  block  <e2> morphine </e2> -induced and nicotine-induced dopamine release in the nucleus accumbens; 
false	The intensity, uniformity and time course of anticoagulant interference by phenobarbital,  <e1> secobarbital </e1> , glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving  <e2> coumarin </e2>  therapy. 
advise	 <e1> Barbiturates </e1>  and glutethimide should not be administered to patients receiving  <e2> coumarin drugs </e2> . 
false	While  <e1> 18-MC </e1>  and  <e2> ibogaine </e2>  have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter. 
false	 <e1> Chloral hydrate </e1>  and  <e2> methaqualone </e2>  interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant. 
false	The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and  <e1> methaqualone </e1>  were systematically investigated in 16 patients receiving  <e2> coumarin </e2>  therapy. 
false	Concomitantly given  <e1> thiazide diuretics </e1>  did not interfere with the absorption of a tablet of  <e2> digoxin </e2> . 
false	 <e1> Phencyclidine </e1>  ( <e2> PCP </e2> ) produces psychotomimetic effects in humans that resemble schizophrenia symptoms. 
false	In the present study, the  <e1> atypical antipsychotic </e1>   <e2> clozapine </e2>  was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 
false	In the present study, the atypical antipsychotic  <e1> clozapine </e1>  was tested in combination with an active dose of  <e2> PCP </e2>  in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures. 
false	The intensity, uniformity and time course of anticoagulant interference by phenobarbital,  <e1> secobarbital </e1> , glutethimide, chloral hydrate and  <e2> methaqualone </e2>  were systematically investigated in 16 patients receiving coumarin therapy. 
false	Since chronic dosing is required for therapeutic efficacy of  <e1> antipsychotics </e1> , future studies should focus on investigation of chronic dosing effects of these drugs in combination with  <e2> PCP </e2> .
false	 <e1> PCP </e1>  produced distinctive effects in each task: it substituted for the training dose in  <e2> PCP </e2>  discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule. 
false	Resveratrol (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with  <e1> noradrenaline </e1>  (8 micromol/l) or  <e2> KCl </e2>  (125 mmol/l) from both lean and dietary-obese rats. 
false	This study indicates that: (a) the maximal effects of  <e1> resveratrol </e1>  on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of  <e2> resveratrol </e2>  in lean animals (where endothelial function is not impaired), but not in dietary-obese rats, are mediated via NO.
false	 <e1> Indomethacin </e1>  was also ineffective in altering  <e2> resveratrol </e2>  activity in arteries from both lean and dietary-obese rats. 
false	 <e1> Resveratrol </e1>  (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with noradrenaline (8 micromol/l) or  <e2> KCl </e2>  (125 mmol/l) from both lean and dietary-obese rats. 
false	However,  <e1> L-NAME </e1>  (100 and 300 micromol/l) did not alter the effects of  <e2> reseveratrol </e2>  on arteries from dietary-obese rats, giving superimposed concentration-responses curves. 
false	Concurrent administration of  <e1> indinavir </e1>  and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration  <e2> indinavir </e2>  may be given safely. 
false	If taken 1 hour before indinavir ( <e1> IDV </e1> ), didanosine does not affect  <e2> IDV </e2>  exposure, despite persistent buffering effects.
false	Acute dosing with  <e1> clozapine </e1>  failed to alter the behavioral effects of  <e2> PCP </e2>  in either procedure even when tested up to doses that produced pharmacological effects alone. 
advise	 <e1> Indinavir </e1>  may be taken with a light meal 1 h following the administration of 400 mg of  <e2> didanosine </e2> .
mechanism	Concurrent administration of  <e1> indinavir </e1>  and  <e2> didanosine </e2>  significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration indinavir may be given safely. 
false	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after  <e1> didanosine </e1>  administration  <e2> indinavir </e2>  may be given safely. 
false	We compared  <e1> indinavir </e1>  pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of  <e2> indinavir </e2>  alone versus 800 mg of indinavir administered 1 h after didanosine administration. 
false	We compared  <e1> indinavir </e1>  pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of indinavir alone versus 800 mg of indinavir administered 1 h after  <e2> didanosine </e2>  administration. 
false	Concurrent administration of indinavir and  <e1> didanosine </e1>  significantly reduces the level of exposure to indinavir, but it is unclear how soon after didanosine administration  <e2> indinavir </e2>  may be given safely. 
false	Concurrent administration of  <e1> indinavir </e1>  and didanosine significantly reduces the level of exposure to indinavir, but it is unclear how soon after  <e2> didanosine </e2>  administration indinavir may be given safely. 
false	If taken 1 hour before  <e1> indinavir </e1>  ( <e2> IDV </e2> ), didanosine does not affect IDV exposure, despite persistent buffering effects.
false	If taken 1 hour before  <e1> indinavir </e1>  (IDV), didanosine does not affect  <e2> IDV </e2>  exposure, despite persistent buffering effects.
false	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to  <e1> indinavir </e1> , but it is unclear how soon after  <e2> didanosine </e2>  administration indinavir may be given safely. 
false	If taken 1 hour before indinavir ( <e1> IDV </e1> ),  <e2> didanosine </e2>  does not affect IDV exposure, despite persistent buffering effects.
false	We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of  <e1> indinavir </e1>  alone versus 800 mg of  <e2> indinavir </e2>  administered 1 h after didanosine administration. 
false	If taken 1 hour before indinavir (IDV),  <e1> didanosine </e1>  does not affect  <e2> IDV </e2>  exposure, despite persistent buffering effects.
false	Concurrent administration of indinavir and didanosine significantly reduces the level of exposure to  <e1> indinavir </e1> , but it is unclear how soon after didanosine administration  <e2> indinavir </e2>  may be given safely. 
effect	 <e1> Cytochalasin D </e1>  inhibited the  <e2> carbachol </e2> -stimulated intracellular Ca(2+) concentration ([Ca(2+)](i)) increase due to release from the Ca(2+) store. 
false	We compared indinavir pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of  <e1> indinavir </e1>  alone versus 800 mg of indinavir administered 1 h after  <e2> didanosine </e2>  administration. 
mechanism	Median gastric pH was significantly higher when  <e1> indinavir </e1>  was taken after  <e2> didanosine </e2>  administration; 
effect	 <e1> Cytochalasin D </e1>  at 10 microM preferentially blocked the secretory effect of  <e2> carbachol </e2>  and its synergism with cAMP, whereas it had no effect on histamine- or cAMP-stimulated acid secretion within 15 min. 
false	The percentage of neurons hyperpolarized by mu-, delta(1)-, and  <e1> kappa-s <e2> elective opioids </e1>  </e2>  was significantly reduced when 1% but not < 
false	The percentage of neurons hyperpolarized by mu-, delta(1)-, and  <e1> kappa-s <e2> elective opioids </e1>  </e2>  was significantly reduced when 1% but not < 
false	Concurrent administration of indinavir and  <e1> didanosine </e1>  significantly reduces the level of exposure to indinavir, but it is unclear how soon after  <e2> didanosine </e2>  administration indinavir may be given safely. 
false	BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride ( <e1> verapamil </e1> ), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  <e2> azoxymethane </e2>  (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of bombesin and  <e1> verapamil hydrochloride </e1>  (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  <e2> azoxymethane </e2>  (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a  <e1> calcium channel blocker </e1> , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  <e2> azoxymethane </e2>  (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of bombesin and  <e1> verapamil hydrochloride </e1>  ( <e2> verapamil </e2> ), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride ( <e1> verapamil </e1> ), a  <e2> calcium channel blocker </e2> , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of  <e1> bombesin </e1>  and  <e2> verapamil hydrochloride </e2>  (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of bombesin and  <e1> verapamil hydrochloride </e1>  (verapamil), a  <e2> calcium channel blocker </e2> , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of bombesin and  <e1> verapamil hydrochloride </e1>  (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( <e2> AOM </e2> ) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by  <e1> azoxymethane </e1>  ( <e2> AOM </e2> ) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of  <e1> AOM </e1>  (7.4 mg/kg body weight) and subcutaneous injections of  <e2> bombesin </e2>  (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45. 
effect	Suppression by  <e1> verapamil </e1>  of  <e2> bombesin </e2> -enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.
false	BACKGROUND: The effects of combined administration of  <e1> bombesin </e1>  and verapamil hydrochloride (verapamil), a  <e2> calcium channel blocker </e2> , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of  <e1> bombesin </e1>  and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( <e2> AOM </e2> ) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	BACKGROUND: The effects of combined administration of  <e1> bombesin </e1>  and verapamil hydrochloride ( <e2> verapamil </e2> ), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats. 
false	In seven experiments reactions to  <e1> norepinephrine </e1>  and oxytocin were  <e2> PGF2alpha </e2> . 
false	In seven experiments reactions to  <e1> norepinephrine </e1>  and  <e2> oxytocin </e2>  were PGF2alpha. 
false	The interaction of  <e1> prostaglandin F2alpha </e1>  and synthetic  <e2> oxytocin </e2>  on placental vessels was studied in vitro. 
false	Suppression by verapamil of  <e1> bombesin </e1> -enhanced peritoneal metastasis of intestinal adenocarcinomas induced by  <e2> azoxymethane </e2>  in wistar rats.
false	Suppression by  <e1> verapamil </e1>  of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by  <e2> azoxymethane </e2>  in wistar rats.
int	In vitro interaction of  <e1> prostaglandin F2alpha </e1>  and  <e2> oxytocin </e2>  in placental vessels.
effect	 <e1> PGF2alpha </e1>  produced significantly increased vasoconstriction after a single administration of  <e2> oxytocin </e2> . 
effect	 <e1> Verapamil </e1>  also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by  <e2> bombesin </e2> . 
false	We report the case of an adolescent with altered consciousness caused by  <e1> carbamazepine </e1>  overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of  <e2> carbamazepine </e2>  with a toxicology screen for tricyclic antidepressants.
effect	We report the case of an adolescent with altered consciousness caused by  <e1> carbamazepine </e1>  overdose with a positive  <e2> tricyclic antidepressant </e2>  level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.
advise	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of  <e1> carbamazepine </e1>  with a toxicology screen for  <e2> tricyclic antidepressants </e2> .
false	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive  <e1> tricyclic antidepressant </e1>  level to alert clinicians to the cross-reactivity of  <e2> carbamazepine </e2>  with a toxicology screen for tricyclic antidepressants.
false	We report the case of an adolescent with altered consciousness caused by  <e1> carbamazepine </e1>  overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for  <e2> tricyclic antidepressants </e2> .
false	We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive  <e1> tricyclic antidepressant </e1>  level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for  <e2> tricyclic antidepressants </e2> .
false	Pretreatment of rats with  <e1> allopurinol </e1>  (100 mg/kg, ip) or  <e2> Vitamin E </e2>  (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral cypermethrin administration within 4 h. 
effect	Pretreatment of rats with  <e1> allopurinol </e1>  (100 mg/kg, ip) or Vitamin E (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral  <e2> cypermethrin </e2>  administration within 4 h. 
false	Thus, the results suggest that cypermethrin exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by  <e1> allopurinol </e1>  and  <e2> Vitamin E </e2> .
effect	 <e1> Cypermethrin </e1> -induced oxidative stress in rat brain and liver is prevented by vitamin E or  <e2> allopurinol </e2> .
effect	 <e1> Cypermethrin </e1> -induced oxidative stress in rat brain and liver is prevented by  <e2> vitamin E </e2>  or allopurinol.
false	Considering that the involvement of reactive oxygen species (ROS) has been implicated in the toxicity of various pesticides, this study was designed to investigate the possibility of oxidative stress induction by  <e1> cypermethrin </e1> , a  <e2> Type II pyrethroid </e2> . 
effect	Thus, the results suggest that  <e1> cypermethrin </e1>  exposure of rats results in free radical-mediated tissue damage, as indicated by elevated cerebral and hepatic lipid peroxidation, which was prevented by  <e2> allopurinol </e2>  and Vitamin E.
false	These data suggest that  <e1> ginsenosides </e1>  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/ <e2> omega-agatoxin VIA </e2> -resistant (presumptive Q-type) channel. 
false	These data suggest that  <e1> ginsenosides </e1>  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an  <e2> omega-agatoxin IVA </e2> -sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 
false	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  <e1> omega-conotoxin GVIA </e1> -sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and  <e2> nimodipine </e2> /omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 
false	 <e1> Nimodipine </e1>  had no effect on  <e2> ginsenosides </e2>  response. 
false	Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by  <e1> ginsenosides </e1>  in bovine chromaffin cell could be the cellular basis of antistress effects induced by  <e2> ginseng </e2> .
false	These data suggest that  <e1> ginsenosides </e1>  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and  <e2> nimodipine </e2> /omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 
false	These data suggest that  <e1> ginsenosides </e1>  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  <e2> omega-conotoxin GVIA </e2> -sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 
effect	Pretreatment of rats with allopurinol (100 mg/kg, ip) or  <e1> Vitamin E </e1>  (100 mg/kg per day, ig, for 3 days and a dose of 40 mg/kg on the 4th day) provided significant protection against the elevation of TBARS levels in cerebral and hepatic tissues, induced by single high dose of oral  <e2> cypermethrin </e2>  administration within 4 h. 
false	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/ <e1> omega-conotoxin GVIA </e1> / <e2> omega-agatoxin VIA </e2> -resistant (presumptive Q-type) channel. 
false	In this study we investigated the effect of  <e1> ginsenosides </e1>  on high threshold voltage-dependent Ca(2+) channel subtypes using their  <e2> selective Ca(2+) channel blockers </e2>  nimodipine (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 
false	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their  <e1> selective Ca(2+) channel blockers </e1>   <e2> nimodipine </e2>  (L-type), omega-conotoxin GVIA (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 
false	In this study we investigated the effect of  <e1> ginsenosides </e1>  on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type), omega-conotoxin GVIA (N-type), or  <e2> omega-agatoxin IVA </e2>  (P-type) in bovine chromaffin cells. 
false	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an  <e1> omega-agatoxin IVA </e1> -sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/ <e2> omega-agatoxin VIA </e2> -resistant (presumptive Q-type) channel. 
false	In this study we investigated the effect of  <e1> ginsenosides </e1>  on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers nimodipine (L-type),  <e2> omega-conotoxin GVIA </e2>  (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 
false	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their  <e1> selective Ca(2+) channel blockers </e1>  nimodipine (L-type),  <e2> omega-conotoxin GVIA </e2>  (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 
false	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and  <e1> nimodipine </e1> /omega-conotoxin GVIA/ <e2> omega-agatoxin VIA </e2> -resistant (presumptive Q-type) channel. 
false	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers  <e1> nimodipine </e1>  (L-type),  <e2> omega-conotoxin GVIA </e2>  (N-type), or omega-agatoxin IVA (P-type) in bovine chromaffin cells. 
false	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and  <e1> nimodipine </e1> / <e2> omega-conotoxin GVIA </e2> /omega-agatoxin VIA-resistant (presumptive Q-type) channel. 
false	When combined with ofloxacin,  <e1> KRM-1648 </e1>  exhibited strong synergistic activity while only additive effects were observed with the combination of  <e2> rifampicin </e2>  (or rifabutin) and ofloxacin. 
effect	When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of  <e1> rifampicin </e1>  (or rifabutin) and  <e2> ofloxacin </e2> . 
false	In vitro activity of  <e1> KRM-1648 </e1> , either singly or in combination with  <e2> ofloxacin </e2> , against Mycobacterium ulcerans.
false	The antimicrobial effect of a  <e1> benzoxazinorifamycin </e1> ,  <e2> KRM-1648 </e2> , either alone or in combination with ofloxacin, was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 
false	When combined with  <e1> ofloxacin </e1> , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or  <e2> rifabutin </e2> ) and ofloxacin. 
false	The antimicrobial effect of a  <e1> benzoxazinorifamycin </e1> , KRM-1648, either alone or in combination with  <e2> ofloxacin </e2> , was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 
false	ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for  <e1> rifampicin </e1>  and  <e2> rifabutin </e2>  were in the range of 0.1-0.8 mg/l and 0.1-0.4 mg/l respectively. 
false	The antimicrobial effect of a benzoxazinorifamycin,  <e1> KRM-1648 </e1> , either alone or in combination with  <e2> ofloxacin </e2> , was evaluated in vitro against two type strains and six clinical isolates of Mycobacterium ulcerans. 
false	When combined with ofloxacin, KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of  <e1> rifampicin </e1>  (or  <e2> rifabutin </e2> ) and ofloxacin. 
false	In this study we investigated the effect of ginsenosides on high threshold voltage-dependent Ca(2+) channel subtypes using their selective Ca(2+) channel blockers  <e1> nimodipine </e1>  (L-type), omega-conotoxin GVIA (N-type), or  <e2> omega-agatoxin IVA </e2>  (P-type) in bovine chromaffin cells. 
false	When combined with ofloxacin,  <e1> KRM-1648 </e1>  exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or  <e2> rifabutin </e2> ) and ofloxacin. 
effect	When combined with  <e1> ofloxacin </e1> ,  <e2> KRM-1648 </e2>  exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and ofloxacin. 
false	In addition, we have shown that  <e1> RR </e1>  is a useful pharmacological tool with which to examine the  <e2> InsP(3) </e2> -mediated responses of megakaryocytes.
false	These data suggest that ginsenosides are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an  <e1> omega-conotoxin GVIA </e1> -sensitive (N-type) channel, an  <e2> omega-agatoxin IVA </e2> -sensitive (P-type) channel and nimodipine/omega-conotoxin GVIA/omega-agatoxin VIA-resistant (presumptive Q-type) channel. 
false	The effects of  <e1> ruthenium red </e1>  (RR) on  <e2> inositol 1,4,5-trisphosphate </e2>  (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 
false	The effects of ruthenium red ( <e1> RR </e1> ) on inositol 1,4,5-trisphosphate ( <e2> InsP(3) </e2> )-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 
false	When combined with ofloxacin,  <e1> KRM-1648 </e1>  exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and  <e2> ofloxacin </e2> . 
effect	Pretreatment of megakaryocytes with extracellular  <e1> RR </e1>  (50 microM) also inhibited  <e2> InsP(3) </e2> -induced responses. 
false	When combined with  <e1> ofloxacin </e1> , KRM-1648 exhibited strong synergistic activity while only additive effects were observed with the combination of rifampicin (or rifabutin) and  <e2> ofloxacin </e2> . 
false	These data suggest that  <e1> ginsenosides </e1>  are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an omega-conotoxin GVIA-sensitive (N-type) channel, an omega-agatoxin IVA-sensitive (P-type) channel and nimodipine/ <e2> omega-conotoxin GVIA </e2> /omega-agatoxin VIA-resistant (presumptive Q-type) channel. 
false	The effects of  <e1> ruthenium red </e1>  ( <e2> RR </e2> ) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry. 
effect	Administering  <e1> InsP(3) </e1>  together with  <e2> RR </e2>  (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion. 
false	The harmonic mean elimination half-life was 45.7 and 43.4 hours for  <e1> rofecoxib </e1>  + digoxin and placebo +  <e2> digoxin </e2>  treatments, respectively. 
false	For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( <e1> rofecoxib </e1>  +  <e2> digoxin </e2> /placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 
false	The harmonic mean elimination half-life was 45.7 and 43.4 hours for  <e1> rofecoxib </e1>  +  <e2> digoxin </e2>  and placebo + digoxin treatments, respectively. 
false	The harmonic mean elimination half-life was 45.7 and 43.4 hours for rofecoxib +  <e1> digoxin </e1>  and placebo +  <e2> digoxin </e2>  treatments, respectively. 
false	For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( <e1> rofecoxib </e1>  + digoxin/placebo +  <e2> digoxin </e2> ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 
false	For  <e1> digoxin </e1>  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for ( <e2> rofecoxib </e2>  + digoxin/placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 
false	Samples for plasma and urine immunoreactive  <e1> digoxin </e1>  concentrations were collected through 120 hours following the  <e2> digoxin </e2>  dose. 
false	 <e1> Rofecoxib </e1>  did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of  <e2> digoxin </e2> .
false	For  <e1> digoxin </e1>  AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib +  <e2> digoxin </e2> /placebo + digoxin) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e1> cyclophosphamide </e1> , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving  <e2> antiretroviral </e2>  therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and  <e1> prednisone </e1>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and  <e2> prednisone </e2>  with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide,  <e1> doxorubicin </e1> , vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving  <e2> antiretroviral </e2>  therapy. 
false	Concomitant  <e1> cyclophosphamide </e1> , doxorubicin,  <e2> vincristine </e2> , and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and  <e1> prednisone </e1>  with vincristine plus  <e2> bleomycin </e2> ) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide,  <e1> doxorubicin </e1> , vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin,  <e2> teniposide </e2> , and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e1> cyclophosphamide </e1> , doxorubicin, vincristine, and  <e2> prednisone </e2>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide,  <e1> doxorubicin </e1> ,  <e2> vincristine </e2> , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin,  <e1> teniposide </e1> , and  <e2> prednisone </e2>  with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	Concomitant cyclophosphamide,  <e1> doxorubicin </e1> , vincristine, and prednisone chemotherapy plus  <e2> highly active antiretroviral </e2>  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin,  <e1> vincristine </e1> , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin,  <e2> teniposide </e2> , and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e1> cyclophosphamide </e1> , doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving  <e2> antiretroviral </e2>  therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and  <e1> prednisone </e1>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide,  <e2> doxorubicin </e2> , teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	Concomitant  <e1> cyclophosphamide </e1> , doxorubicin, vincristine, and prednisone chemotherapy plus  <e2> highly active antiretroviral </e2>  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e1> cyclophosphamide </e1> , doxorubicin, teniposide, and prednisone with vincristine plus  <e2> bleomycin </e2> ) without receiving antiretroviral therapy. 
advise	However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between antiretroviral and  <e1> antineoplastic d <e2> rugs </e1>  </e2> . 
false	Concomitant cyclophosphamide,  <e1> doxorubicin </e1> , vincristine, and  <e2> prednisone </e2>  chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin,  <e1> teniposide </e1> , and prednisone with  <e2> vincristine </e2>  plus bleomycin) without receiving antiretroviral therapy. 
false	For digoxin AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (rofecoxib +  <e1> digoxin </e1> /placebo +  <e2> digoxin </e2> ) were 1.04 (0.94, 1.14), 1.02 (0.94, 1.09), and 1.00 (0.91, 1.10), respectively. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with  <e1> vincristine </e1>  plus bleomycin) without receiving  <e2> antiretroviral </e2>  therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide,  <e1> doxorubicin </e1> , vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus  <e2> bleomycin </e2> ) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e1> cyclophosphamide </e1> , doxorubicin, teniposide, and prednisone with  <e2> vincristine </e2>  plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e1> cyclophosphamide </e1> , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus  <e2> bleomycin </e2> ) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide,  <e1> doxorubicin </e1> , vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with  <e2> vincristine </e2>  plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with  <e1> vincristine </e1>  plus  <e2> bleomycin </e2> ) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin,  <e1> vincristine </e1> , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving  <e2> antiretroviral </e2>  therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide,  <e1> doxorubicin </e1> , teniposide, and prednisone with vincristine plus  <e2> bleomycin </e2> ) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide,  <e1> doxorubicin </e1> , teniposide, and  <e2> prednisone </e2>  with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	Antiretroviral regimens consisted of two  <e1> reverse transcriptase inhibitors </e1>  and one  <e2> protease inhibitor </e2> . 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin,  <e1> vincristine </e1> , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide,  <e2> doxorubicin </e2> , teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e1> cyclophosphamide </e1> , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and  <e2> prednisone </e2>  with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin,  <e1> vincristine </e1> , and  <e2> prednisone </e2>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide,  <e1> doxorubicin </e1> ,  <e2> teniposide </e2> , and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor,  <e1> rofecoxib </e1> , at steady state on the pharmacokinetics of  <e2> digoxin </e2>  following a single dose in healthy subjects. 
false	The mean (SD) cumulative urinary excretion of immunoreactive  <e1> digoxin </e1>  after concurrent treatment with  <e2> rofecoxib </e2>  or placebo was 228.2 (+/- 30.8) and 235.1 (+/- 39.1) micrograms/120 hours, respectively. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e1> cyclophosphamide </e1> , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with  <e2> vincristine </e2>  plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and  <e1> prednisone </e1>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin,  <e2> teniposide </e2> , and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus  <e1> bleomycin </e1> ) without receiving  <e2> antiretroviral </e2>  therapy. 
false	Concomitant cyclophosphamide, doxorubicin, vincristine, and  <e1> prednisone </e1>  chemotherapy plus  <e2> highly active antiretroviral </e2>  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e1> cyclophosphamide </e1> , doxorubicin,  <e2> teniposide </e2> , and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	Concomitant  <e1> cyclophosphamide </e1> ,  <e2> doxorubicin </e2> , vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide,  <e1> doxorubicin </e1> , teniposide, and prednisone with vincristine plus bleomycin) without receiving  <e2> antiretroviral </e2>  therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin,  <e1> teniposide </e1> , and prednisone with vincristine plus  <e2> bleomycin </e2> ) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and  <e1> prednisone </e1>  (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving  <e2> antiretroviral </e2>  therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide,  <e1> doxorubicin </e1> , vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and  <e2> prednisone </e2>  with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	 <e1> Imipramine </e1>  and  <e2> clonazepam </e2>  did not change fasting or overload glycemia. 
false	In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of  <e1> glucose </e1>  tolerance 30 min after  <e2> glucose </e2>  overload. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e1> cyclophosphamide </e1> , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e2> cyclophosphamide </e2> , doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e.,  <e1> cyclophosphamide </e1> ,  <e2> doxorubicin </e2> , teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide,  <e1> doxorubicin </e1> , teniposide, and prednisone with  <e2> vincristine </e2>  plus bleomycin) without receiving antiretroviral therapy. 
false	 <e1> Antiretroviral </e1>  regimens consisted of two reverse transcriptase inhibitors and one  <e2> protease inhibitor </e2> . 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin,  <e1> vincristine </e1> , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and  <e2> prednisone </e2>  with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	Concomitant cyclophosphamide, doxorubicin,  <e1> vincristine </e1> , and prednisone chemotherapy plus  <e2> highly active antiretroviral </e2>  therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
false	 <e1> Fluoxetine </e1>  and  <e2> moclobemide </e2>  increased blood glucose at different times after the glucose overload. 
false	 <e1> Imipramine </e1>  (5 mg/kg), moclobemide (30 mg/kg),  <e2> clonazepam </e2>  (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 
false	Concomitant cyclophosphamide,  <e1> doxorubicin </e1> ,  <e2> vincristine </e2> , and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.
false	 <e1> Imipramine </e1>  (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg),  <e2> fluoxetine </e2>  (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 
false	Again,  <e1> sertraline </e1>  neutralized the increase in glycemia after  <e2> glucose </e2>  overload both in diabetic and non-diabetic rats. 
false	 <e1> Fluoxetine </e1>  and moclobemide increased blood  <e2> glucose </e2>  at different times after the glucose overload. 
int	Treatment with  <e1> antidepressant drugs </e1>  can directly interfere with blood glucose levels or may interact with  <e2> hypoglycemic agents </e2> . 
false	An oral  <e1> glucose </e1>  overload of 1 ml of a 50%  <e2> glucose </e2>  solution was given to rats and blood glucose was determined after 30, 60 and 90 min. 
false	Imipramine (5 mg/kg),  <e1> moclobemide </e1>  (30 mg/kg), clonazepam (0.25 mg/kg),  <e2> fluoxetine </e2>  (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin,  <e1> vincristine </e1> , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with  <e2> vincristine </e2>  plus bleomycin) without receiving antiretroviral therapy. 
false	 <e1> Imipramine </e1>  (5 mg/kg),  <e2> moclobemide </e2>  (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 
false	Imipramine (5 mg/kg), moclobemide (30 mg/kg),  <e1> clonazepam </e1>  (0.25 mg/kg),  <e2> fluoxetine </e2>  (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 
false	Activity of buforin II alone and in combination with  <e1> azithromycin </e1>  and  <e2> minocycline </e2>  against Cryptosporidium parvum in cell culture.
false	Activity of  <e1> buforin II </e1>  alone and in combination with azithromycin and  <e2> minocycline </e2>  against Cryptosporidium parvum in cell culture.
false	Buforin II may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either  <e1> azithromycin </e1>  or  <e2> minocycline </e2> .
effect	 <e1> Buforin II </e1>  may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either azithromycin or  <e2> minocycline </e2> .
false	To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the  <e1> cyclophosphamide </e1> , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin,  <e2> teniposide </e2> , and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy. 
false	The in vitro anti-cryptosporidial activity of  <e1> buforin II </e1>  alone and in combination with  <e2> azithromycin </e2>  and minocycline was investigated. 
false	Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg),  <e1> fluoxetine </e1>  (20 mg/kg)  <e2> sertraline </e2>  (30 mg/kg) or vehicle was administered. 
false	The in vitro anti-cryptosporidial activity of  <e1> buforin II </e1>  alone and in combination with azithromycin and  <e2> minocycline </e2>  was investigated. 
false	Activity of  <e1> buforin II </e1>  alone and in combination with  <e2> azithromycin </e2>  and minocycline against Cryptosporidium parvum in cell culture.
false	therefore, the use of  <e1> dofetilide </e1>  does not necessitate an adjustment in  <e2> digoxin </e2>  dose to maintain therapeutic digoxin levels.
effect	 <e1> Buforin II </e1>  may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either  <e2> azithromycin </e2>  or minocycline.
false	Imipramine (5 mg/kg),  <e1> moclobemide </e1>  (30 mg/kg),  <e2> clonazepam </e2>  (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered. 
false	The effect of  <e1> dofetilide </e1>  on the steady-state pharmacokinetics of  <e2> digoxin </e2>  was evaluated in a randomized, double-blind study. 
false	The in vitro anti-cryptosporidial activity of buforin II alone and in combination with  <e1> azithromycin </e1>  and  <e2> minocycline </e2>  was investigated. 
false	Numerous drug interactions are possible with some anticonvulsant agents, such as  <e1> phenobarbitone </e1>  and  <e2> phenytoin </e2> , which affect hepatic microsomal enzyme systems. 
false	Numerous drug interactions are possible with some  <e1> anticonvulsant agents </e1> , such as phenobarbitone and  <e2> phenytoin </e2> , which affect hepatic microsomal enzyme systems. 
false	Moreover, its activity was enhanced when it was combined with either  <e1> azithromycin </e1>  or  <e2> minocycline </e2>  with 90% parasite reduction at the highest concentration tested. 
false	The interaction of intramuscularly injected  <e1> ketamine </e1>  and its N-demethylated metabolite (metabolite I) with  <e2> halothane </e2>  was evaluated in rats. 
false	Numerous drug interactions are possible with some  <e1> anticonvulsant agents </e1> , such as  <e2> phenobarbitone </e2>  and phenytoin, which affect hepatic microsomal enzyme systems. 
mechanism	However,  <e1> halothane </e1>  anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of  <e2> ketamine </e2> , 50 mg/kg, im. 
effect	It is concluded that  <e1> ketamine </e1>  is not a short-acting drug and that concomitant use with  <e2> halothane </e2>  would be expected to prolong further the duration of its action on the central nervous system.
false	The reduction in MAC was correlated with brain levels of  <e1> ketamine </e1>  or metabolite I, suggesting a  <e2> ketamine </e2> :metabolite I potency ration of 3:1. 
int	Interaction of  <e1> ketamine </e1>  and  <e2> halothane </e2>  in rats.
mechanism	The concomitant administration of  <e1> rifampin </e1>  and  <e2> warfarin </e2>  resulted in the need for an unusually high maintenance dose of warfarin (20 mg per day) in order to produce a therapeutic effect. 
false	The effect of rifampin on the  <e1> warfarin </e1>  requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after  <e2> rifampin </e2>  withdrawal. 
false	The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of  <e1> rifampin </e1>  and extended a similar length of time after  <e2> rifampin </e2>  withdrawal. 
false	The concomitant administration of  <e1> rifampin </e1>  and warfarin resulted in the need for an unusually high maintenance dose of  <e2> warfarin </e2>  (20 mg per day) in order to produce a therapeutic effect. 
false	The effect of rifampin on the  <e1> warfarin </e1>  requirement of our patient appeared to be maximal 5 to 7 days after the initiation of  <e2> rifampin </e2>  and extended a similar length of time after rifampin withdrawal. 
mechanism	 <e1> Rifampin </e1>  has been reported to increase the  <e2> warfarin </e2>  requirements in human subjects ingesting these agents simultaneously. 
int	 <e1> Rifampin </e1>  and  <e2> warfarin </e2> : a drug interaction.
effect	The effect of  <e1> rifampin </e1>  on the  <e2> warfarin </e2>  requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal. 
false	The concomitant administration of rifampin and  <e1> warfarin </e1>  resulted in the need for an unusually high maintenance dose of  <e2> warfarin </e2>  (20 mg per day) in order to produce a therapeutic effect. 
mechanism	This effect may be mediated by the ability of  <e1> rifampin </e1>  to induce microsomal enzymes and, thus, the catabolism of  <e2> warfarin </e2> . 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose ( <e1> NaCMC </e1> ) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs,  <e2> bacitracin </e2>  and insulin. 
false	Conjugation at NaCMC with  <e1> cysteine </e1>  moieties significantly improves the intestinal permeation of the hydrophilic molecule  <e2> NaFlu </e2>  and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs,  <e1> bacitracin </e1>  and  <e2> insulin </e2> . 
false	Unmodified  <e1> NaCMC </e1>  (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v) NaCMC conjugated with  <e2> cysteine </e2>  further enhanced the permeation. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and  <e1> carboxymethylcellulose-cysteine </e1>  (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein ( <e2> NaFlu </e2> ) and model peptide drugs, bacitracin and insulin. 
false	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule  <e1> NaFlu </e1>  and the model peptide drugs bacitracin and  <e2> insulin </e2>  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
false	Formulation of fluorescence labelled  <e1> bacitracin </e1>  and  <e2> insulin </e2>  in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine ( <e1> CMC-Cys </e1> ) conjugates on the intestinal permeation of  <e2> sodium fluorescein </e2>  (NaFlu) and model peptide drugs, bacitracin and insulin. 
false	Conjugation at NaCMC with  <e1> cysteine </e1>  moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs  <e2> bacitracin </e2>  and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
false	The purpose of this study was to evaluate the effect of  <e1> sodium carboxymethylcellulose </e1>  ( <e2> NaCMC </e2> ) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 
int	The drug interaction between  <e1> warfarin </e1>  and  <e2> rifampin </e2>  is not well known. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and  <e1> carboxymethylcellulose-cysteine </e1>  (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs,  <e2> bacitracin </e2>  and insulin. 
false	Conjugation at  <e1> NaCMC </e1>  with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs  <e2> bacitracin </e2>  and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
false	The purpose of this study was to evaluate the effect of  <e1> sodium carboxymethylcellulose </e1>  (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs,  <e2> bacitracin </e2>  and insulin. 
false	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule  <e1> NaFlu </e1>  and the model peptide drugs  <e2> bacitracin </e2>  and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
false	Formulation of fluorescence labelled  <e1> bacitracin </e1>  and insulin in unconjugated  <e2> NaCMC </e2>  (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of  <e1> sodium fluorescein </e1>  (NaFlu) and model peptide drugs,  <e2> bacitracin </e2>  and insulin. 
false	Conjugation at NaCMC with cysteine moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs  <e1> bacitracin </e1>  and  <e2> insulin </e2>  in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
false	Unmodified  <e1> NaCMC </e1>  (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v)  <e2> NaCMC </e2>  conjugated with cysteine further enhanced the permeation. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine ( <e1> CMC-Cys </e1> ) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and  <e2> insulin </e2> . 
false	Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of NaFlu to 1.3 and 1% (m/v)  <e1> NaCMC </e1>  conjugated with  <e2> cysteine </e2>  further enhanced the permeation. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and  <e1> carboxymethylcellulose-cysteine </e1>  (CMC-Cys) conjugates on the intestinal permeation of  <e2> sodium fluorescein </e2>  (NaFlu) and model peptide drugs, bacitracin and insulin. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine ( <e1> CMC-Cys </e1> ) conjugates on the intestinal permeation of sodium fluorescein ( <e2> NaFlu </e2> ) and model peptide drugs, bacitracin and insulin. 
false	 <e1> NaCMC </e1>  at 1% (m/v) in the presence of free  <e2> cysteine </e2>  had no significant effect on the R-value of NaFlu compared to NaCMC alone. 
false	 <e1> NaCMC </e1>  at 1% (m/v) in the presence of free cysteine had no significant effect on the R-value of  <e2> NaFlu </e2>  compared to NaCMC alone. 
false	Conjugation at  <e1> NaCMC </e1>  with  <e2> cysteine </e2>  moieties significantly improves the intestinal permeation of the hydrophilic molecule NaFlu and the model peptide drugs bacitracin and insulin in vitro, therefore this conjugated system maybe useful for peroral administration of peptide drugs in the future.
false	Unmodified  <e1> NaCMC </e1>  (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of  <e2> NaFlu </e2>  to 1.3 and 1% (m/v) NaCMC conjugated with cysteine further enhanced the permeation. 
mechanism	Withdrawal of  <e1> rifampin </e1>  decreased the  <e2> warfarin </e2>  requirement by 50%. 
false	Unmodified NaCMC (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of  <e1> NaFlu </e1>  to 1.3 and 1% (m/v) NaCMC conjugated with  <e2> cysteine </e2>  further enhanced the permeation. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose ( <e1> NaCMC </e1> ) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and  <e2> insulin </e2> . 
false	Formulation of fluorescence labelled bacitracin and  <e1> insulin </e1>  in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v)  <e2> CMC-Cys </e2> 7.3 a significantly improved permeation was observed (R= 1.3). 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein ( <e1> NaFlu </e1> ) and model peptide drugs, bacitracin and  <e2> insulin </e2> . 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and  <e1> carboxymethylcellulose-cysteine </e1>  (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and  <e2> insulin </e2> . 
false	NaCMC at 1% (m/v) in the presence of free  <e1> cysteine </e1>  had no significant effect on the R-value of  <e2> NaFlu </e2>  compared to NaCMC alone. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of  <e1> sodium fluorescein </e1>  (NaFlu) and model peptide drugs, bacitracin and  <e2> insulin </e2> . 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose ( <e1> NaCMC </e1> ) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein ( <e2> NaFlu </e2> ) and model peptide drugs, bacitracin and insulin. 
false	Decreasing the concentration of  <e1> CMC-Cys </e1> , exhibiting 7.3% (m/m) of immobilised cysteine (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of  <e2> NaFlu </e2>  from 1.8 to 1.2. 
false	 <e1> Cysteine </e1>  was covalently linked to carbodiimide activated  <e2> NaCMC </e2> . 
false	The purpose of this study was to evaluate the effect of  <e1> sodium carboxymethylcellulose </e1>  (NaCMC) and carboxymethylcellulose-cysteine ( <e2> CMC-Cys </e2> ) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose ( <e1> NaCMC </e1> ) and carboxymethylcellulose-cysteine ( <e2> CMC-Cys </e2> ) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 
false	Formulation of fluorescence labelled  <e1> bacitracin </e1>  and insulin in unconjugated NaCMC (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v)  <e2> CMC-Cys </e2> 7.3 a significantly improved permeation was observed (R= 1.3). 
false	The purpose of this study was to evaluate the effect of  <e1> sodium carboxymethylcellulose </e1>  (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and  <e2> insulin </e2> . 
false	Decreasing the concentration of CMC-Cys, exhibiting 7.3% (m/m) of immobilised  <e1> cysteine </e1>  (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of  <e2> NaFlu </e2>  from 1.8 to 1.2. 
false	The purpose of this study was to evaluate the effect of  <e1> sodium carboxymethylcellulose </e1>  (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of  <e2> sodium fluorescein </e2>  (NaFlu) and model peptide drugs, bacitracin and insulin. 
false	Formulation of fluorescence labelled bacitracin and  <e1> insulin </e1>  in unconjugated  <e2> NaCMC </e2>  (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) CMC-Cys7.3 a significantly improved permeation was observed (R= 1.3). 
false	The purpose of this study was to evaluate the effect of sodium carboxymethylcellulose (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein ( <e1> NaFlu </e1> ) and model peptide drugs,  <e2> bacitracin </e2>  and insulin. 
false	The purpose of this study was to evaluate the effect of  <e1> sodium carboxymethylcellulose </e1>  (NaCMC) and carboxymethylcellulose-cysteine (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein ( <e2> NaFlu </e2> ) and model peptide drugs, bacitracin and insulin. 
false	The purpose of this study was to evaluate the effect of  <e1> sodium carboxymethylcellulose </e1>  (NaCMC) and  <e2> carboxymethylcellulose-cysteine </e2>  (CMC-Cys) conjugates on the intestinal permeation of sodium fluorescein (NaFlu) and model peptide drugs, bacitracin and insulin. 
false	All subjects received  <e1> amprenavir </e1>  (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or  <e2> rifampin </e2>  (600 mg QD) (cohort 2) for 14 days. 
false	Cohort 1 then received  <e1> amprenavir </e1>  plus  <e2> rifabutin </e2>  for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days. 
false	Serial plasma and urine samples for measurement of  <e1> amprenavir </e1> ,  <e2> rifabutin </e2> , and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 
false	 <e1> Rifabutin </e1>  did not significantly affect  <e2> amprenavir </e2> 's pharmacokinetics. 
false	The objective of this study was to determine if there is a pharmacokinetic interaction when  <e1> amprenavir </e1>  is given with rifabutin or  <e2> rifampin </e2>  and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 
mechanism	 <e1> Amprenavir </e1>  significantly increased the area under the curve at steady state (AUC(ss)) of  <e2> rifabutin </e2>  by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold. 
false	All subjects received  <e1> amprenavir </e1>  (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either  <e2> rifabutin </e2>  (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days. 
effect	 <e1> Amprenavir </e1>  plus  <e2> rifabutin </e2>  was poorly tolerated, and 5 of 11 subjects discontinued therapy. 
mechanism	 <e1> Amprenavir </e1>  significantly decreases clearance of rifabutin and  <e2> 25-O-desacetylrifabutin </e2> , and the combination is poorly tolerated. 
false	Pharmacokinetic Interaction between  <e1> amprenavir </e1>  and rifabutin or  <e2> rifampin </e2>  in healthy males.
false	 <e1> Amprenavir </e1>  plus  <e2> rifampin </e2>  was well tolerated. 
false	Rifampin significantly decreased the AUC(ss) of  <e1> amprenavir </e1>  by 82%, but amprenavir had no effect on  <e2> rifampin </e2>  pharmacokinetics. 
false	Pharmacokinetic Interaction between amprenavir and  <e1> rifabutin </e1>  or  <e2> rifampin </e2>  in healthy males.
false	Cohort 1 then received  <e1> amprenavir </e1>  plus rifabutin for 10 days, and cohort 2 received  <e2> amprenavir </e2>  plus rifampin for 4 days. 
false	The objective of this study was to determine if there is a pharmacokinetic interaction when  <e1> amprenavir </e1>  is given with  <e2> rifabutin </e2>  or rifampin and to determine the effects of these drugs on the erythromycin breath test (ERMBT). 
mechanism	 <e1> Rifampin </e1>  markedly increases the metabolic clearance of  <e2> amprenavir </e2> , and coadministration is contraindicated. 
false	All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either  <e1> rifabutin </e1>  (300 mg once a day [QD]) (cohort 1) or  <e2> rifampin </e2>  (600 mg QD) (cohort 2) for 14 days. 
false	Cohort 1 then received  <e1> amprenavir </e1>  plus rifabutin for 10 days, and cohort 2 received amprenavir plus  <e2> rifampin </e2>  for 4 days. 
false	Serial plasma and urine samples for measurement of  <e1> amprenavir </e1> , rifabutin, and  <e2> rifampin </e2>  and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 
false	Rifampin significantly decreased the AUC(ss) of  <e1> amprenavir </e1>  by 82%, but  <e2> amprenavir </e2>  had no effect on rifampin pharmacokinetics. 
false	 <e1> Rifampin </e1>  significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on  <e2> rifampin </e2>  pharmacokinetics. 
false	 <e1> Rifampin </e1>  significantly decreased the AUC(ss) of amprenavir by 82%, but  <e2> amprenavir </e2>  had no effect on rifampin pharmacokinetics. 
false	Serial plasma and urine samples for measurement of amprenavir, rifabutin, and  <e1> rifampin </e1>  and their  <e2> 25-O-desacetyl metabolites </e2> , were measured by high-performance liquid chromatography. 
false	Amprenavir significantly decreases clearance of  <e1> rifabutin </e1>  and  <e2> 25-O-desacetylrifabutin </e2> , and the combination is poorly tolerated. 
mechanism	 <e1> Amprenavir </e1>  significantly decreases clearance of  <e2> rifabutin </e2>  and 25-O-desacetylrifabutin, and the combination is poorly tolerated. 
false	The thiazolidinediones (rosiglitazone and  <e1> pioglitazone </e1> ), a new class of oral  <e2> antidiabetic agents </e2> , are "insulin sensitizers" 
false	 <e1> Amprenavir </e1>  inhibits the ERMBT, and rifampin and  <e2> rifabutin </e2>  are equipotent inducers of the ERMBT.
mechanism	 <e1> Rifampin </e1>  significantly decreased the AUC(ss) of  <e2> amprenavir </e2>  by 82%, but amprenavir had no effect on rifampin pharmacokinetics. 
false	The thiazolidinediones ( <e1> rosiglitazone </e1>  and  <e2> pioglitazone </e2> ), a new class of oral antidiabetic agents, are "insulin sensitizers" 
false	Cohort 1 then received amprenavir plus  <e1> rifabutin </e1>  for 10 days, and cohort 2 received amprenavir plus  <e2> rifampin </e2>  for 4 days. 
false	Serial plasma and urine samples for measurement of amprenavir,  <e1> rifabutin </e1> , and  <e2> rifampin </e2>  and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography. 
false	The  <e1> thiazolidinediones </e1>  (rosiglitazone and  <e2> pioglitazone </e2> ), a new class of oral antidiabetic agents, are "insulin sensitizers" 
false	Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but  <e1> amprenavir </e1>  had no effect on  <e2> rifampin </e2>  pharmacokinetics. 
false	The  <e1> thiazolidinediones </e1>  ( <e2> rosiglitazone </e2>  and pioglitazone), a new class of oral antidiabetic agents, are "insulin sensitizers" 
false	 <e1> Arginine </e1> , in the presence of  <e2> glucose </e2>  and theophylline, caused excessive glucagon release but nearly normal insulin release in the diabetics. 
false	 <e1> Arginine </e1> , in the absence of glucose or  <e2> theophylline </e2> , caused excessive glucagon release in the diabetics and undetectable insulin release in either diabetics or normals. 
false	Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to  <e1> theophylline </e1> , but are relatively insensitive to  <e2> glucose </e2> .
false	To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of  <e1> arginine </e1>  (20mM),  <e2> glucose </e2>  (100 or 150 mg. per 100 ml.), and theophylline (10 mM). 
false	The results of the ERMBT after 2 weeks of  <e1> rifabutin </e1>  and  <e2> rifampin </e2>  therapy were increased 187 and 156%, respectively. 
false	 <e1> Glucose </e1> , alone and in the presence of  <e2> theophylline </e2> , caused subnormal insulin release and less suppression of glucagon release in the diabectics than in the normals. 
false	Arginine, in the presence of  <e1> glucose </e1>  and  <e2> theophylline </e2> , caused excessive glucagon release but nearly normal insulin release in the diabetics. 
false	 <e1> Arginine </e1> , in the presence of glucose and  <e2> theophylline </e2> , caused excessive glucagon release but nearly normal insulin release in the diabetics. 
false	In this study, the effects of  <e1> etofibrate </e1>  upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day  <e2> etofibrate </e2>  or placebo for 1-month. 
false	The  <e1> thiazolidinediones </e1>  (rosiglitazone and pioglitazone), a new class of oral  <e2> antidiabetic agents </e2> , are "insulin sensitizers" 
effect	 <e1> Etofibrate </e1>  elicited 62% enhancement of post- <e2> heparin </e2>  lipolytic activity and 100% increase of 3H-triglyceride fractional clearance rate compared with placebo treatment. 
false	Animals dosed with 1,3-difluoroacetone did not display the 2-3 hour lag phase in either  <e1> (-)-erythro-fluorocitrate </e1>  synthesis or in citrate and fluoride accumulation characteristic of animals dosed with  <e2> 1,3-difluoro-2-propanol </e2> . 
false	Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to  <e1> (-)-erythro-fluorocitrate </e1>  in vivo and to eliminate the fluoride and citrate elevations seen in  <e2> 1,3-difluoro-2-propanol </e2> -intoxicated animals. 
effect	Prior administration of  <e1> 4-methylpyrazole </e1>  (90 mg kg(-1) body weight) was shown to prevent the conversion of  <e2> 1,3-difluoro-2-propanol </e2>  (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 
false	However, administration of 4-methylpyrazole (90 mg kg(-1) body weight) to rats 2 hours prior to  <e1> 1,3-difluoroacetone </e1>  (100 mg kg(-1) body weight) was ineffective in preventing  <e2> (-)-erythro-fluorocitrate </e2>  synthesis and did not diminish fluoride or citrate accumulation in vivo. 
false	Prior administration of 4-methylpyrazole (90 mg kg(-1) body weight) was shown to prevent the conversion of  <e1> 1,3-difluoro-2-propanol </e1>  (100 mg kg(-1) body weight) to  <e2> (-)-erythro-fluorocitrate </e2>  in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 
false	We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with  <e1> 1,3-difluoro-2-propanol </e1>  derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to  <e2> 1,3-difluoroacetone </e2>  in the committed step of the toxic pathway.
false	The mode of toxic action of the pesticide gliftor: the metabolism of  <e1> 1,3-difluoroacetone </e1>  to  <e2> (-)-erythro-fluorocitrate </e2> .
false	However, administration of  <e1> 4-methylpyrazole </e1>  (90 mg kg(-1) body weight) to rats 2 hours prior to  <e2> 1,3-difluoroacetone </e2>  (100 mg kg(-1) body weight) was ineffective in preventing (-)-erythro-fluorocitrate synthesis and did not diminish fluoride or citrate accumulation in vivo. 
false	Prior administration of  <e1> 4-methylpyrazole </e1>  (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to (-)-erythro-fluorocitrate in vivo and to eliminate the fluoride and citrate elevations seen in  <e2> 1,3-difluoro-2-propanol </e2> -intoxicated animals. 
false	Administration of  <e1> 1,3-difluoroacetone </e1>  (100 mg kg(-1) body weight) to rats in vivo resulted in  <e2> (-)-erythro-fluorocitrate </e2>  synthesis in the kidney, which was preceded by an elevation in fluoride levels and followed by citrate accumulation. 
false	We demonstrate that the conversion of 1,3-difluoro-2-propanol to  <e1> 1,3-difluoroacetone </e1>  by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product,  <e2> (-)-erythro-fluorocitrate </e2>  from 1,3-difluoro-2-propanol. 
false	The biochemical toxicology of  <e1> 1,3-difluoroacetone </e1> , a known metabolite of the major ingredient of the pesticide  <e2> Gliftor </e2>  (1,3-difluoro-2-propanol), was investigated in vivo and in vitro. 
false	Prior administration of  <e1> 4-methylpyrazole </e1>  (90 mg kg(-1) body weight) was shown to prevent the conversion of 1,3-difluoro-2-propanol (100 mg kg(-1) body weight) to  <e2> (-)-erythro-fluorocitrate </e2>  in vivo and to eliminate the fluoride and citrate elevations seen in 1,3-difluoro-2-propanol-intoxicated animals. 
false	The biochemical toxicology of  <e1> 1,3-difluoroacetone </e1> , a known metabolite of the major ingredient of the pesticide Gliftor ( <e2> 1,3-difluoro-2-propanol </e2> ), was investigated in vivo and in vitro. 
false	The biochemical toxicology of 1,3-difluoroacetone, a known metabolite of the major ingredient of the pesticide  <e1> Gliftor </e1>  ( <e2> 1,3-difluoro-2-propanol </e2> ), was investigated in vivo and in vitro. 
false	We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting  <e1> 1,3-difluoro-2-propanol </e1>  to  <e2> 1,3-difluoroacetone </e2>  in the committed step of the toxic pathway.
false	The mode of toxic action of the pesticide  <e1> gliftor </e1> : the metabolism of  <e2> 1,3-difluoroacetone </e2>  to (-)-erythro-fluorocitrate.
false	Rat kidney homogenates supplemented with coenzyme A, ATP, oxaloacetate, and Mg2+ converted  <e1> 1,3-difluoroacetone </e1>  to  <e2> (-)-erythro-fluorocitrate </e2>  in vitro. 
false	We demonstrate that the conversion of 1,3-difluoro-2-propanol to 1,3-difluoroacetone by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product,  <e1> (-)-erythro-fluorocitrate </e1>  from  <e2> 1,3-difluoro-2-propanol </e2> . 
false	Animals dosed with  <e1> 1,3-difluoroacetone </e1>  did not display the 2-3 hour lag phase in either (-)-erythro-fluorocitrate synthesis or in citrate and fluoride accumulation characteristic of animals dosed with  <e2> 1,3-difluoro-2-propanol </e2> . 
false	We conclude that the prophylactic and antidotal properties of 4-methylpyrazole seen in animals treated with  <e1> 1,3-difluoro-2-propanol </e1>  derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting  <e2> 1,3-difluoro-2-propanol </e2>  to 1,3-difluoroacetone in the committed step of the toxic pathway.
effect	We conclude that the prophylactic and antidotal properties of  <e1> 4-methylpyrazole </e1>  seen in animals treated with  <e2> 1,3-difluoro-2-propanol </e2>  derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting 1,3-difluoro-2-propanol to 1,3-difluoroacetone in the committed step of the toxic pathway.
false	The mode of toxic action of the pesticide  <e1> gliftor </e1> : the metabolism of 1,3-difluoroacetone to  <e2> (-)-erythro-fluorocitrate </e2> .
false	We conclude that the prophylactic and antidotal properties of  <e1> 4-methylpyrazole </e1>  seen in animals treated with 1,3-difluoro-2-propanol derive from its capacity to inhibit the NAD+-dependent oxidation responsible for converting  <e2> 1,3-difluoro-2-propanol </e2>  to 1,3-difluoroacetone in the committed step of the toxic pathway.
false	 <e1> Green tea polyphenols </e1>  as potent  <e2> enhancers </e2>  of glucocorticoid-induced mouse mammary tumor virus gene expression.
false	We demonstrate that the conversion of  <e1> 1,3-difluoro-2-propanol </e1>  to  <e2> 1,3-difluoroacetone </e2>  by an NAD+-dependent oxidation is the rate-limiting step in the synthesis of the toxic product, (-)-erythro-fluorocitrate from 1,3-difluoro-2-propanol. 
mechanism	CONCLUSIONS: Single-dose  <e1> diltiazem </e1>  coadministration leads to higher  <e2> sirolimus </e2>  exposure, presumably by inhibition of the first-pass metabolism of sirolimus. 
false	AIM AND BACKGROUND: The pharmacokinetic interaction between  <e1> sirolimus </e1> , a macrolide immunosuppressant metabolized by CYP3A4, and the  <e2> calcium channel blocker </e2>  diltiazem was studied in 18 healthy subjects. 
mechanism	RESULTS: The geometric mean (90% confidence interval) whole blood  <e1> sirolimus </e1>  area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with  <e2> diltiazem </e2>  coadministration, whereas the mean elimination half-life of sirolimus decreased slightly, from 79 to 67 hours. 
false	Because of the pronounced intersubject variability in the extent of the sirolimus- <e1> diltiazem </e1>  interaction, whole blood  <e2> sirolimus </e2>  concentrations should be monitored closely in patients treated with the two drugs.
false	AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a  <e1> macrolide immunosuppressant </e1>  metabolized by CYP3A4, and the calcium channel blocker  <e2> diltiazem </e2>  was studied in 18 healthy subjects. 
false	AIM AND BACKGROUND: The pharmacokinetic interaction between  <e1> sirolimus </e1> , a  <e2> macrolide immunosuppressant </e2>  metabolized by CYP3A4, and the calcium channel blocker diltiazem was studied in 18 healthy subjects. 
false	Several clinically important interactions have previously been reported for other  <e1> immunosuppressive drugs </e1>  that are metabolized by the same enzyme and for  <e2> calcium antagonists </e2> . 
false	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of  <e1> sirolimus </e1> , and no potentiation of the effects of  <e2> diltiazem </e2>  on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 
false	CONCLUSIONS: Single-dose  <e1> diltiazem </e1>  coadministration leads to higher sirolimus exposure, presumably by inhibition of the first-pass metabolism of  <e2> sirolimus </e2> . 
false	AIM AND BACKGROUND: The pharmacokinetic interaction between sirolimus, a macrolide immunosuppressant metabolized by CYP3A4, and the  <e1> calcium channel blocker </e1>   <e2> diltiazem </e2>  was studied in 18 healthy subjects. 
false	RESULTS: The geometric mean (90% confidence interval) whole blood sirolimus area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with  <e1> diltiazem </e1>  coadministration, whereas the mean elimination half-life of  <e2> sirolimus </e2>  decreased slightly, from 79 to 67 hours. 
advise	Because of the pronounced intersubject variability in the extent of the  <e1> sirolimus </e1> - <e2> diltiazem </e2>  interaction, whole blood sirolimus concentrations should be monitored closely in patients treated with the two drugs.
false	RESULTS: The geometric mean (90% confidence interval) whole blood  <e1> sirolimus </e1>  area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with diltiazem coadministration, whereas the mean elimination half-life of  <e2> sirolimus </e2>  decreased slightly, from 79 to 67 hours. 
false	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem,  <e1> desacetyldiltiazem </e1> , and  <e2> desmethyldiltiazem </e2>  were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 
false	The plasma maximum concentration and area under the plasma concentration-time curve of  <e1> diltiazem </e1> , desacetyldiltiazem, and  <e2> desmethyldiltiazem </e2>  were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 
false	AIM AND BACKGROUND: The pharmacokinetic interaction between  <e1> sirolimus </e1> , a macrolide immunosuppressant metabolized by CYP3A4, and the calcium channel blocker  <e2> diltiazem </e2>  was studied in 18 healthy subjects. 
false	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem,  <e1> desacetyldiltiazem </e1> , and desmethyldiltiazem were unchanged after coadministration of  <e2> sirolimus </e2> , and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 
false	CONCLUSIONS: Single-dose diltiazem coadministration leads to higher  <e1> sirolimus </e1>  exposure, presumably by inhibition of the first-pass metabolism of  <e2> sirolimus </e2> . 
false	Apparent oral clearance and volume of distribution of  <e1> sirolimus </e1>  decreased with 38% and 45%, respectively, when  <e2> sirolimus </e2>  was given with diltiazem. 
false	The clearance by means of  <e1> 4-hydroxytolbutamide </e1>  and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of  <e2> tolbutamide </e2>  per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 
false	Plasma was analyzed for  <e1> tolbutamide </e1> , and urine was analyzed for  <e2> tolbutamide </e2>  and its two metabolites, 4-hydroxytolbutamide and carboxytolbutamide by means of HPLC. 
false	Plasma was analyzed for  <e1> tolbutamide </e1> , and urine was analyzed for tolbutamide and its two metabolites, 4-hydroxytolbutamide and  <e2> carboxytolbutamide </e2>  by means of HPLC. 
false	Plasma was analyzed for  <e1> tolbutamide </e1> , and urine was analyzed for tolbutamide and its two metabolites,  <e2> 4-hydroxytolbutamide </e2>  and carboxytolbutamide by means of HPLC. 
false	The plasma maximum concentration and area under the plasma concentration-time curve of  <e1> diltiazem </e1> , desacetyldiltiazem, and desmethyldiltiazem were unchanged after coadministration of  <e2> sirolimus </e2> , and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 
false	The clearance by means of 4-hydroxytolbutamide and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of  <e1> tolbutamide </e1>  per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of  <e2> tolbutamide </e2>  per day). 
false	Plasma was analyzed for tolbutamide, and urine was analyzed for  <e1> tolbutamide </e1>  and its two metabolites, 4-hydroxytolbutamide and  <e2> carboxytolbutamide </e2>  by means of HPLC. 
false	The clearance by means of  <e1> 4-hydroxytolbutamide </e1>  and carboxytolbutamide was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of  <e2> tolbutamide </e2>  per day). 
mechanism	RESULTS: During treatment with  <e1> fluvoxamine </e1> , there was a statistically significant decrease in the median of the total clearance of  <e2> tolbutamide </e2> , from 845 mL/h to 688 mL/h, among the volunteers who received 75 mg/d. 
false	Because of the pronounced intersubject variability in the extent of the  <e1> sirolimus </e1> -diltiazem interaction, whole blood  <e2> sirolimus </e2>  concentrations should be monitored closely in patients treated with the two drugs.
false	The plasma maximum concentration and area under the plasma concentration-time curve of diltiazem, desacetyldiltiazem, and  <e1> desmethyldiltiazem </e1>  were unchanged after coadministration of  <e2> sirolimus </e2> , and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 
false	OBJECTIVE: Our objective was to examine the interaction between fluvoxamine and  <e1> tolbutamide </e1>  to confirm that  <e2> fluvoxamine </e2>  inhibits CYP2C9. 
false	The plasma maximum concentration and area under the plasma concentration-time curve of  <e1> diltiazem </e1> ,  <e2> desacetyldiltiazem </e2> , and desmethyldiltiazem were unchanged after coadministration of sirolimus, and no potentiation of the effects of diltiazem on diastolic or systolic blood pressure or on the electrocardiographic parameters was seen. 
mechanism	 <e1> Fluvoxamine </e1>  inhibits the CYP2C9 catalyzed biotransformation of  <e2> tolbutamide </e2> .
false	The clearance by means of 4-hydroxytolbutamide and  <e1> carboxytolbutamide </e1>  was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of  <e2> tolbutamide </e2>  per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of tolbutamide per day). 
false	METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive  <e1> everolimus </e1>  tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and  <e2> prednisone </e2> . 
false	For a 4-fold range of  <e1> everolimus </e1>  doses there were no differential effects on  <e2> cyclosporine </e2>  dosing or pharmacokinetics.
false	METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with  <e1> cyclosporine </e1>  and  <e2> prednisone </e2> . 
false	Plasma was analyzed for tolbutamide, and urine was analyzed for  <e1> tolbutamide </e1>  and its two metabolites,  <e2> 4-hydroxytolbutamide </e2>  and carboxytolbutamide by means of HPLC. 
false	Longitudinal assessment of  <e1> everolimus </e1>  in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on  <e2> cyclosporine </e2> .
false	OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and  <e1> cyclosporine </e1>  (INN,  <e2> ciclosporin </e2> ) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 
false	OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of  <e1> everolimus </e1>  and  <e2> cyclosporine </e2>  (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation. 
false	Blood sampling for the pharmacokinetics of  <e1> everolimus </e1>  and  <e2> cyclosporine </e2>  was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12. 
false	Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous morphine (0.05 mg x kg(-1)), and oral  <e1> ADL 8-2698 </e1>  (4 mg) and intravenous  <e2> morphine </e2>  (0.05 mg x kg(-1)) in a double blind, cross-over study. 
false	The clearance by means of 4-hydroxytolbutamide and  <e1> carboxytolbutamide </e1>  was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of tolbutamide per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of  <e2> tolbutamide </e2>  per day). 
false	 <e1> Morphine </e1>  analgesia and pupil constriction were unaffected by  <e2> ADL 8-2698 </e2>  and differed from placebo (P < .002). 
effect	 <e1> Morphine </e1>  prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by  <e2> ADL 8-2698 </e2>  (P = .004). 
false	 <e1> ADL-8-2698 </e1>  is a novel  <e2> peripherally restricted opioid antagonist </e2>  that may selectively prevent opioid-induced gastrointestinal effects without reversing analgesia. 
effect	We conclude that  <e1> ADL 8-2698 </e1>  prevents  <e2> morphine </e2> -induced increases in gastrointestinal transit time by means of selective peripheral opioid anitagonism without affecting central opioid analgesia.
false	Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous  <e1> morphine </e1>  (0.05 mg x kg(-1)), and oral ADL 8-2698 (4 mg) and intravenous  <e2> morphine </e2>  (0.05 mg x kg(-1)) in a double blind, cross-over study. 
false	METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive  <e1> everolimus </e1>  tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with  <e2> cyclosporine </e2>  and prednisone. 
false	Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous  <e1> morphine </e1>  (0.05 mg x kg(-1)), and oral  <e2> ADL 8-2698 </e2>  (4 mg) and intravenous morphine (0.05 mg x kg(-1)) in a double blind, cross-over study. 
effect	 <e1> ADL 8-2698 </e1> , a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous  <e2> morphine </e2>  without affecting analgesia.
false	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of  <e1> HMG-CoA reductase inhibitors </e1>  that are metabolized by CYP3A4 (i.e., atorvastatin,  <e2> cerivastatin </e2> , lovastatin, simvastatin). 
mechanism	CONCLUSIONS:  <e1> Macrolide antibiotics </e1>  inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin,  <e2> simvastatin </e2> ). 
false	CONCLUSIONS:  <e1> Macrolide antibiotics </e1>  inhibit the metabolism of  <e2> HMG-CoA reductase inhibitors </e2>  that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin). 
false	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e.,  <e1> atorvastatin </e1> , cerivastatin, lovastatin,  <e2> simvastatin </e2> ). 
effect	Rhabdomyolysis secondary to a drug interaction between  <e1> simvastatin </e1>  and  <e2> clarithromycin </e2> .
false	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin,  <e1> cerivastatin </e1> ,  <e2> lovastatin </e2> , simvastatin). 
false	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e.,  <e1> atorvastatin </e1> , cerivastatin,  <e2> lovastatin </e2> , simvastatin). 
false	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of  <e1> HMG-CoA reductase inhibitors </e1>  that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin,  <e2> lovastatin </e2> , simvastatin). 
mechanism	DISCUSSION:  <e1> Clarithromycin </e1>  is a potent inhibitor of CYP3A4, the major enzyme responsible for  <e2> simvastatin </e2>  metabolism. 
mechanism	CONCLUSIONS:  <e1> Macrolide antibiotics </e1>  inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e.,  <e2> atorvastatin </e2> , cerivastatin, lovastatin, simvastatin). 
false	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of  <e1> HMG-CoA reductase inhibitors </e1>  that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin,  <e2> simvastatin </e2> ). 
false	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin,  <e1> cerivastatin </e1> , lovastatin,  <e2> simvastatin </e2> ). 
mechanism	CONCLUSIONS:  <e1> Macrolide antibiotics </e1>  inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin,  <e2> lovastatin </e2> , simvastatin). 
false	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e.,  <e1> atorvastatin </e1> ,  <e2> cerivastatin </e2> , lovastatin, simvastatin). 
effect	The concomitant administration of  <e1> macrolide antibiotics </e1>  and other  <e2> hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors </e2>  have resulted in previous reports of rhabdomyolysis. 
false	CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of  <e1> HMG-CoA reductase inhibitors </e1>  that are metabolized by CYP3A4 (i.e.,  <e2> atorvastatin </e2> , cerivastatin, lovastatin, simvastatin). 
false	The effects of concomitant  <e1> phenytoin </e1>  administration on the steady-state pharmacokinetics of  <e2> quetiapine </e2> .
mechanism	This study demonstrated that the potent cytochrome P450 enzyme-inducer  <e1> phenytoin </e1>  did indeed have a marked effect on the metabolism of  <e2> quetiapine </e2> , resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder. 
false	Quetiapine fumarate (' <e1> Seroquel </e1> ') is a newly introduced  <e2> atypical antipsychotic </e2>  with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/ <e1> valproic acid </e1> ,  <e2> quinidine </e2> /lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	 <e1> Quetiapine fumarate </e1>  (' <e2> Seroquel </e2> ') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia. 
false	 <e1> acetaminophen </e1> /theophylline, lidocaine/quinidine, phenobarbital/acetaminophen,  <e2> phenobarbital </e2> /valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	 <e1> acetaminophen </e1> / <e2> theophylline </e2> , lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	Coingestion of acetaminophen with  <e1> theophylline </e1> , phenobarbital with  <e2> acetaminophen </e2> , and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 
mechanism	 <e1> Theophylline </e1>  decreased the binding of  <e2> acetaminophen </e2>  by a net change of 6.8% (percentage increase in FDF, 8.8%) at 277.5 micromol/L; 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen,  <e1> phenobarbital </e1> /valproic acid,  <e2> quinidine </e2> /lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	Coingestion of acetaminophen with theophylline,  <e1> phenobarbital </e1>  with acetaminophen, and  <e2> valproic acid </e2>  with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/ <e1> theophylline </e1> , lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/ <e2> valproic acid </e2> , quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid,  <e1> quinidine </e1> /lidocaine,  <e2> theophylline </e2> /acetaminophen, and valproic acid/phenobarbital. 
false	Similarly dialyzed were  <e1> phenobarbital </e1> ,  <e2> quinidine </e2> , and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 
false	Acetaminophen,  <e1> lidocaine </e1> , phenobarbital,  <e2> quinidine </e2> , theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 
mechanism	 <e1> Valproic acid </e1>  diminished binding of  <e2> phenobarbital </e2>  by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L. 
false	 <e1> Acetaminophen </e1> , lidocaine,  <e2> phenobarbital </e2> , quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/ <e1> valproic acid </e1> , quinidine/lidocaine, theophylline/acetaminophen, and  <e2> valproic acid </e2> /phenobarbital. 
false	acetaminophen/ <e1> theophylline </e1> , lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/ <e2> acetaminophen </e2> , and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/ <e1> lidocaine </e1> , theophylline/ <e2> acetaminophen </e2> , and valproic acid/phenobarbital. 
false	 <e1> acetaminophen </e1> /theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/ <e2> phenobarbital </e2> . 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/ <e1> valproic acid </e1> , quinidine/lidocaine, theophylline/ <e2> acetaminophen </e2> , and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen,  <e1> phenobarbital </e1> /valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/ <e2> phenobarbital </e2> . 
false	acetaminophen/theophylline, lidocaine/quinidine,  <e1> phenobarbital </e1> /acetaminophen, phenobarbital/valproic acid,  <e2> quinidine </e2> /lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	 <e1> Acetaminophen </e1> ,  <e2> lidocaine </e2> , phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/ <e1> acetaminophen </e1> , phenobarbital/valproic acid,  <e2> quinidine </e2> /lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	 <e1> acetaminophen </e1> /theophylline, lidocaine/quinidine, phenobarbital/ <e2> acetaminophen </e2> , phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	 <e1> Acetaminophen </e1> , lidocaine, phenobarbital,  <e2> quinidine </e2> , theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen,  <e1> phenobarbital </e1> /valproic acid, quinidine/lidocaine,  <e2> theophylline </e2> /acetaminophen, and valproic acid/phenobarbital. 
false	 <e1> acetaminophen </e1> /theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine,  <e2> theophylline </e2> /acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline,  <e1> lidocaine </e1> /quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine,  <e2> theophylline </e2> /acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline,  <e1> lidocaine </e1> /quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid,  <e2> quinidine </e2> /lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	Coingestion of acetaminophen with theophylline, phenobarbital with  <e1> acetaminophen </e1> , and  <e2> valproic acid </e2>  with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/theophylline, lidocaine/ <e1> quinidine </e1> , phenobarbital/acetaminophen, phenobarbital/ <e2> valproic acid </e2> , quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/ <e1> theophylline </e1> , lidocaine/quinidine, phenobarbital/acetaminophen,  <e2> phenobarbital </e2> /valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline,  <e1> lidocaine </e1> /quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/ <e2> acetaminophen </e2> , and valproic acid/phenobarbital. 
false	Coingestion of acetaminophen with theophylline,  <e1> phenobarbital </e1>  with acetaminophen, and valproic acid with  <e2> phenobarbital </e2>  at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/ <e1> lidocaine </e1> , theophylline/acetaminophen, and  <e2> valproic acid </e2> /phenobarbital. 
false	Acetaminophen,  <e1> lidocaine </e1> , phenobarbital, quinidine, theophylline, and  <e2> valproic acid </e2>  were added to pooled human serum at therapeutic concentrations. 
false	Coingestion of acetaminophen with  <e1> theophylline </e1> , phenobarbital with acetaminophen, and valproic acid with  <e2> phenobarbital </e2>  at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/theophylline, lidocaine/quinidine,  <e1> phenobarbital </e1> /acetaminophen, phenobarbital/ <e2> valproic acid </e2> , quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
effect	Coingestion of  <e1> acetaminophen </e1>  with  <e2> theophylline </e2> , phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen,  <e1> phenobarbital </e1> / <e2> valproic acid </e2> , quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine,  <e1> phenobarbital </e1> /acetaminophen,  <e2> phenobarbital </e2> /valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/ <e1> acetaminophen </e1> , phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/ <e2> phenobarbital </e2> . 
false	acetaminophen/theophylline, lidocaine/quinidine,  <e1> phenobarbital </e1> /acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and  <e2> valproic acid </e2> /phenobarbital. 
false	acetaminophen/theophylline,  <e1> lidocaine </e1> /quinidine,  <e2> phenobarbital </e2> /acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	Acetaminophen, lidocaine, phenobarbital,  <e1> quinidine </e1> , theophylline, and  <e2> valproic acid </e2>  were added to pooled human serum at therapeutic concentrations. 
false	Coingestion of  <e1> acetaminophen </e1>  with theophylline,  <e2> phenobarbital </e2>  with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/ <e1> lidocaine </e1> ,  <e2> theophylline </e2> /acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/ <e1> theophylline </e1> , lidocaine/quinidine, phenobarbital/ <e2> acetaminophen </e2> , phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	 <e1> acetaminophen </e1> /theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/ <e2> acetaminophen </e2> , and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine,  <e1> theophylline </e1> /acetaminophen, and valproic acid/ <e2> phenobarbital </e2> . 
false	acetaminophen/ <e1> theophylline </e1> , lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine,  <e2> theophylline </e2> /acetaminophen, and valproic acid/phenobarbital. 
false	Coingestion of  <e1> acetaminophen </e1>  with theophylline, phenobarbital with acetaminophen, and valproic acid with  <e2> phenobarbital </e2>  at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/ <e1> valproic acid </e1> , quinidine/lidocaine,  <e2> theophylline </e2> /acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid,  <e1> quinidine </e1> / <e2> lidocaine </e2> , theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/ <e1> quinidine </e1> , phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and  <e2> valproic acid </e2> /phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen,  <e1> phenobarbital </e1> /valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and  <e2> valproic acid </e2> /phenobarbital. 
false	Similarly dialyzed were phenobarbital,  <e1> quinidine </e1> , and theophylline, both alone at therapeutic concentrations in serum and with  <e2> ethanol </e2>  at three different concentrations in serum. 
false	Coingestion of acetaminophen with theophylline, phenobarbital with  <e1> acetaminophen </e1> , and valproic acid with  <e2> phenobarbital </e2>  at high to toxic concentrations decreases the binding of the target drug. 
false	The following eight target drug/added drug combinations were studied:  <e1> acetaminophen </e1> / <e2> phenobarbital </e2> . 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen,  <e1> phenobarbital </e1> /valproic acid, quinidine/ <e2> lidocaine </e2> , theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline,  <e1> lidocaine </e1> /quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and  <e2> valproic acid </e2> /phenobarbital. 
false	Acetaminophen,  <e1> lidocaine </e1> , phenobarbital, quinidine,  <e2> theophylline </e2> , and valproic acid were added to pooled human serum at therapeutic concentrations. 
false	 <e1> acetaminophen </e1> /theophylline,  <e2> lidocaine </e2> /quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/ <e1> theophylline </e1> , lidocaine/ <e2> quinidine </e2> , phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/ <e1> theophylline </e1> , lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/ <e2> lidocaine </e2> , theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	 <e1> acetaminophen </e1> /theophylline, lidocaine/quinidine,  <e2> phenobarbital </e2> /acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline,  <e1> lidocaine </e1> / <e2> quinidine </e2> , phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
effect	Coingestion of acetaminophen with theophylline,  <e1> phenobarbital </e1>  with  <e2> acetaminophen </e2> , and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 
false	acetaminophen/theophylline, lidocaine/ <e1> quinidine </e1> , phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/ <e2> lidocaine </e2> , theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/ <e1> quinidine </e1> , phenobarbital/ <e2> acetaminophen </e2> , phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid,  <e1> quinidine </e1> /lidocaine, theophylline/acetaminophen, and  <e2> valproic acid </e2> /phenobarbital. 
false	acetaminophen/theophylline, lidocaine/ <e1> quinidine </e1> , phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/ <e2> acetaminophen </e2> , and valproic acid/phenobarbital. 
false	Similarly dialyzed were phenobarbital, quinidine, and  <e1> theophylline </e1> , both alone at therapeutic concentrations in serum and with  <e2> ethanol </e2>  at three different concentrations in serum. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/ <e1> acetaminophen </e1> , and  <e2> valproic acid </e2> /phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/ <e1> acetaminophen </e1> , phenobarbital/ <e2> valproic acid </e2> , quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/ <e1> theophylline </e1> , lidocaine/quinidine,  <e2> phenobarbital </e2> /acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/ <e1> valproic acid </e1> , quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/ <e2> phenobarbital </e2> . 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/ <e1> acetaminophen </e1> , and valproic acid/ <e2> phenobarbital </e2> . 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid,  <e1> quinidine </e1> /lidocaine, theophylline/acetaminophen, and valproic acid/ <e2> phenobarbital </e2> . 
false	Acetaminophen, lidocaine,  <e1> phenobarbital </e1> , quinidine,  <e2> theophylline </e2> , and valproic acid were added to pooled human serum at therapeutic concentrations. 
false	acetaminophen/theophylline,  <e1> lidocaine </e1> /quinidine, phenobarbital/acetaminophen,  <e2> phenobarbital </e2> /valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	 <e1> acetaminophen </e1> /theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and  <e2> valproic acid </e2> /phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/ <e1> acetaminophen </e1> , phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and  <e2> valproic acid </e2> /phenobarbital. 
false	The serum concentration of  <e1> phenytoin </e1>  increased dramatically from 16.6 to 49.1 microg/mL when  <e2> fluvoxamine </e2>  was coadministered, although the daily dosage of phenytoin and other drugs had not changed. 
false	Similarly dialyzed were  <e1> phenobarbital </e1> , quinidine, and  <e2> theophylline </e2> , both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/ <e1> acetaminophen </e1> , phenobarbital/valproic acid, quinidine/lidocaine, theophylline/ <e2> acetaminophen </e2> , and valproic acid/phenobarbital. 
false	acetaminophen/ <e1> theophylline </e1> , lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid,  <e2> quinidine </e2> /lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when  <e1> fluvoxamine </e1>  was coadministered, although the daily dosage of phenytoin and other  <e2> drugs </e2>  had not changed. 
false	acetaminophen/theophylline, lidocaine/quinidine,  <e1> phenobarbital </e1> /acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/ <e2> phenobarbital </e2> . 
false	Similarly dialyzed were  <e1> phenobarbital </e1> , quinidine, and theophylline, both alone at therapeutic concentrations in serum and with  <e2> ethanol </e2>  at three different concentrations in serum. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/ <e1> lidocaine </e1> , theophylline/acetaminophen, and valproic acid/ <e2> phenobarbital </e2> . 
false	acetaminophen/theophylline,  <e1> lidocaine </e1> /quinidine, phenobarbital/ <e2> acetaminophen </e2> , phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine,  <e1> theophylline </e1> /acetaminophen, and  <e2> valproic acid </e2> /phenobarbital. 
false	The serum concentration of phenytoin increased dramatically from 16.6 to 49.1 microg/mL when  <e1> fluvoxamine </e1>  was coadministered, although the daily dosage of  <e2> phenytoin </e2>  and other drugs had not changed. 
false	acetaminophen/theophylline,  <e1> lidocaine </e1> /quinidine, phenobarbital/acetaminophen, phenobarbital/ <e2> valproic acid </e2> , quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	During  <e1> phenytoin </e1>  and fluvoxamine treatment, ataxia, a typical side effect of  <e2> phenytoin </e2> , was observed. 
false	Coingestion of acetaminophen with  <e1> theophylline </e1> , phenobarbital with acetaminophen, and  <e2> valproic acid </e2>  with phenobarbital at high to toxic concentrations decreases the binding of the target drug. 
false	 <e1> Acetaminophen </e1> , lidocaine, phenobarbital, quinidine,  <e2> theophylline </e2> , and valproic acid were added to pooled human serum at therapeutic concentrations. 
false	 <e1> acetaminophen </e1> /theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/ <e2> valproic acid </e2> , quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital. 
false	acetaminophen/theophylline, lidocaine/quinidine,  <e1> phenobarbital </e1> /acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/ <e2> acetaminophen </e2> , and valproic acid/phenobarbital. 
false	Here we show that a combination of  <e1> galangin </e1>  or 3,7-dihydroxyflavone with  <e2> vancomycin </e2>  may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains. 
false	The genotypes of  <e1> CYP2C9 </e1>  and 2C19, the enzymes responsible for phenytoin metabolism, were homozygous for the wild-type alleles ( <e2> CYP2C9 </e2> *1/*1 and 2C19*1/ *1). 
false	acetaminophen/theophylline,  <e1> lidocaine </e1> /quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/ <e2> phenobarbital </e2> . 
false	The serum concentration of  <e1> phenytoin </e1>  increased dramatically from 16.6 to 49.1 microg/mL when fluvoxamine was coadministered, although the daily dosage of  <e2> phenytoin </e2>  and other drugs had not changed. 
false	Acetaminophen,  <e1> lidocaine </e1> ,  <e2> phenobarbital </e2> , quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations. 
false	AIMS/HYPOTHESIS: There is evidence that  <e1> insulin </e1>  and  <e2> glucose </e2>  cause renal and ocular vasodilation. 
false	Haemodynamic effects of  <e1> glucose </e1>  and  <e2> insulin </e2>  were additive when somatostatin was co-administered but not under basal conditions. 
false	Haemodynamic effects of glucose and  <e1> insulin </e1>  were additive when  <e2> somatostatin </e2>  was co-administered but not under basal conditions. 
false	 <e1> Glucose </e1>  and  <e2> insulin </e2>  exert additive ocular and renal vasodilator effects on healthy humans.
mechanism	Previous studies have demonstrated a significant reduction in the oral bioavailability of  <e1> trovafloxacin </e1>  and ciprofloxacin when administered concomitantly with an intravenous opiate such as  <e2> morphine </e2> . 
false	1 hour after starting the  <e1> oxycodone </e1>  or  <e2> levofloxacin </e2>  500 mg p.o. 
false	Previous studies have demonstrated a significant reduction in the oral bioavailability of  <e1> trovafloxacin </e1>  and  <e2> ciprofloxacin </e2>  when administered concomitantly with an intravenous opiate such as morphine. 
mechanism	Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and  <e1> ciprofloxacin </e1>  when administered concomitantly with an intravenous  <e2> opiate </e2>  such as morphine. 
false	Haemodynamic effects of  <e1> glucose </e1>  and insulin were additive when  <e2> somatostatin </e2>  was co-administered but not under basal conditions. 
false	There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for  <e1> levofloxacin </e1>  versus levofloxacin/ <e2> oxycodone </e2>  regimens. 
false	There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus  <e1> levofloxacin </e1> / <e2> oxycodone </e2>  regimens. 
false	The authors investigated the possibility of a similar interaction between  <e1> oxycodone </e1>  and  <e2> levofloxacin </e2> . 
false	This decrease in absorption results in a 36% and 50% lower AUC for  <e1> trovafloxacin </e1>  and  <e2> ciprofloxacin </e2> , respectively, which could cause clinical failures. 
false	The  <e1> zidovudine </e1>  study dosed subjects with 1200 mg/day of  <e2> azithromycin </e2>  (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine. 
false	The  <e1> zidovudine </e1>  study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of  <e2> zidovudine </e2> . 
false	Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the  <e1> zidovudine </e1>  tmax by 44% and increased the intracellular exposure to phosphorylated  <e2> zidovudine </e2>  by 110%. 
false	Azithromycin had no significant impact on the Cmax and AUC of  <e1> zidovudine </e1> , although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated  <e2> zidovudine </e2>  by 110%. 
false	Lack of an effect of  <e1> azithromycin </e1>  on the disposition of  <e2> zidovudine </e2>  and dideoxyinosine in HIV-infected patients.
false	The zidovudine study dosed subjects with 1200 mg/day of  <e1> azithromycin </e1>  (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of  <e2> zidovudine </e2> . 
false	Lack of an effect of  <e1> azithromycin </e1>  on the disposition of zidovudine and  <e2> dideoxyinosine </e2>  in HIV-infected patients.
false	Antiretroviral plasma and urine sampling were conducted on Days 1, 7, and 21 for  <e1> zidovudine </e1>  and on Days 7 and 21 for  <e2> dideoxyinosine </e2> . 
false	 <e1> Azithromycin </e1>  had no significant impact on the Cmax and AUC of  <e2> zidovudine </e2> , although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 
false	Two studies were conducted in HIV-infected subjects to assess the potential for azithromycin to interact with  <e1> zidovudine </e1>  and  <e2> dideoxyinosine </e2> . 
mechanism	 <e1> Azithromycin </e1>  had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the  <e2> zidovudine </e2>  tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 
mechanism	 <e1> Azithromycin </e1>  had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated  <e2> zidovudine </e2>  by 110%. 
false	Two studies were conducted in HIV-infected subjects to assess the potential for  <e1> azithromycin </e1>  to interact with zidovudine and  <e2> dideoxyinosine </e2> . 
false	Based on the results of these studies, it is concluded that  <e1> azithromycin </e1>  may be safely coadministered with both  <e2> zidovudine </e2>  and dideoxyinosine.
false	 <e1> Antiretroviral </e1>  plasma and urine sampling were conducted on Days 1, 7, and 21 for  <e2> zidovudine </e2>  and on Days 7 and 21 for dideoxyinosine. 
false	Based on the results of these studies, it is concluded that  <e1> azithromycin </e1>  may be safely coadministered with both zidovudine and  <e2> dideoxyinosine </e2> .
false	Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both  <e1> zidovudine </e1>  and  <e2> dideoxyinosine </e2> .
effect	Similarly,  <e1> diazepam </e1>  decreased the antinociceptive effect of  <e2> metamizol </e2>  (only in the tail-flick test) and indomethacin. 
false	Effect of diazepam and midazolam on the antinociceptive effect of  <e1> morphine </e1> , metamizol and  <e2> indomethacin </e2>  in mice.
effect	Similarly,  <e1> diazepam </e1>  decreased the antinociceptive effect of metamizol (only in the tail-flick test) and  <e2> indomethacin </e2> . 
false	The influence of midazolam and  <e1> diazepam </e1>  on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and  <e2> indomethacin </e2>  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 
false	The influence of midazolam and diazepam on antinociceptive effect of morphine (10 mg/kg),  <e1> metamizol </e1>  (500 mg/kg) and  <e2> indomethacin </e2>  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 
false	 <e1> Azithromycin </e1>  had no significant effect on  <e2> dideoxyinosine </e2>  pharmacokinetics. 
false	Effect of  <e1> diazepam </e1>  and midazolam on the antinociceptive effect of morphine, metamizol and  <e2> indomethacin </e2>  in mice.
false	Diazepam at doses of 0.25 mg/kg and 2.5 mg/kg injected with  <e1> morphine </e1>  was found to decrease the antinociceptive effect of  <e2> morphine </e2> . 
false	Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of  <e1> morphine </e1> , metamizol (only in the tail-flick test) and  <e2> indomethacin </e2> .
false	Effect of diazepam and midazolam on the antinociceptive effect of  <e1> morphine </e1> ,  <e2> metamizol </e2>  and indomethacin in mice.
false	The influence of midazolam and diazepam on antinociceptive effect of  <e1> morphine </e1>  (10 mg/kg),  <e2> metamizol </e2>  (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 
false	Subjects treated with 200 mg of  <e1> dideoxyinosine </e1>  twice daily for 21 days received 1200 mg of  <e2> azithromycin </e2>  or an equivalent amount of placebo/day for Days 8 to 21. 
false	Effect of diazepam and  <e1> midazolam </e1>  on the antinociceptive effect of morphine,  <e2> metamizol </e2>  and indomethacin in mice.
false	The influence of midazolam and diazepam on antinociceptive effect of  <e1> morphine </e1>  (10 mg/kg), metamizol (500 mg/kg) and  <e2> indomethacin </e2>  (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 
false	 <e1> Acetaminophen </e1> , lidocaine, phenobarbital, quinidine, theophylline, and  <e2> valproic acid </e2>  were added to pooled human serum at therapeutic concentrations. 
false	Effect of diazepam and  <e1> midazolam </e1>  on the antinociceptive effect of morphine, metamizol and  <e2> indomethacin </e2>  in mice.
false	Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of  <e1> morphine </e1> ,  <e2> metamizol </e2>  (only in the tail-flick test) and indomethacin.
false	 <e1> Benzodiazepines </e1>  were administered to mice 30 min before applying the  <e2> analgesic drugs </e2> . 
effect	 <e1> Diazepam </e1>  at doses of 0.25 mg/kg and 2.5 mg/kg injected with  <e2> morphine </e2>  was found to decrease the antinociceptive effect of morphine. 
false	Similarly, diazepam decreased the antinociceptive effect of  <e1> metamizol </e1>  (only in the tail-flick test) and  <e2> indomethacin </e2> . 
effect	 <e1> Midazolam </e1>  used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine,  <e2> metamizol </e2>  (only in the tail-flick test) and indomethacin.
false	The influence of midazolam and  <e1> diazepam </e1>  on antinociceptive effect of  <e2> morphine </e2>  (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 
false	Effect of  <e1> diazepam </e1>  and  <e2> midazolam </e2>  on the antinociceptive effect of morphine, metamizol and indomethacin in mice.
false	Effect of diazepam and  <e1> midazolam </e1>  on the antinociceptive effect of  <e2> morphine </e2> , metamizol and indomethacin in mice.
false	Azithromycin had no significant impact on the Cmax and AUC of  <e1> zidovudine </e1> , although it significantly decreased the  <e2> zidovudine </e2>  tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%. 
false	The influence of  <e1> midazolam </e1>  and  <e2> diazepam </e2>  on antinociceptive effect of morphine (10 mg/kg), metamizol (500 mg/kg) and indomethacin (10 mg/kg) was investigated in a mouse model using the tail-flick and hot-plate tests. 
effect	 <e1> Midazolam </e1>  used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine, metamizol (only in the tail-flick test) and  <e2> indomethacin </e2> .
false	Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-,  <e1> progesterone </e1> - and  <e2> progesterone </e2>  + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 
false	Endothelium-intact aortic rings from high- <e1> estradiol </e1>  rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and  <e2> progesterone </e2>  + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 
false	Midazolam used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of morphine,  <e1> metamizol </e1>  (only in the tail-flick test) and  <e2> indomethacin </e2> .
false	Endothelium-intact aortic rings from high- <e1> estradiol </e1>  rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and progesterone + high- <e2> estradiol </e2> -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 
effect	Aortic rings with intact endothelium from the high-dose (4 mg/kg/day)  <e1> estradiol </e1>  group were supersensitive to  <e2> noradrenaline </e2>  compared to the vehicle or low-dose (10 microg/kg/day) estradiol groups (pD2 values = 7.86+/-0.09, 7.30+/-0.11 and 7.35+/-0.04, respectively). 
false	Influence of  <e1> estradiol </e1>  and  <e2> progesterone </e2>  on the sensitivity of rat thoracic aorta to noradrenaline.
false	Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-, progesterone- and  <e1> progesterone </e1>  + high- <e2> estradiol </e2> -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 
false	injection of vehicle (corn oil, 0.1 mL/day),  <e1> estradiol </e1>  (10 microg/kg/day or 4 mg/kg/day) and/or  <e2> progesterone </e2>  (20 mg/kg/day), for eight days. 
false	Endothelium-intact aortic rings from high-estradiol rats were supersensitive to  <e1> noradrenaline </e1>  when compared to vehicle-, progesterone- and progesterone + high- <e2> estradiol </e2> -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 
false	Endothelium-intact aortic rings from high-estradiol rats were supersensitive to noradrenaline when compared to vehicle-,  <e1> progesterone </e1> - and progesterone + high- <e2> estradiol </e2> -treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 
false	Endothelium-intact aortic rings from high-estradiol rats were supersensitive to  <e1> noradrenaline </e1>  when compared to vehicle-, progesterone- and  <e2> progesterone </e2>  + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 
false	The aim of this study was to investigate the effects of low and high doses of estradiol, and of  <e1> progesterone </e1>  on the response to  <e2> noradrenaline </e2>  in rat thoracic aorta. 
false	No interactions have been observed with  <e1> beta-receptor blockers </e1> , calcium antagonists, thiazide and  <e2> loop diuretics </e2>  and ACE inhibitors. 
false	No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and loop  <e1> diuretics </e1>  and  <e2> ACE inhibitors </e2> . 
false	No interactions have been observed with  <e1> beta-receptor blockers </e1> , calcium antagonists, thiazide and loop  <e2> diuretics </e2>  and ACE inhibitors. 
false	 <e1> Diazepam </e1>  at doses of 0.25 mg/kg and 2.5 mg/kg injected with morphine was found to decrease the antinociceptive effect of  <e2> morphine </e2> . 
effect	Endothelium-intact aortic rings from high- <e1> estradiol </e1>  rats were supersensitive to  <e2> noradrenaline </e2>  when compared to vehicle-, progesterone- and progesterone + high-estradiol-treated rats (pD2 values = 7.77+/-0.12, 7.21+/-0.13, 6.93+/-0.04 and 7.22+/-0.18, respectively). 
false	No interactions have been observed with  <e1> beta-receptor blockers </e1> , calcium antagonists, thiazide and loop diuretics and  <e2> ACE inhibitors </e2> . 
false	No interactions have been observed with beta-receptor blockers,  <e1> calcium antagonists </e1> , thiazide and loop  <e2> diuretics </e2>  and ACE inhibitors. 
false	Sildenafil is contraindicated in patients using  <e1> long-acting nitrates </e1>  or who may need to use  <e2> short-acting nitrates </e2> , because the combination may cause a sharp fall of the blood pressure. 
false	No interactions have been observed with beta-receptor blockers,  <e1> calcium antagonists </e1> , thiazide and loop diuretics and  <e2> ACE inhibitors </e2> . 
advise	 <e1> Sildenafil </e1>  is contraindicated in patients using  <e2> long-acting nitrates </e2>  or who may need to use short-acting nitrates, because the combination may cause a sharp fall of the blood pressure. 
false	Influence of  <e1> estradiol </e1>  and progesterone on the sensitivity of rat thoracic aorta to  <e2> noradrenaline </e2> .
false	No interactions have been observed with beta-receptor blockers, calcium antagonists, thiazide and  <e1> loop diuretics </e1>  and  <e2> ACE inhibitors </e2> . 
mechanism	Coadministration of  <e1> fluoxetine </e1>  significantly decreased  <e2> cisapride </e2>  plasma concentrations. 
false	Influence of coadministration of  <e1> fluoxetine </e1>  on  <e2> cisapride </e2>  pharmacokinetics and QTc intervals in healthy volunteers.
false	The aim of this study was to investigate the effects of low and high doses of  <e1> estradiol </e1> , and of progesterone on the response to  <e2> noradrenaline </e2>  in rat thoracic aorta. 
advise	 <e1> Sildenafil </e1>  is contraindicated in patients using long-acting nitrates or who may need to use  <e2> short-acting nitrates </e2> , because the combination may cause a sharp fall of the blood pressure. 
false	STUDY OBJECTIVE: To evaluate the effect of  <e1> fluoxetine </e1>  on the pharmacokinetics and cardiovascular safety of  <e2> cisapride </e2>  at steady state in healthy men. 
false	 <e1> Cisapride </e1>  was well tolerated when administered alone or with  <e2> fluoxetine </e2> . 
false	The reduced risk of adverse events and therapeutic superiority compared with haloperidol and  <e1> risperidone </e1>  in the treatment of negative and depressive symptoms support the choice of  <e2> olanzapine </e2>  as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
false	Improvements in general cognitive function seen with olanzapine treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either  <e1> risperidone </e1>  or  <e2> haloperidol </e2> . 
false	Pharmacoeconomic analyses indicate that  <e1> olanzapine </e1>  does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with  <e2> haloperidol </e2> . 
false	 <e1> Olanzapine </e1> , a thienobenzodiazepine derivative, is a  <e2> second generation (atypical) antipsychotic agent </e2>  which has proven efficacy against the positive and negative symptoms of schizophrenia. 
false	In the first double-blind comparative study (28-week) of olanzapine and  <e1> risperidone </e1> ,  <e2> olanzapine </e2>  10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 
false	In comparison with  <e1> haloperidol </e1> , the adverse events reported significantly more frequently with olanzapine in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with  <e2> olanzapine </e2> . 
false	The reduced risk of adverse events and therapeutic superiority compared with  <e1> haloperidol </e1>  and  <e2> risperidone </e2>  in the treatment of negative and depressive symptoms support the choice of olanzapine as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
false	CONCLUSIONS:  <e1> Olanzapine </e1>  demonstrated superior antipsychotic efficacy compared with  <e2> haloperidol </e2>  in the treatment of acute phase schizophrenia, and in the treatment of some patients with first-episode or treatment-resistant schizophrenia. 
false	The reduced risk of adverse events and therapeutic superiority compared with  <e1> haloperidol </e1>  and risperidone in the treatment of negative and depressive symptoms support the choice of  <e2> olanzapine </e2>  as a first-line option in the management of schizophrenia in the acute phase and for the maintenance of treatment response.
false	In contrast, preliminary results from an 8-week controlled study suggested  <e1> risperidone </e1>  2 to 6 mg/day was superior to  <e2> olanzapine </e2>  5 to 20 mg/day against positive and anxiety/depressive symptoms (p < 0.05), although consistent with the first study, both agents demonstrated similar efficacy on measures of overall psychopathology. 
false	Olanzapine treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than  <e1> haloperidol </e1> , and to broadly the same extent as  <e2> risperidone </e2> . 
false	 <e1> Olanzapine </e1>  is associated with significantly fewer extrapyramidal symptoms than  <e2> haloperidol </e2>  and risperidone. 
false	In the first double-blind comparative study (28-week) of olanzapine and  <e1> risperidone </e1> , olanzapine 10 to 20 mg/day proved to be significantly more effective than  <e2> risperidone </e2>  4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 
false	No interactions have been observed with  <e1> beta-receptor blockers </e1> ,  <e2> calcium antagonists </e2> , thiazide and loop diuretics and ACE inhibitors. 
false	In comparison with haloperidol, the adverse events reported significantly more frequently with  <e1> olanzapine </e1>  in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with  <e2> risperidone </e2> , only bodyweight gain occurred significantly more frequently with olanzapine. 
false	In the first double-blind comparative study (28-week) of olanzapine and risperidone,  <e1> olanzapine </e1>  10 to 20 mg/day proved to be significantly more effective than  <e2> risperidone </e2>  4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 
false	However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of  <e1> olanzapine </e1>  and  <e2> risperidone </e2>  treatment in patients with schizophrenia or schizoaffective disorder. 
false	In the first double-blind comparative study (28-week) of  <e1> olanzapine </e1>  and risperidone,  <e2> olanzapine </e2>  10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 
false	In comparison with haloperidol, the adverse events reported significantly more frequently with  <e1> olanzapine </e1>  in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with  <e2> olanzapine </e2> . 
false	 <e1> Olanzapine </e1>  is associated with significantly fewer extrapyramidal symptoms than haloperidol and  <e2> risperidone </e2> . 
false	In the first double-blind comparative study (28-week) of  <e1> olanzapine </e1>  and  <e2> risperidone </e2> , olanzapine 10 to 20 mg/day proved to be significantly more effective than risperidone 4 to 12 mg/day in the treatment of negative and depressive symptoms but not on overall psychopathology symptoms. 
false	 <e1> Olanzapine </e1> , a  <e2> thienobenzodiazepine derivative </e2> , is a second generation (atypical) antipsychotic agent which has proven efficacy against the positive and negative symptoms of schizophrenia. 
false	 <e1> Olanzapine </e1>  treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than haloperidol, and to broadly the same extent as  <e2> risperidone </e2> . 
false	In comparison with  <e1> haloperidol </e1> , the adverse events reported significantly more frequently with  <e2> olanzapine </e2>  in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with risperidone, only bodyweight gain occurred significantly more frequently with olanzapine. 
false	Both efavirenz and nevirapine have been compared to triple therapy with the  <e1> PI </e1>  indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with  <e2> efavirenz </e2> . 
false	 <e1> NNRTI </e1> -based regimens may have several advantages over  <e2> PI </e2> -based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration. 
false	Both  <e1> efavirenz </e1>  and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with  <e2> nevirapine </e2>  regimens and superiority observed with efavirenz. 
false	Both  <e1> efavirenz </e1>  and nevirapine have been compared to triple therapy with the PI  <e2> indinavir </e2>  over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 
false	The availability of potent non-nucleoside reverse transcriptase inhibitor ( <e1> NNRTI </e1> )-based regimens for  <e2> antiretroviral </e2>  therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 
false	The availability of potent non-nucleoside reverse transcriptase inhibitor ( <e1> NNRTI </e1> )-based regimens for antiretroviral therapy and concerns regarding protease inhibitor ( <e2> PI </e2> )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 
false	The superiority of  <e1> efavirenz </e1>  over  <e2> indinavir </e2> -based regimens has been observed in comparative data in a subset of patients with high viral loads. 
false	A smaller 24-week study has suggested  <e1> nevirapine </e1>  may be superior to the  <e2> PI </e2>  nelfinavir. 
false	A smaller 24-week study has suggested  <e1> nevirapine </e1>  may be superior to the PI  <e2> nelfinavir </e2> . 
false	Both  <e1> efavirenz </e1>  and nevirapine have been compared to triple therapy with the  <e2> PI </e2>  indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 
false	Both efavirenz and  <e1> nevirapine </e1>  have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with  <e2> nevirapine </e2>  regimens and superiority observed with efavirenz. 
false	In addition, olanzapine is not associated with a risk of agranulocytosis as seen with  <e1> clozapine </e1>  or clinically significant hyperprolactinaemia as seen with  <e2> risperidone </e2>  or prolongation of the QT interval. 
false	 <e1> Efavirenz </e1>  has demonstrated superiority over  <e2> nelfinavir </e2>  in nucleoside-experienced patients, although combining these 2 agents may represent the best approach in these circumstances. 
false	The availability of potent  <e1> non-nucleoside reverse transcriptase inhibitor </e1>  ( <e2> NNRTI </e2> )-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 
false	 <e1> Olanzapine </e1>  treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than  <e2> haloperidol </e2> , and to broadly the same extent as risperidone. 
false	No data from prospective clinical trials currently exist comparing the 3 approved agents ( <e1> efavirenz </e1> , nevirapine or  <e2> delavirdine </e2> ). 
false	Both efavirenz and nevirapine have been compared to triple therapy with the PI  <e1> indinavir </e1>  over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with  <e2> efavirenz </e2> . 
false	The availability of potent  <e1> non-nucleoside reverse transcriptase inhibitor </e1>  (NNRTI)-based regimens for antiretroviral therapy and concerns regarding  <e2> protease inhibitor </e2>  (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 
false	A smaller 24-week study has suggested nevirapine may be superior to the  <e1> PI </e1>   <e2> nelfinavir </e2> . 
false	In addition,  <e1> olanzapine </e1>  is not associated with a risk of agranulocytosis as seen with clozapine or clinically significant hyperprolactinaemia as seen with  <e2> risperidone </e2>  or prolongation of the QT interval. 
false	The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for  <e1> antiretroviral </e1>  therapy and concerns regarding protease inhibitor ( <e2> PI </e2> )-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 
false	Both efavirenz and nevirapine have been compared to triple therapy with the  <e1> PI </e1>   <e2> indinavir </e2>  over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 
false	The availability of potent non-nucleoside reverse transcriptase inhibitor ( <e1> NNRTI </e1> )-based regimens for antiretroviral therapy and concerns regarding  <e2> protease inhibitor </e2>  (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 
false	Both  <e1> efavirenz </e1>  and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with  <e2> efavirenz </e2> . 
false	Both efavirenz and  <e1> nevirapine </e1>  have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with  <e2> efavirenz </e2> . 
false	Both efavirenz and nevirapine have been compared to triple therapy with the PI  <e1> indinavir </e1>  over 48 weeks as initial therapy, with similar responses being observed with  <e2> nevirapine </e2>  regimens and superiority observed with efavirenz. 
false	CONCLUSION:  <e1> Cisapride </e1>  can be administered safely to patients receiving low therapeutic dosages of  <e2> fluoxetine </e2> .
false	In large, well controlled trials in patients with schizophrenia or related psychoses,  <e1> olanzapine </e1>  5 to 20 mg/day was significantly superior to  <e2> haloperidol </e2>  5 to 20 mg/day in overall improvements in psychopathology rating scales and in the treatment of depressive and negative symptoms, and was comparable in effects on positive psychotic symptoms. 
false	Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with  <e1> nevirapine </e1>  regimens and superiority observed with  <e2> efavirenz </e2> . 
false	The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for  <e1> antiretroviral </e1>  therapy and concerns regarding  <e2> protease inhibitor </e2>  (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection. 
false	Limited comparative data in patients with high viral loads treated with  <e1> nevirapine </e1> - or  <e2> delavirdine </e2> -based regimens currently exist. 
false	Both efavirenz and  <e1> nevirapine </e1>  have been compared to triple therapy with the PI  <e2> indinavir </e2>  over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 
false	Both  <e1> efavirenz </e1>  and  <e2> nevirapine </e2>  have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz. 
false	In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes  <e1> sildenafil </e1> , may experience increased drug concentrations and possible toxicity from normal doses of  <e2> sildenafil </e2> . 
effect	however, patients with moderate to severe cardiovascular disease or those taking  <e1> nitrate </e1>  therapy are at increased risk for potentially serious cardiovascular adverse effects with  <e2> sildenafil </e2>  therapy. 
false	METHODS: Clinical studies, case reports, and commentaries and editorials concerning  <e1> sildenafil </e1>  published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms  <e2> sildenafil </e2> , Viagra, and erectile dysfunction. 
false	RESULTS:  <e1> Sildenafil </e1>  has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, selective serotonin reuptake inhibitors [ <e2> SSRIs </e2> ]). 
false	RESULTS:  <e1> Sildenafil </e1>  has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg,  <e2> selective serotonin reuptake inhibitors </e2>  [SSRIs]). 
false	However, the effects of stress and  <e1> glucocorticoids </e1>  on the subjective and behavioral effects of  <e2> psychostimulants </e2>  have not been well studied in humans. 
false	Acute  <e1> hydrocortisone </e1>  administration does not affect subjective responses to  <e2> d-amphetamine </e2>  in humans.
false	CONCLUSIONS: In contrast to the effects of  <e1> glucocorticoids </e1>  in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of  <e2> d-amphetamine </e2>  in humans.
false	However,  <e1> hydrocortisone </e1>  pretreatment did not affect any of the physiological, behavioral, or subjective effects of  <e2> d-amphetamine </e2> . 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or  <e1> pentobarbital </e1> , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with  <e2> ketamine </e2>  or Innovar than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of  <e1> ouabain </e1>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with  <e2> ketamine </e2>  or Innovar than with pentobarbital. 
false	In a comparison of  <e1> digitalis </e1>  tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e2> ouabain </e2> , with ketamine or Innovar than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with  <e1> ketamine </e1> , Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e2> ouabain </e2> , with ketamine or Innovar than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine,  <e1> Innovar Vet </e1> , or  <e2> pentobarbital </e2> , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e1> ouabain </e1> , with  <e2> ketamine </e2>  or Innovar than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of  <e1> ouabain </e1>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with  <e2> pentobarbital </e2> . 
false	Ventricular tachycardia induced by  <e1> ouabain </e1>  was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of  <e2> fentayl </e2>  alone or after pentobarbital.
false	OBJECTIVES: To examine the effects of acute  <e1> hydrocortisone </e1>  pretreatment on the subjective and behavioral effects of  <e2> d-amphetamine </e2> . 
false	In a comparison of digitalis tolerance in dogs anesthetized with  <e1> ketamine </e1> ,  <e2> Innovar Vet </e2> , or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 
false	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar,  <e1> ketamine </e1> , or droperidol but not after administration of fentayl alone or after  <e2> pentobarbital </e2> .
false	The effects of  <e1> ketamine </e1>  and of  <e2> Innovar </e2>  anesthesia on digitalis tolerance in dogs.
false	In a comparison of  <e1> digitalis </e1>  tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with  <e2> pentobarbital </e2> . 
effect	Ventricular tachycardia induced by  <e1> ouabain </e1>  was generally converted to sinus rhythm following administration of Innovar,  <e2> ketamine </e2> , or droperidol but not after administration of fentayl alone or after pentobarbital.
false	METHODS: Clinical studies, case reports, and commentaries and editorials concerning sildenafil published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms  <e1> sildenafil </e1> ,  <e2> Viagra </e2> , and erectile dysfunction. 
false	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar,  <e1> ketamine </e1> , or  <e2> droperidol </e2>  but not after administration of fentayl alone or after pentobarbital.
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or  <e1> Innovar </e1>  than with  <e2> pentobarbital </e2> . 
effect	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or  <e1> pentobarbital </e1> , the dosage of  <e2> ouabain </e2>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of  <e1> ouabain </e1>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e2> ouabain </e2> , with ketamine or Innovar than with pentobarbital. 
false	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or  <e1> droperidol </e1>  but not after administration of fentayl alone or after  <e2> pentobarbital </e2> .
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine,  <e1> Innovar Vet </e1> , or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with  <e2> pentobarbital </e2> . 
false	In a comparison of digitalis tolerance in dogs anesthetized with  <e1> ketamine </e1> , Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with  <e2> ketamine </e2>  or Innovar than with pentobarbital. 
effect	In a comparison of digitalis tolerance in dogs anesthetized with ketamine,  <e1> Innovar Vet </e1> , or pentobarbital, the dosage of  <e2> ouabain </e2>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 
false	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar,  <e1> ketamine </e1> , or droperidol but not after administration of  <e2> fentayl </e2>  alone or after pentobarbital.
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine,  <e1> Innovar Vet </e1> , or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with  <e2> ketamine </e2>  or Innovar than with pentobarbital. 
false	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of  <e1> fentayl </e1>  alone or after  <e2> pentobarbital </e2> .
false	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of  <e1> Innovar </e1> , ketamine, or  <e2> droperidol </e2>  but not after administration of fentayl alone or after pentobarbital.
false	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of  <e1> Innovar </e1> , ketamine, or droperidol but not after administration of fentayl alone or after  <e2> pentobarbital </e2> .
effect	Ventricular tachycardia induced by  <e1> ouabain </e1>  was generally converted to sinus rhythm following administration of  <e2> Innovar </e2> , ketamine, or droperidol but not after administration of fentayl alone or after pentobarbital.
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with  <e1> ketamine </e1>  or  <e2> Innovar </e2>  than with pentobarbital. 
false	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of  <e1> Innovar </e1> ,  <e2> ketamine </e2> , or droperidol but not after administration of fentayl alone or after pentobarbital.
false	In a comparison of digitalis tolerance in dogs anesthetized with  <e1> ketamine </e1> , Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or  <e2> Innovar </e2>  than with pentobarbital. 
false	The effects of ketamine and of  <e1> Innovar </e1>  anesthesia on  <e2> digitalis </e2>  tolerance in dogs.
false	In a comparison of  <e1> digitalis </e1>  tolerance in dogs anesthetized with  <e2> ketamine </e2> , Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 
effect	Ventricular tachycardia induced by  <e1> ouabain </e1>  was generally converted to sinus rhythm following administration of Innovar, ketamine, or  <e2> droperidol </e2>  but not after administration of fentayl alone or after pentobarbital.
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or  <e1> pentobarbital </e1> , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of  <e2> ouabain </e2> , with ketamine or Innovar than with pentobarbital. 
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with  <e1> ketamine </e1>  or Innovar than with  <e2> pentobarbital </e2> . 
false	Ventricular tachycardia induced by ouabain was generally converted to sinus rhythm following administration of Innovar, ketamine, or  <e1> droperidol </e1>  but not after administration of  <e2> fentayl </e2>  alone or after pentobarbital.
false	In a comparison of  <e1> digitalis </e1>  tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of  <e2> ouabain </e2>  needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital. 
false	Ventricular tachycardia induced by  <e1> ouabain </e1>  was generally converted to sinus rhythm following administration of Innovar, ketamine, or droperidol but not after administration of fentayl alone or after  <e2> pentobarbital </e2> .
false	The effects of  <e1> ketamine </e1>  and of Innovar anesthesia on  <e2> digitalis </e2>  tolerance in dogs.
false	The minimal inhibitory concentrations of  <e1> clindamycin </e1>  and  <e2> gentamicin </e2>  alone and in combinations were determined by a microdilution method for 163 aerobic, facultative, and anaerobic clinical isolates. 
false	All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both  <e1> clindamycin </e1>  (minimal inhibitory concentration greater than 3.1 mug/ml) and  <e2> gentamicin </e2>  (minimal inhibitory concentration greater than 6.2 mug/ml). 
int	Interaction of  <e1> clindamycin </e1>  and  <e2> gentamicin </e2>  in vitro.
false	In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or  <e1> pentobarbital </e1> , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or  <e2> Innovar </e2>  than with pentobarbital. 
effect	Combinations of  <e1> clindamycin </e1>  and  <e2> gentamicin </e2>  were indifferent for 29 strains and synergistic for 33 strains. 
false	 <e1> filipin </e1>  was more potent in lysing human red blood cells, whereas  <e2> amphotericin B </e2>  was more potent in inhibiting yeast cell growth; 
false	Both the toxicity of  <e1> filipin </e1>  and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these  <e2> polyene antibiotics </e2>  showed differential effects on cells; 
false	Molecular basis for the selective toxicity of  <e1> amphotericin B </e1>  for yeast and  <e2> filipin </e2>  for animal cells.
false	Both the toxicity of  <e1> filipin </e1>  and the therapeutic value of  <e2> amphotericin B </e2>  can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells; 
effect	Combinations of  <e1> clindamycin </e1>  and  <e2> gentamicin </e2>  were indifferent for 16 and synergistic for 11 of the resistant strains. 
false	Both the toxicity of filipin and the therapeutic value of  <e1> amphotericin B </e1>  can be rationalized at the cellular and molecular level by the following observations: (i) these  <e2> polyene antibiotics </e2>  showed differential effects on cells; 
false	and (ii) the effects of  <e1> filipin </e1>  were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of  <e2> amphotericin B </e2>  were more efficiently inhibited by ergosterol, the major membrane sterol in yeast. 
false	Studies on the mechanism of action of  <e1> miconazole </e1> : effect of  <e2> miconazole </e2>  on respiration and cell permeability of Candida albicans.
false	To determine whether probenecid has a direct effect on the distribution of  <e1> cloxacillin </e1> , the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  <e2> probenecid </e2> . 
mechanism	(1968, 1970), the higher serum concentrations of penicillins and  <e1> cephaloridine </e1>  reached after administration of  <e2> probenecid </e2>  are due not only to slower renal elimination but also to an altered distribution in the body. 
false	To determine whether  <e1> probenecid </e1>  has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  <e2> probenecid </e2> . 
false	Effect of  <e1> probenecid </e1>  on the apparent volume of distribution and elimination of  <e2> cloxacillin </e2> .
false	(1968, 1970), the higher serum concentrations of  <e1> penicillins </e1>  and  <e2> cephaloridine </e2>  reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body. 
false	To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of  <e1> cloxacillin </e1>  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of  <e2> probenecid </e2> . 
mechanism	This might be explained by a blockade by  <e1> probenecid </e1>  of the elimination of  <e2> cloxacillin </e2>  by the liver.
false	To determine whether  <e1> probenecid </e1>  has a direct effect on the distribution of  <e2> cloxacillin </e2> , the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 
false	Many people use both  <e1> alcohol </e1>  and  <e2> nicotine </e2>  (i.e., cigarettes and other tobacco products). 
false	Moreover, the mechanisms underlying the development of dependence may be similar for  <e1> alcohol </e1>  and  <e2> nicotine </e2> . 
false	[Dose-time effects of competitive displacement of radiopertechnetate by  <e1> sodium perchlorate </e1>  following oral and intravenous administration];The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of r <e2> adiopertechnetate, </e2>  in dependence on application mode, was studied. 
false	[Dose-time effects of competitive displacement of  <e1> radiopertechnetate </e1>  by sodium perchlorate following oral and intravenous administration];The effect of various doses of sodium perchlorate in several dose fractions on the extent and the time scale of displacement of r <e2> adiopertechnetate, </e2>  in dependence on application mode, was studied. 
false	[Dose-time effects of competitive displacement of  <e1> radiopertechnetate </e1>  by sodium perchlorate following oral and intravenous administration];The effect of various doses of s <e2> odium perchlorate  </e2> in several dose fractions on the extent and the time scale of displacement of radiopertechnetate, in dependence on application mode, was studied. 
mechanism	An intravenous injection of  <e1> perchlorate </e1>  given later also produces a complete and immediately beginning depletion of  <e2> pertechnetate </e2>  already accumulated in the thyroid, within a period of 195 min after 99m-TcO-4-injection with a corresponding increase in blood levels. 
false	An intravenous dose of 50 mg  <e1> perchlorate </e1>  was in respect of competitive suppression of organs actively concentrating  <e2> pertechnetate </e2>  as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of radiopertechnetate. 
false	An intravenous dose of 50 mg  <e1> perchlorate </e1>  was in respect of competitive suppression of organs actively concentrating pertechnetate as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of  <e2> radiopertechnetate </e2> . 
false	To determine whether  <e1> probenecid </e1>  has a direct effect on the distribution of cloxacillin, the elimination and distribution of  <e2> cloxacillin </e2>  was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid. 
false	[Dose-time effects of competitive displacement of radiopertechnetate by sodium perchlorate following oral and intravenous administration];The effect of various doses of s <e1> odium perchlorate  </e1> in several dose fractions on the extent and the time scale of displacement of r <e2> adiopertechnetate, </e2>  in dependence on application mode, was studied. 
false	Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with  <e1> cyclosporine </e1>  or  <e2> tacrolimus </e2> . 
false	Sirolimus works differently from the  <e1> immunosuppressants </e1>  currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or  <e2> tacrolimus </e2> . 
false	While additional research is needed, the initial clinical data in kidney recipients suggest that  <e1> sirolimus </e1> , in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in  <e2> cyclosporine </e2>  or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).
false	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with  <e1> cyclosporine </e1>  or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or  <e2> tacrolimus </e2>  dosage, and permit steroid withdrawal (Kelly, 1999).
false	 <e1> Sirolimus </e1>  works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or  <e2> tacrolimus </e2> . 
false	Sirolimus works differently from the  <e1> immunosuppressants </e1>  currently available, and except for increased lipid levels, the adverse reaction profile of  <e2> sirolimus </e2>  does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 
false	Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of  <e1> sirolimus </e1>  does not appear to overlap to any great extent with that associated with cyclosporine or  <e2> tacrolimus </e2> . 
false	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or  <e1> tacrolimus </e1> , might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or  <e2> tacrolimus </e2>  dosage, and permit steroid withdrawal (Kelly, 1999).
false	Sirolimus works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of  <e1> sirolimus </e1>  does not appear to overlap to any great extent with that associated with  <e2> cyclosporine </e2>  or tacrolimus. 
false	 <e1> Sirolimus </e1>  works differently from the  <e2> immunosuppressants </e2>  currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 
false	An intravenous dose of 50 mg perchlorate was in respect of competitive suppression of organs actively concentrating  <e1> pertechnetate </e1>  as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of  <e2> radiopertechnetate </e2> . 
false	 <e1> Sirolimus </e1>  works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of  <e2> sirolimus </e2>  does not appear to overlap to any great extent with that associated with cyclosporine or tacrolimus. 
false	 <e1> Sirolimus </e1>  works differently from the immunosuppressants currently available, and except for increased lipid levels, the adverse reaction profile of sirolimus does not appear to overlap to any great extent with that associated with  <e2> cyclosporine </e2>  or tacrolimus. 
false	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with  <e1> cyclosporine </e1>  or  <e2> tacrolimus </e2> , might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).
false	While additional research is needed, the initial clinical data in kidney recipients suggest that  <e1> sirolimus </e1> , in combination with  <e2> cyclosporine </e2>  or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).
false	The effects of chlordiazepoxide,  <e1> amphetamine </e1>  and  <e2> cocaine </e2>  on bar-press behavior in normal and genetically nervous dogs.
false	The concomitant administration of either  <e1> cocaine </e1>  or  <e2> amphetamine </e2> , compounds which inhibit neuronal reuptake of norepinephrine, disrupts the behavioral response of the genetically nervous E-strain subjects to a far greater extent than the stable A-strain subjects. 
false	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with  <e1> cyclosporine </e1>  or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in  <e2> cyclosporine </e2>  or tacrolimus dosage, and permit steroid withdrawal (Kelly, 1999).
false	While additional research is needed, the initial clinical data in kidney recipients suggest that sirolimus, in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in  <e1> cyclosporine </e1>  or  <e2> tacrolimus </e2>  dosage, and permit steroid withdrawal (Kelly, 1999).
false	While additional research is needed, the initial clinical data in kidney recipients suggest that  <e1> sirolimus </e1> , in combination with cyclosporine or tacrolimus, might have the potential to reduce the frequency of rejection episodes, permit reductions in cyclosporine or  <e2> tacrolimus </e2>  dosage, and permit steroid withdrawal (Kelly, 1999).
false	It is structurally distinct from the other currently available  <e1> HMGCoA reductase inhibitors </e1>  (lovastatin, simvastatin, and  <e2> pravastatin </e2> ), leading to unique biopharmaceutical properties relative to the other agents of this class. 
false	 <e1> Fluvastatin </e1>  is the first  <e2> synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor </e2>  to be approved for clinical use, and has been studied extensively in humans since 1986. 
false	It is structurally distinct from the other currently available HMGCoA reductase inhibitors ( <e1> lovastatin </e1> ,  <e2> simvastatin </e2> , and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 
mechanism	 <e1> Cholestyramine </e1> , an anionic-binding resin, has a considerable effect in lowering the rate and extent of  <e2> fluvastatin </e2>  bioavailability. 
false	Studies on two strains of pointer dogs have demonstrated that administration of a  <e1> benzodiazepine </e1>  ( <e2> chlordiazepoxide </e2> ) facilitates acquisition of goal-directed behavior in "genetically nervous"
false	Moreover, additional interaction studies with  <e1> niacin </e1>  and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving  <e2> digoxin </e2>  resulted in no difference in the extent of bioavailability of digoxin relative to control data. 
false	Further, no effects on either  <e1> warfarin </e1>  levels or prothrombin times were observed in a study involving concomitant administration of warfarin and  <e2> fluvastatin </e2> . 
false	It is structurally distinct from the other currently available HMGCoA reductase inhibitors ( <e1> lovastatin </e1> , simvastatin, and  <e2> pravastatin </e2> ), leading to unique biopharmaceutical properties relative to the other agents of this class. 
false	Moreover, additional interaction studies with niacin and  <e1> propranolol </e1>  have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving  <e2> digoxin </e2>  resulted in no difference in the extent of bioavailability of digoxin relative to control data. 
false	It is structurally distinct from the other currently available  <e1> HMGCoA reductase inhibitors </e1>  ( <e2> lovastatin </e2> , simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class. 
false	Further, no effects on either  <e1> warfarin </e1>  levels or prothrombin times were observed in a study involving concomitant administration of  <e2> warfarin </e2>  and fluvastatin. 
false	Moreover, additional interaction studies with  <e1> niacin </e1>  and propranolol have not demonstrated any effect on  <e2> fluvastatin </e2>  plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 
false	It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin,  <e1> simvastatin </e1> , and  <e2> pravastatin </e2> ), leading to unique biopharmaceutical properties relative to the other agents of this class. 
effect	Although this effect was noted even when  <e1> cholestyramine </e1>  was given 4 hours prior to  <e2> fluvastatin </e2> , this regimen did not result in diminished efficacy. 
false	Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on  <e1> fluvastatin </e1>  plasma levels, and administration to a patient population chronically receiving  <e2> digoxin </e2>  resulted in no difference in the extent of bioavailability of digoxin relative to control data. 
false	Moreover, additional interaction studies with niacin and  <e1> propranolol </e1>  have not demonstrated any effect on  <e2> fluvastatin </e2>  plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data. 
false	Moreover, additional interaction studies with niacin and  <e1> propranolol </e1>  have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of  <e2> digoxin </e2>  relative to control data. 
false	Those for which effectiveness is reported includes  <e1> diphenhydramine </e1> , hydroxyzine, orphenadrine, pyrilamine,  <e2> phenyltoloxamine </e2> , promethazine, methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine,  <e1> orphenadrine </e1> , pyrilamine, phenyltoloxamine,  <e2> promethazine </e2> , methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine,  <e1> hydroxyzine </e1> , orphenadrine, pyrilamine, phenyltoloxamine, promethazine,  <e2> methdilazine </e2> , and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine,  <e1> orphenadrine </e1> , pyrilamine, phenyltoloxamine, promethazine, methdilazine, and  <e2> tripelennamine </e2> . 
false	Those for which effectiveness is reported includes  <e1> diphenhydramine </e1> ,  <e2> hydroxyzine </e2> , orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine,  <e1> phenyltoloxamine </e1> ,  <e2> promethazine </e2> , methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine,  <e1> pyrilamine </e1> , phenyltoloxamine, promethazine,  <e2> methdilazine </e2> , and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine,  <e1> hydroxyzine </e1> , orphenadrine, pyrilamine,  <e2> phenyltoloxamine </e2> , promethazine, methdilazine, and tripelennamine. 
false	The literature provides considerable evidence indicating that several, but not all  <e1> antihistaminics </e1> , are indeed  <e2> analgesic agents </e2>  and some are analgesic adjuvants as well.
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine,  <e1> promethazine </e1> , methdilazine, and  <e2> tripelennamine </e2> . 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine,  <e1> orphenadrine </e1> , pyrilamine,  <e2> phenyltoloxamine </e2> , promethazine, methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine,  <e1> methdilazine </e1> , and  <e2> tripelennamine </e2> . 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine,  <e1> pyrilamine </e1> ,  <e2> phenyltoloxamine </e2> , promethazine, methdilazine, and tripelennamine. 
false	The literature provides considerable evidence indicating that several, but not all antihistaminics, are indeed  <e1> analgesic agents </e1>  and some are  <e2> analgesic adjuvants </e2>  as well.
false	Those for which effectiveness is reported includes  <e1> diphenhydramine </e1> , hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine,  <e2> methdilazine </e2> , and tripelennamine. 
false	Those for which effectiveness is reported includes  <e1> diphenhydramine </e1> , hydroxyzine, orphenadrine,  <e2> pyrilamine </e2> , phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine,  <e1> orphenadrine </e1> , pyrilamine, phenyltoloxamine, promethazine,  <e2> methdilazine </e2> , and tripelennamine. 
false	Those for which effectiveness is reported includes  <e1> diphenhydramine </e1> , hydroxyzine,  <e2> orphenadrine </e2> , pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine,  <e1> promethazine </e1> ,  <e2> methdilazine </e2> , and tripelennamine. 
false	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, p <e1> henibut  </e1> and amizyl and reduces the action of p <e2> hentolamine. </e2>  
false	Those for which effectiveness is reported includes  <e1> diphenhydramine </e1> , hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine,  <e2> promethazine </e2> , methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes  <e1> diphenhydramine </e1> , hydroxyzine, orphenadrine, pyrilamine, phenyltoloxamine, promethazine, methdilazine, and  <e2> tripelennamine </e2> . 
effect	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that p <e1> icrotoxin  </e1> (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and amizyl and reduces the action of p <e2> hentolamine. </e2>  
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine,  <e1> orphenadrine </e1> ,  <e2> pyrilamine </e2> , phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 
false	Those for which effectiveness is reported includes diphenhydramine,  <e1> hydroxyzine </e1> ,  <e2> orphenadrine </e2> , pyrilamine, phenyltoloxamine, promethazine, methdilazine, and tripelennamine. 
effect	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that p <e1> icrotoxin  </e1> (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, p <e2> henibut  </e2> and amizyl and reduces the action of phentolamine. 
false	Those for which effectiveness is reported includes diphenhydramine, hydroxyzine, orphenadrine, pyrilamine,  <e1> phenyltoloxamine </e1> , promethazine,  <e2> methdilazine </e2> , and tripelennamine. 
false	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of d <e1> iazepam, </e1>  phenazepam, p <e2> henibut  </e2> and amizyl and reduces the action of phentolamine. 
false	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, p <e1> henibut  </e1> and a <e2> mizyl  </e2> and reduces the action of phentolamine. 
effect	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that p <e1> icrotoxin  </e1> (1 mg/kg) removes the antiedematous action of d <e2> iazepam, </e2>  phenazepam, phenibut and amizyl and reduces the action of phentolamine. 
false	The literature provides considerable evidence indicating that several, but not all  <e1> antihistaminics </e1> , are indeed analgesic agents and some are  <e2> analgesic adjuvants </e2>  as well.
false	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of d <e1> iazepam, </e1>  p <e2> henazepam, </e2>  phenibut and amizyl and reduces the action of phentolamine. 
false	It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for  <e1> apomorphine </e1>  on dopamine2- and serotonin2-receptors underlies the antipsychotic action of  <e2> neuroleptics </e2>  after their prolonged administration. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and p <e1> yreneperone  </e1> (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for a <e2> pomorphine  </e2> increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of  <e1> 3H-spiroperidol </e1>  binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for a <e2> pomorphine  </e2> in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of  <e1> 3H-spiroperidol </e1>  binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3 <e2> H-spiroperidol  </e2> and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by  <e1> cerulein </e1> --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3 <e2> H-spiroperidol  </e2> and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of h <e1> aloperidol  </e1> (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for a <e2> pomorphine  </e2> in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of  <e1> neuroleptics </e1> ];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for a <e2> pomorphine  </e2> increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by  <e1> cerulein </e1> --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3 <e2> H-spiroperidol  </e2> binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and a <e1> mizyl  </e1> and reduces the action of p <e2> hentolamine. </e2>  
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of  <e1> neuroleptics </e1> ];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of h <e2> aloperidol  </e2> (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of  <e1> 3H-spiroperidol </e1>  binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3 <e2> H-spiroperidol  </e2> binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by  <e1> cerulein </e1> --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for a <e2> pomorphine  </e2> increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for a <e1> pomorphine  </e1> in subcortical structures, whereas 3 <e2> H-spiroperidol  </e2> binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and p <e1> yreneperone  </e1> (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for a <e2> pomorphine  </e2> in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of  <e1> 3H-spiroperidol </e1>  binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of h <e2> aloperidol  </e2> (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
effect	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that p <e1> icrotoxin  </e1> (1 mg/kg) removes the antiedematous action of diazepam, phenazepam, phenibut and a <e2> mizyl  </e2> and reduces the action of phentolamine. 
false	[Stimulation by  <e1> cerulein </e1> --an analog of the octapeptide cholecystokinin--of  <e2> 3H-spiroperidol </e2>  binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of  <e1> neuroleptics </e1> ];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and p <e2> yreneperone  </e2> (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of  <e1> 3H-spiroperidol </e1>  binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for a <e2> pomorphine  </e2> increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of  <e1> 3H-spiroperidol </e1>  binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and p <e2> yreneperone  </e2> (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3 <e1> H-spiroperidol  </e1> and low affinity binding sites for a <e2> pomorphine  </e2> in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and p <e1> yreneperone  </e1> (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3 <e2> H-spiroperidol  </e2> binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	It is assumed that increased interaction between  <e1> 3H-spiroperidol </e1>  and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of  <e2> neuroleptics </e2>  after their prolonged administration. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of h <e1> aloperidol  </e1> (0.25 mg/kg) and p <e2> yreneperone  </e2> (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by  <e1> cerulein </e1> --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and p <e2> yreneperone  </e2> (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	It is assumed that increased interaction between  <e1> 3H-spiroperidol </e1>  and high affinity binding sites for  <e2> apomorphine </e2>  on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of  <e1> neuroleptics </e1> ];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3 <e2> H-spiroperidol  </e2> and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	After prolonged administration of neuroleptics the displacing effect of  <e1> cerulein </e1> , an analog of cholecystokinin octapeptide, was replaced by the stimulant action on  <e2> 3H-spiroperidol </e2>  binding. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of  <e1> neuroleptics </e1> ];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3 <e2> H-spiroperidol  </e2> binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of diazepam, p <e1> henazepam, </e1>  p <e2> henibut  </e2> and amizyl and reduces the action of phentolamine. 
false	When  <e1> ouabain </e1>  was applied to the muscle in the presence of phentolamine, both first and second contractile responses to  <e2> PTX </e2>  were abolished. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3 <e1> H-spiroperidol  </e1> and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for a <e2> pomorphine  </e2> increased both in the frontal cortex and subcortical structures of the forebrain. 
false	After prolonged administration of  <e1> neuroleptics </e1>  the displacing effect of cerulein, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on  <e2> 3H-spiroperidol </e2>  binding. 
effect	When  <e1> ouabain </e1>  was applied to the muscle in the presence of  <e2> phentolamine </e2> , both first and second contractile responses to PTX were abolished. 
false	[The GABA-ergic system and brain edema];It has been shown in rats with experimental toxic and traumatic edemas that picrotoxin (1 mg/kg) removes the antiedematous action of d <e1> iazepam, </e1>  phenazepam, phenibut and a <e2> mizyl  </e2> and reduces the action of phentolamine. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of  <e1> 3H-spiroperidol </e1>  binding after the long-term administration of  <e2> neuroleptics </e2> ];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of haloperidol (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	[Stimulation by cerulein--an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of h <e1> aloperidol  </e1> (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3 <e2> H-spiroperidol  </e2> binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	After prolonged administration of  <e1> neuroleptics </e1>  the displacing effect of  <e2> cerulein </e2> , an analog of cholecystokinin octapeptide, was replaced by the stimulant action on 3H-spiroperidol binding. 
effect	In the presence of  <e1> ouabain </e1>  (10(-5) M),  <e2> PTX </e2>  (10(-8) M) failed to cause the first contraction; 
false	[Stimulation by  <e1> cerulein </e1> --an analog of the octapeptide cholecystokinin--of 3H-spiroperidol binding after the long-term administration of neuroleptics];It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of h <e2> aloperidol  </e2> (0.25 mg/kg) and pyreneperone (0.25 mg/kg) resulted in the reduced interaction between 3H-spiroperidol and low affinity binding sites for apomorphine in subcortical structures, whereas 3H-spiroperidol binding with high affinity binding sites for apomorphine increased both in the frontal cortex and subcortical structures of the forebrain. 
false	When ouabain was applied to the muscle in the presence of  <e1> phentolamine </e1> , both first and second contractile responses to  <e2> PTX </e2>  were abolished. 
false	At stable  <e1> As(V) </e1>  concentrations greater than 1 mM, fractional mucosal cell accumulation of  <e2> As(V) </e2>  remains constant, while fractional transfer to the body declines. 
mechanism	 <e1> Vitamin D3 </e1>  administration to rachitic chicks was effective in significantly elevating duodenal  <e2> arsenate </e2>  absorption, acting primarily to enhance serosal transport.
false	[Quantitative approach to treatment with incisive  <e1> neuroleptics </e1>  by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with  <e2> neuroleptics </e2>  are illustrated by six typical case reports. 
false	Furthermore,  <e1> arsenate </e1>  and  <e2> phosphate </e2>  do not appear to share a common transport pathway in the duodenum and no evidence was obtained for any interaction between the two at this level. 
false	However, total mucosal accumulation of  <e1> As(V) </e1>  and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm  <e2> As(V) </e2> . 
false	By contrast,  <e1> spermidine </e1>  (1 mM) and  <e2> putrescine </e2>  (1 mM) had no significant effect on the translocation when added alone. 
false	By this procedure, it was observed that  <e1> arsenate </e1>  is rapidly and essentially completely absorbed (80-95%) from the lumen at  <e2> As(V) </e2>  concentrations up to 5 mM, declining to about 50% absorption at 50 mM. 
false	 <e1> Slow-channel calcium blockers </e1> , such as verapamil,  <e2> diltiazem </e2>  and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 
false	 <e1> Slow-channel calcium blockers </e1> , such as  <e2> verapamil </e2> , diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 
false	Slow-channel calcium blockers, such as  <e1> verapamil </e1> ,  <e2> diltiazem </e2>  and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 
false	 <e1> Slow-channel calcium blockers </e1> , such as verapamil, diltiazem and  <e2> nifedipine </e2> , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 
false	Intrathecal injection of  <e1> naloxone </e1>  at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of  <e2> naloxone </e2>  (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 
false	The results indicate that a spinal  <e1> naloxone </e1> -sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular  <e2> beta-endorphin </e2>  and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 
false	The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not  <e1> morphine </e1> -induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and  <e2> morphine </e2>  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 
false	descending epsilon and mu systems for  <e1> beta-endorphin </e1>  and  <e2> morphine </e2> , respectively, are proposed.
effect	Intrathecal injection of  <e1> naloxone </e1>  at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of  <e2> beta-endorphin </e2> , and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 
false	The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular  <e1> beta-endorphin </e1>  and  <e2> morphine </e2>  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 
false	Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of  <e1> beta-endorphin </e1> , and a high dose of  <e2> naloxone </e2>  (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular beta-endorphin (16 micrograms). 
false	The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of  <e1> beta-endorphin </e1>  but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and  <e2> morphine </e2>  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 
false	Intrathecal injection of  <e1> naloxone </e1>  at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of naloxone (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular  <e2> beta-endorphin </e2>  (16 micrograms). 
false	The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of  <e1> beta-endorphin </e1>  but not  <e2> morphine </e2> -induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 
false	The results indicate that a spinal  <e1> naloxone </e1> -sensitive endorphinergic system is involved in the production of beta-endorphin but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and  <e2> morphine </e2>  elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 
effect	Intrathecal injection of naloxone at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of beta-endorphin, and a high dose of  <e1> naloxone </e1>  (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular  <e2> beta-endorphin </e2>  (16 micrograms). 
false	Differential actions of intrathecal  <e1> naloxone </e1>  on blocking the tail-flick inhibition induced by intraventricular beta-endorphin and  <e2> morphine </e2>  in rats.
false	The results indicate that a spinal  <e1> naloxone </e1> -sensitive endorphinergic system is involved in the production of  <e2> beta-endorphin </e2>  but not morphine-induced tail-flick inhibition, and suggest that intraventricular beta-endorphin and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 
effect	On the other hand, intrathecal  <e1> naloxone </e1>  (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular  <e2> morphine </e2>  (40 micrograms). 
false	Intraventricular injection of naloxone at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular  <e1> beta-endorphin </e1>  and  <e2> morphine </e2> . 
false	Slow-channel calcium blockers, such as verapamil,  <e1> diltiazem </e1>  and  <e2> nifedipine </e2> , inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly. 
false	Differential actions of intrathecal  <e1> naloxone </e1>  on blocking the tail-flick inhibition induced by intraventricular  <e2> beta-endorphin </e2>  and morphine in rats.
false	Differential actions of intrathecal naloxone on blocking the tail-flick inhibition induced by intraventricular  <e1> beta-endorphin </e1>  and  <e2> morphine </e2>  in rats.
false	 <e1> Methamphetamine </e1> , like  <e2> MPTP </e2> , produced depletions of striatal dopamine but these actions were potentiated by pargyline pretreatment. 
effect	The  <e1> MPTP </e1> -induced neuronal damage produced a tolerance to the disruptive effects of  <e2> amphetamine </e2>  and a supersensitivity to the disruptive effects of apomorphine in rats responding in a schedule controlled paradigm. 
false	Methamphetamine, like  <e1> MPTP </e1> , produced depletions of striatal dopamine but these actions were potentiated by  <e2> pargyline </e2>  pretreatment. 
false	The results indicate that a spinal naloxone-sensitive endorphinergic system is involved in the production of beta-endorphin but not  <e1> morphine </e1> -induced tail-flick inhibition, and suggest that intraventricular  <e2> beta-endorphin </e2>  and morphine elicit their pharmacological actions via the activation of different descending pain inhibitory systems; 
effect	Intraventricular injection of  <e1> naloxone </e1>  at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular  <e2> beta-endorphin </e2>  and morphine. 
false	Neurochemical and functional consequences following  <e1> 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine </e1>  ( <e2> MPTP </e2> ) and methamphetamine.
false	Intraventricular injection of  <e1> beta-endorphin </e1>  and  <e2> morphine </e2>  produced an inhibition of the tail-flick response to the heat stimulus in rats. 
effect	 <e1> Methamphetamine </e1> , like MPTP, produced depletions of striatal dopamine but these actions were potentiated by  <e2> pargyline </e2>  pretreatment. 
false	Neurochemical and functional consequences following  <e1> 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine </e1>  (MPTP) and  <e2> methamphetamine </e2> .
effect	It was observed that  <e1> MPTP </e1>  induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by  <e2> pargyline </e2>  pretreatment. 
false	Neurochemical and functional consequences following 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine ( <e1> MPTP </e1> ) and  <e2> methamphetamine </e2> .
false	Although neither  <e1> dexamethasone </e1>  nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing  <e2> transferrin </e2>  alone, they modify the mitogenic effect of EGF and insulin. 
effect	Dexamethasone and  <e1> retinyl acetate </e1>  similarly inhibit and stimulate EGF- or  <e2> insulin </e2> -induced proliferation of prostatic epithelium.
effect	Dexamethasone and  <e1> retinyl acetate </e1>  similarly inhibit and stimulate  <e2> EGF </e2> - or insulin-induced proliferation of prostatic epithelium.
effect	 <e1> Dexamethasone </e1>  at 10(-10) M or retinyl acetate at about 3 X 10(-9) M inhibits proliferation stimulated by  <e2> EGF </e2> . 
effect	These results suggest that both dexamethasone and  <e1> retinyl acetate </e1> , and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  <e2> insulin </e2>  and EGF.
false	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml),  <e1> EGF </e1>  (10 ng/ml), and  <e2> insulin </e2>  (3.7 micrograms/ml or 0.1 IU/ml). 
false	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  <e1> insulin </e1>  and  <e2> EGF </e2> .
false	These results suggest that both dexamethasone and  <e1> retinyl acetate </e1> , and possibly other  <e2> glucocorticoids </e2>  and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
effect	These results suggest that both dexamethasone and retinyl acetate, and possibly other  <e1> glucocorticoids </e1>  and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  <e2> insulin </e2>  and EGF.
false	Dexamethasone and retinyl acetate similarly inhibit and stimulate  <e1> EGF </e1> - or  <e2> insulin </e2> -induced proliferation of prostatic epithelium.
effect	 <e1> Dexamethasone </e1>  and retinyl acetate similarly inhibit and stimulate EGF- or  <e2> insulin </e2> -induced proliferation of prostatic epithelium.
effect	Although neither  <e1> dexamethasone </e1>  nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of  <e2> EGF </e2>  and insulin. 
effect	These results suggest that both dexamethasone and retinyl acetate, and possibly other  <e1> glucocorticoids </e1>  and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and  <e2> EGF </e2> .
false	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of  <e1> EGF </e1>  and  <e2> insulin </e2> . 
effect	Although neither  <e1> dexamethasone </e1>  nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and  <e2> insulin </e2> . 
effect	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and  <e1> retinoids </e1> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of  <e2> insulin </e2>  and EGF.
false	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing  <e1> transferrin </e1>  (1 microgram/ml),  <e2> EGF </e2>  (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml). 
false	 <e1> Dexamethasone </e1>  had a similar effect in the presence of  <e2> insulin </e2> . 
false	These results suggest that both  <e1> dexamethasone </e1>  and  <e2> retinyl acetate </e2> , and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
effect	These results suggest that both  <e1> dexamethasone </e1>  and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and  <e2> EGF </e2> .
false	These results suggest that both dexamethasone and  <e1> retinyl acetate </e1> , and possibly other glucocorticoids and  <e2> retinoids </e2> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
false	Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing  <e1> transferrin </e1>  (1 microgram/ml), EGF (10 ng/ml), and  <e2> insulin </e2>  (3.7 micrograms/ml or 0.1 IU/ml). 
false	These results suggest that both dexamethasone and retinyl acetate, and possibly other  <e1> glucocorticoids </e1>  and  <e2> retinoids </e2> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
effect	These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and  <e1> retinoids </e1> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and  <e2> EGF </e2> .
false	Although neither  <e1> dexamethasone </e1>  nor  <e2> retinyl acetate </e2>  affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin. 
effect	 <e1> Dexamethasone </e1>  and retinyl acetate similarly inhibit and stimulate  <e2> EGF </e2> - or insulin-induced proliferation of prostatic epithelium.
false	For the calcium-entry blocking agents now available in the United States ( <e1> verapamil </e1> ,  <e2> nifedipine </e2>  and diltiazem), these data appeared well after clinical patterns of use evolved. 
false	 <e1> Dexamethasone </e1>  and  <e2> retinyl acetate </e2>  similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.
false	by the nonlinear kinetic characteristics for  <e1> verapamil </e1>  and  <e2> diltiazem </e2>  (and probably for nifedipine, as well) and the derivative implications for decreased dosing frequency requirements; 
false	by the nonlinear kinetic characteristics for verapamil and  <e1> diltiazem </e1>  (and probably for  <e2> nifedipine </e2> , as well) and the derivative implications for decreased dosing frequency requirements; 
effect	Dexamethasone at 10(-10) M or  <e1> retinyl acetate </e1>  at about 3 X 10(-9) M inhibits proliferation stimulated by  <e2> EGF </e2> . 
false	For the calcium-entry blocking agents now available in the United States ( <e1> verapamil </e1> , nifedipine and  <e2> diltiazem </e2> ), these data appeared well after clinical patterns of use evolved. 
false	by the nonlinear kinetic characteristics for  <e1> verapamil </e1>  and diltiazem (and probably for  <e2> nifedipine </e2> , as well) and the derivative implications for decreased dosing frequency requirements; 
false	Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing  <e1> transferrin </e1>  alone, they modify the mitogenic effect of EGF and  <e2> insulin </e2> . 
false	These results suggest that both  <e1> dexamethasone </e1>  and retinyl acetate, and possibly other glucocorticoids and  <e2> retinoids </e2> , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.
effect	These results suggest that both dexamethasone and  <e1> retinyl acetate </e1> , and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and  <e2> EGF </e2> .
effect	Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that  <e1> tripelennamine </e1>  was responsible for the inhibitory activity, which was partially antagonized by  <e2> pentazocine </e2> . 
false	Twelve strains of Staphylococcus aureus (a frequent cause of infection in  <e1> heroin </e1> , but not in  <e2> pentazocine </e2>  and tripelennamine, addicts) were completely inhibited by the drug combination. 
false	aureus, to survive in  <e1> pentazocine </e1>  and  <e2> tripelennamine </e2>  may explain in part a shift from S. 
false	The growth of Pseudomonas aeruginosa, particularly serotype O11, in  <e1> pentazocine </e1>  and  <e2> tripelennamine </e2>  
effect	Twelve strains of Staphylococcus aureus (a frequent cause of infection in heroin, but not in  <e1> pentazocine </e1>  and  <e2> tripelennamine </e2> , addicts) were completely inhibited by the drug combination. 
false	Selective survival in  <e1> pentazocine </e1>  and  <e2> tripelennamine </e2>  of Pseudomonas aeruginosa serotype O11 from drug addicts.
false	These alterations in  <e1> digoxin </e1>  pharmacokinetics produced by amiodarone explain the increase in serum  <e2> digoxin </e2>  level that has been observed when this drug combination has been used clinically.
false	The pharmacokinetic variables for digoxin were determined after a 1.0 mg intravenous dose of  <e1> digoxin </e1>  in each subject, before and after oral  <e2> amiodarone </e2> , 400 mg daily for 3 weeks. 
false	Pharmacokinetic evaluation of the  <e1> digoxin </e1> - <e2> amiodarone </e2>  interaction.
false	 <e1> Amiodarone </e1>  caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in  <e2> digoxin </e2>  pharmacokinetics. 
mechanism	During  <e1> amiodarone </e1>  administration, systemic clearance of  <e2> digoxin </e2>  was reduced from 234 +/- 72 ml/min (mean +/- standard deviation) to 172 +/- 33 ml/min (p less than 0.01). 
false	For the  <e1> calcium-entry blocking agents </e1>  now available in the United States (verapamil,  <e2> nifedipine </e2>  and diltiazem), these data appeared well after clinical patterns of use evolved. 
mechanism	These alterations in  <e1> digoxin </e1>  pharmacokinetics produced by  <e2> amiodarone </e2>  explain the increase in serum digoxin level that has been observed when this drug combination has been used clinically.
effect	 <e1> Misonidazole </e1>  protects mouse tumour and normal tissues from the toxicity of oral  <e2> CCNU </e2> .
false	Because the nitrosourea  <e1> CCNU </e1>  is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral  <e2> CCNU </e2> , either alone or in combination with the chemosensitizer misonidazole. 
false	Because the  <e1> nitrosourea </e1>  CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer  <e2> misonidazole </e2> . 
false	Because the nitrosourea CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral  <e1> CCNU </e1> , either alone or in combination with the chemosensitizer  <e2> misonidazole </e2> . 
false	Because the  <e1> nitrosourea </e1>  CCNU is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral  <e2> CCNU </e2> , either alone or in combination with the chemosensitizer misonidazole. 
false	Because the  <e1> nitrosourea </e1>   <e2> CCNU </e2>  is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral CCNU, either alone or in combination with the chemosensitizer misonidazole. 
mechanism	 <e1> Misonidazole </e1>  has a complex effect on oral  <e2> CCNU </e2>  pharmacokinetics. 
effect	 <e1> Misonidazole </e1>  reduced the antitumour activity of oral  <e2> CCNU </e2>  by dose modifying factors (DMF) of 0.58-0.71. 
false	Twelve strains of Staphylococcus aureus (a frequent cause of infection in  <e1> heroin </e1> , but not in pentazocine and  <e2> tripelennamine </e2> , addicts) were completely inhibited by the drug combination. 
mechanism	We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral  <e1> CCNU </e1>  cytotoxicity by  <e2> misonidazole </e2> . 
mechanism	Enhanced  <e1> theophylline </e1>  clearance secondary to  <e2> phenytoin </e2>  therapy.
false	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or  <e1> PCP </e1>  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  <e2> NANM </e2> . 
false	In pigeons, naloxone did not systematically alter the effects of  <e1> (-)-NANM </e1> ,  <e2> (+)-NANM </e2>  or PCP. 
false	In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons  <e1> (-)-NANM </e1>  was about equipotent with  <e2> (+)-NANM </e2> . 
effect	the doses of  <e1> naloxone </e1>  required to antagonize the effects of  <e2> (-)-NANM </e2>  were more than 100 times higher than those required to antagonize the effects of morphine. 
false	Intermediate doses of  <e1> (+)-NANM </e1>  or  <e2> PCP </e2>  produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons; 
false	In monkeys, (-)-NANM was about 10 times more potent than  <e1> (+)-NANM </e1>  in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with  <e2> (+)-NANM </e2> . 
false	In pigeons,  <e1> naloxone </e1>  did not systematically alter the effects of  <e2> (-)-NANM </e2> , (+)-NANM or PCP. 
false	The behavioral effects of the stereoisomers of  <e1> N-allylnormetazocine </e1>  ( <e2> NANM </e2> ) were compared with those of phencyclidine (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 
false	In monkeys,  <e1> (-)-NANM </e1>  was about 10 times more potent than  <e2> (+)-NANM </e2>  in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM. 
effect	 <e1> Haloperidol </e1>  reduced or eliminated the increases in FI responding produced by intermediate doses of either  <e2> (+)-NANM </e2>  or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 
false	In monkeys,  <e1> (-)-NANM </e1>  was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with  <e2> (+)-NANM </e2> . 
false	The behavioral effects of the stereoisomers of  <e1> N-allylnormetazocine </e1>  (NANM) were compared with those of  <e2> phencyclidine </e2>  (PCP) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 
false	In monkeys, the effects of (-)-NANM, but not  <e1> (+)-NANM </e1>  or  <e2> PCP </e2> , were antagonized by naloxone; 
false	In both species,  <e1> (-)-NANM </e1> , but not  <e2> (+)-NANM </e2> , antagonized the rate-decreasing effects of morphine on FI and FR responding. 
effect	 <e1> Haloperidol </e1>  reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or  <e2> PCP </e2>  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 
false	The behavioral effects of the stereoisomers of  <e1> N-allylnormetazocine </e1>  (NANM) were compared with those of phencyclidine ( <e2> PCP </e2> ) in pigeons and squirrel monkeys responding under a multiple fixed-interval fixed-ratio (FI FR) schedule of food presentation. 
false	In pigeons,  <e1> naloxone </e1>  did not systematically alter the effects of (-)-NANM,  <e2> (+)-NANM </e2>  or PCP. 
false	In pigeons,  <e1> naloxone </e1>  did not systematically alter the effects of (-)-NANM, (+)-NANM or  <e2> PCP </e2> . 
false	In both species, (-)-NANM, but not  <e1> (+)-NANM </e1> , antagonized the rate-decreasing effects of  <e2> morphine </e2>  on FI and FR responding. 
false	 <e1> Haloperidol </e1>  reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  <e2> NANM </e2> . 
false	In monkeys, the effects of (-)-NANM, but not (+)-NANM or  <e1> PCP </e1> , were antagonized by  <e2> naloxone </e2> ; 
effect	In both species,  <e1> (-)-NANM </e1> , but not (+)-NANM, antagonized the rate-decreasing effects of  <e2> morphine </e2>  on FI and FR responding. 
false	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either  <e1> (+)-NANM </e1>  or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of  <e2> NANM </e2> . 
false	Since  <e1> caffeine </e1>  is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of  <e2> caffeine </e2>  on the hepatotoxicity of acetaminophen. 
effect	Increased hepatotoxicity of  <e1> acetaminophen </e1>  by concomitant administration of  <e2> caffeine </e2>  in the rat.
effect	the doses of  <e1> naloxone </e1>  required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of  <e2> morphine </e2> . 
false	Since caffeine is frequently co-administered with  <e1> acetaminophen </e1> , it is of clinical interest to study the effect of  <e2> caffeine </e2>  on the hepatotoxicity of acetaminophen. 
false	Since caffeine is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of  <e1> caffeine </e1>  on the hepatotoxicity of  <e2> acetaminophen </e2> . 
false	Since  <e1> caffeine </e1>  is frequently co-administered with  <e2> acetaminophen </e2> , it is of clinical interest to study the effect of caffeine on the hepatotoxicity of acetaminophen. 
false	In pigeons, naloxone did not systematically alter the effects of  <e1> (-)-NANM </e1> , (+)-NANM or  <e2> PCP </e2> . 
false	Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either  <e1> (+)-NANM </e1>  or  <e2> PCP </e2>  in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM. 
false	Since caffeine is frequently co-administered with  <e1> acetaminophen </e1> , it is of clinical interest to study the effect of caffeine on the hepatotoxicity of  <e2> acetaminophen </e2> . 
false	 <e1> Cisplatin </e1>  was administered over the last two hours of the  <e2> thiosulfate </e2>  infusion. 
false	To determine whether injection of thiosulfate would permit larger doses of  <e1> cisplatin </e1>  to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of  <e2> cisplatin </e2> . 
false	Comparison of  <e1> cisplatin </e1>  pharmacokinetics in patients treated with 202.5 mg/m2 plus  <e2> thiosulfate </e2>  to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 
false	To determine whether injection of thiosulfate would permit larger doses of  <e1> cisplatin </e1>  to be administered, a fixed 9.9-g/m2 dose of  <e2> thiosulfate </e2>  was given intravenously over three hours concurrently with escalating doses of cisplatin. 
false	Since  <e1> caffeine </e1>  is frequently co-administered with acetaminophen, it is of clinical interest to study the effect of caffeine on the hepatotoxicity of  <e2> acetaminophen </e2> . 
false	Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus  <e1> thiosulfate </e1>  to those in patients treated with 100 mg/m2 without thiosulfate indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  <e2> cisplatin </e2> . 
false	To determine whether injection of  <e1> thiosulfate </e1>  would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of  <e2> thiosulfate </e2>  was given intravenously over three hours concurrently with escalating doses of cisplatin. 
false	Comparison of cisplatin pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without  <e1> thiosulfate </e1>  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of  <e2> cisplatin </e2> . 
effect	Careful observations on hepatotoxicity are suggested when  <e1> acetaminophen </e1>  is prescribed with  <e2> caffeine </e2> .
false	In monkeys, the effects of  <e1> (-)-NANM </e1> , but not (+)-NANM or  <e2> PCP </e2> , were antagonized by naloxone; 
effect	 <e1> Sodium thiosulfate </e1>  is a neutralizing agent for  <e2> cisplatin </e2>  that protects against renal damage. 
false	Comparison of  <e1> cisplatin </e1>  pharmacokinetics in patients treated with 202.5 mg/m2 plus thiosulfate to those in patients treated with 100 mg/m2 without  <e2> thiosulfate </e2>  indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of cisplatin. 
mechanism	This study demonstrates that concurrent administration of  <e1> thiosulfate </e1>  permits at least a twofold increase in dose and total exposure to  <e2> cisplatin </e2> .
false	To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of  <e1> thiosulfate </e1>  was given intravenously over three hours concurrently with escalating doses of  <e2> cisplatin </e2> . 
false	To determine whether injection of  <e1> thiosulfate </e1>  would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of  <e2> cisplatin </e2> . 
false	Repeated oral administration of coumaphos in sheep: interactions of coumaphos with  <e1> bishydroxycoumarin </e1> ,  <e2> trichlorfon </e2> , and phenobarbital sodium.
false	Interactions between treatments with  <e1> coumaphos </e1> , bishydroxycoumarin (an anticoagulant), trichlorfon (an organophosphorous compound), and  <e2> phenobarbital sodium </e2>  (an inducer of microsomal enzymes) were investigated in sheep. 
false	Repeated oral administration of coumaphos in sheep: interactions of  <e1> coumaphos </e1>  with  <e2> bishydroxycoumarin </e2> , trichlorfon, and phenobarbital sodium.
false	Interactions between treatments with  <e1> coumaphos </e1> ,  <e2> bishydroxycoumarin </e2>  (an anticoagulant), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 
false	Interactions between treatments with  <e1> coumaphos </e1> , bishydroxycoumarin (an anticoagulant), trichlorfon (an  <e2> organophosphorous compound </e2> ), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 
false	Interactions between treatments with  <e1> coumaphos </e1> , bishydroxycoumarin (an anticoagulant),  <e2> trichlorfon </e2>  (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 
false	Interactions between treatments with coumaphos,  <e1> bishydroxycoumarin </e1>  (an  <e2> anticoagulant </e2> ), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 
false	Repeated oral administration of  <e1> coumaphos </e1>  in sheep: interactions of coumaphos with bishydroxycoumarin, trichlorfon, and  <e2> phenobarbital sodium </e2> .
false	Repeated oral administration of coumaphos in sheep: interactions of coumaphos with  <e1> bishydroxycoumarin </e1> , trichlorfon, and  <e2> phenobarbital sodium </e2> .
false	Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant), trichlorfon (an  <e1> organophosphorous compound </e1> ), and  <e2> phenobarbital sodium </e2>  (an inducer of microsomal enzymes) were investigated in sheep. 
effect	In ewes given 40 mg of  <e1> phenobarbital sodium </e1> /kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of  <e2> coumaphos </e2> /kg was significantly reduced and signs of toxicity were not present. 
false	Repeated oral administration of  <e1> coumaphos </e1>  in sheep: interactions of coumaphos with bishydroxycoumarin,  <e2> trichlorfon </e2> , and phenobarbital sodium.
false	Interactions between treatments with  <e1> coumaphos </e1> , bishydroxycoumarin (an  <e2> anticoagulant </e2> ), trichlorfon (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 
false	Interactions between treatments with coumaphos,  <e1> bishydroxycoumarin </e1>  (an anticoagulant), trichlorfon (an organophosphorous compound), and  <e2> phenobarbital sodium </e2>  (an inducer of microsomal enzymes) were investigated in sheep. 
false	A daily dose of 2 mg of  <e1> coumaphos </e1> /kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of  <e2> bishydroxy-coumarin </e2>  in wethers. 
false	Interactions between treatments with coumaphos,  <e1> bishydroxycoumarin </e1>  (an anticoagulant),  <e2> trichlorfon </e2>  (an organophosphorous compound), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 
false	Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant),  <e1> trichlorfon </e1>  (an  <e2> organophosphorous compound </e2> ), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 
effect	The treatment of ewes with an intravenous (IV) injection of  <e1> trichlorfon </e1> , insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of  <e2> coumaphos </e2> /kg/day. 
false	Repeated oral administration of coumaphos in sheep: interactions of  <e1> coumaphos </e1>  with bishydroxycoumarin, trichlorfon, and  <e2> phenobarbital sodium </e2> .
false	Interactions between treatments with coumaphos,  <e1> bishydroxycoumarin </e1>  (an anticoagulant), trichlorfon (an  <e2> organophosphorous compound </e2> ), and phenobarbital sodium (an inducer of microsomal enzymes) were investigated in sheep. 
false	Repeated oral administration of  <e1> coumaphos </e1>  in sheep: interactions of coumaphos with  <e2> bishydroxycoumarin </e2> , trichlorfon, and phenobarbital sodium.
effect	Studies in rats have shown that  <e1> neomycin </e1>  administration attenuates certain types of adrenocortical steroid dependent hypertension, including  <e2> ACTH </e2>  hypertension. 
false	 <e1> Neomycin </e1>  has no effect on the blood pressure or metabolic responses to  <e2> ACTH </e2>  in sheep.
false	Interactions between treatments with coumaphos, bishydroxycoumarin (an anticoagulant),  <e1> trichlorfon </e1>  (an organophosphorous compound), and  <e2> phenobarbital sodium </e2>  (an inducer of microsomal enzymes) were investigated in sheep. 
false	Failure of  <e1> neomycin </e1>  to modify  <e2> ACTH </e2>  induced hypertension in sheep.
false	Studies in rats have shown that  <e1> neomycin </e1>  administration attenuates certain types of  <e2> adrenocortical steroid </e2>  dependent hypertension, including ACTH hypertension. 
false	The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and  <e1> levonorgestrel </e1> -treated rats and the levels shown by rats treated with  <e2> ethynyl estradiol </e2> . 
false	Studies in rats have shown that neomycin administration attenuates certain types of  <e1> adrenocortical steroid </e1>  dependent hypertension, including  <e2> ACTH </e2>  hypertension. 
effect	These results suggest that exposure to environmental  <e1> lead </e1>  may alter the biological and behavioral responsiveness of an animal to  <e2> alcohol </e2> .
false	Changes in urinary homocysteine following  <e1> synthetic steroidal estrogen </e1>  and  <e2> progestogen </e2>  administration to rats.
false	The 20% v/v solution of  <e1> alcohol </e1>  was prepared in water from a stock solution of 95%  <e2> ethanol </e2> . 
false	Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of  <e1> alcohol </e1>  on these components may help to trace pathways which are affected by  <e2> alcohol </e2> . 
false	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, ethanol (2.0 g/kg),  <e1> physostigmine </e1>  (0.6 mg/kg) or  <e2> atropine </e2>  (15.0 mg/kg) on separate days. 
false	Physostigmine pretreatment augmented the depressant effect of  <e1> alcohol </e1>  on the early components P1 and N1, while attenuating  <e2> alcohol </e2> 's influence on components P2 and P3. 
false	In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline,  <e1> ethanol </e1>  (2.0 g/kg),  <e2> physostigmine </e2>  (0.6 mg/kg) or atropine (15.0 mg/kg) on separate days. 
effect	 <e1> Physostigmine </e1>  pretreatment augmented the depressant effect of  <e2> alcohol </e2>  on the early components P1 and N1, while attenuating alcohol's influence on components P2 and P3. 
effect	Core temperature was decreased in rats in a dose-dependent manner when  <e1> ethanol </e1>  was administered to rats treated with  <e2> disulfiram </e2>  8 hours before the ethanol challenge. 
false	The decrease in temperature began within 20 minutes after  <e1> ethanol </e1>  administration, reaching a maximal decrease between 60 and 120 minutes post  <e2> ethanol </e2> . 
false	Decreased core temperature in female rats was investigated as one possible index of the  <e1> disulfiram </e1> - <e2> ethanol </e2>  reaction (DER). 
false	Core temperature was decreased in rats in a dose-dependent manner when ethanol was administered to rats treated with  <e1> disulfiram </e1>  8 hours before the  <e2> ethanol </e2>  challenge. 
false	Maximal hypotension was found 120 minutes post  <e1> ethanol </e1> , and returned to normal 300 minutes after  <e2> ethanol </e2> . 
effect	 <e1> Physostigmine </e1>  pretreatment augmented the depressant effect of alcohol on the early components P1 and N1, while attenuating  <e2> alcohol </e2> 's influence on components P2 and P3. 
false	 <e1> Atropine </e1> , either alone or in combination with  <e2> alcohol </e2> , produced approximately the same degree of enhancement of component P2. 
effect	It was shown that  <e1> neurotensin </e1>  antagonized evidently the antinociceptive effect of  <e2> enkephalins </e2>  and their analogue. 
false	The aim of this paper was to study the interaction between  <e1> neurotensin </e1>  and both  <e2> enkephalins </e2>  or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 
false	The aim of this paper was to study the interaction between  <e1> neurotensin </e1>  and both enkephalins or its synthetic analogue  <e2> D-Ala2-metenkephalinamide </e2> , or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 
effect	Interaction on the antinociceptive effect between  <e1> neurotensin </e1>  and  <e2> enkephalins </e2>  or tuftsin.
false	Interaction on the antinociceptive effect between neurotensin and  <e1> enkephalins </e1>  or  <e2> tuftsin </e2> .
effect	It is concluded that  <e1> neurotensin </e1>  modulates in an opposite way the function of the enkephalinergic neurons and the central action of  <e2> tuftsin </e2> .
false	The aim of this paper was to study the interaction between  <e1> neurotensin </e1>  and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or  <e2> tuftsin </e2> , on the antinonciceptive effect of these peptides in mice after intracisternal injection. 
false	The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue  <e1> D-Ala2-metenkephalinamide </e1> , or  <e2> tuftsin </e2> , on the antinonciceptive effect of these peptides in mice after intracisternal injection. 
false	The aim of this paper was to study the interaction between neurotensin and both  <e1> enkephalins </e1>  or its synthetic analogue  <e2> D-Ala2-metenkephalinamide </e2> , or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection. 
effect	Interaction on the antinociceptive effect between  <e1> neurotensin </e1>  and enkephalins or  <e2> tuftsin </e2> .
effect	Among the risk factors studied, two appear to increase the risk of ARE: the prescription of  <e1> thiabendazole </e1>  to treat strongyloidiasis during the  <e2> melarsoprol </e2>  cure and the bad general clinical conditions of patients. 
false	Recommendations were to avoid administration of diffusible  <e1> anti-helminthic </e1>  treatment during the cure, and to improve the general conditions of patients before the cure of  <e2> melarsoprol </e2> .
mechanism	Consequently, the effect of  <e1> iron </e1>  on the retention of  <e2> cobalt </e2>  was lower than on absorption. 
false	The effects of supplementary oral cobalt and  <e1> iron </e1> , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of  <e2> Fe </e2>  over a period of 19 days in a total of 24 rats. 
mechanism	Interactions of  <e1> cobalt </e1>  and  <e2> iron </e2>  in absorption and retention.
false	Because of the low dietary  <e1> cobalt </e1>  concentration as compared to the iron contents of the diets, no effect of  <e2> cobalt </e2>  on iron absorption and excretion occurred. 
false	The effects of supplementary oral cobalt and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of  <e1> Co </e1>  and 48 or 446 mg/kg of  <e2> Fe </e2>  over a period of 19 days in a total of 24 rats. 
false	The effects of supplementary oral  <e1> cobalt </e1>  and  <e2> iron </e2> , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 
false	Additional iron significantly inhibited the absorption of  <e1> cobalt </e1>  in both dietary  <e2> cobalt </e2>  treatments. 
false	The effects of supplementary oral cobalt and  <e1> iron </e1> , as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of  <e2> Co </e2>  and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 
false	The effects of supplementary oral  <e1> cobalt </e1>  and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of Co and 48 or 446 mg/kg of  <e2> Fe </e2>  over a period of 19 days in a total of 24 rats. 
mechanism	Additional  <e1> iron </e1>  significantly inhibited the absorption of  <e2> cobalt </e2>  in both dietary cobalt treatments. 
false	Because of the low dietary cobalt concentration as compared to the  <e1> iron </e1>  contents of the diets, no effect of cobalt on  <e2> iron </e2>  absorption and excretion occurred. 
false	Because of the low dietary  <e1> cobalt </e1>  concentration as compared to the iron contents of the diets, no effect of cobalt on  <e2> iron </e2>  absorption and excretion occurred. 
false	The lower rate of absorption in the groups receiving 446 mg Fe instead of 48 mg of  <e1> Fe </e1>  per kg diet resulted in a decreased renal excretion of  <e2> cobalt </e2> . 
false	We examined the effect of exogenous  <e1> estradiol </e1>  on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli endotoxin in male rats and the deaths due to nonlethal and lethal doses of  <e2> endotoxin </e2> . 
false	We examined the effect of exogenous  <e1> estradiol </e1>  on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli  <e2> endotoxin </e2>  in male rats and the deaths due to nonlethal and lethal doses of endotoxin. 
false	Because of the low dietary cobalt concentration as compared to the  <e1> iron </e1>  contents of the diets, no effect of  <e2> cobalt </e2>  on iron absorption and excretion occurred. 
false	The effects of supplementary oral  <e1> cobalt </e1>  and iron, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of  <e2> Co </e2>  and 48 or 446 mg/kg of Fe over a period of 19 days in a total of 24 rats. 
false	Because of the low dietary  <e1> cobalt </e1>  concentration as compared to the  <e2> iron </e2>  contents of the diets, no effect of cobalt on iron absorption and excretion occurred. 
mechanism	The serum estrogen concentrations of  <e1> estradiol </e1>  +  <e2> endotoxin </e2> -treated rats decreased by 50%, while those of the endotoxin-treated rats increased (2- to 5-fold). 
false	Injection of estradiol 5 min before a nonlethal dose of  <e1> endotoxin </e1>  changed the serum sex steroid hormone response of male rats to  <e2> endotoxin </e2> . 
effect	Injection of  <e1> estradiol </e1>  5 min before a nonlethal dose of  <e2> endotoxin </e2>  changed the serum sex steroid hormone response of male rats to endotoxin. 
false	The serum androgen concentrations of  <e1> estradiol </e1>  + endotoxin-treated rats did not change significantly, while those of  <e2> endotoxin </e2> -treated rats dropped to 30-40%
false	Injection of  <e1> estradiol </e1>  5 min before a nonlethal dose of endotoxin changed the serum sex steroid hormone response of male rats to  <e2> endotoxin </e2> . 
false	Differences in  <e1> iron </e1>  balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further  <e2> Fe </e2> .(ABSTRACT TRUNCATED AT 250 WORDS)
false	The serum estrogen concentrations of  <e1> estradiol </e1>  + endotoxin-treated rats decreased by 50%, while those of the  <e2> endotoxin </e2> -treated rats increased (2- to 5-fold). 
effect	Exogenous  <e1> estradiol </e1>  also appeared to influence the percentage of  <e2> endotoxin </e2> -induced deaths in a dose-dependent manner. 
effect	 <e1> N-methyllevallorphan </e1>  (5 mg/kg, s.c.) completely antagonized the inhibitory effect of loperamide and partly antagonized the effect of  <e2> morphine </e2> . 
false	On the other hand, the enhanced secretion of colonic fluid by  <e1> dmPGE2 </e1> , given intraluminally, was only half of that in control rats, whereas the colonic transit-enhancing effect of  <e2> dmPGE2 </e2>  in cecectomized rats was more pronounced than in control rats at 15 but not at 30 min after its administration. 
effect	 <e1> N-methyllevallorphan </e1>  (5 mg/kg, s.c.) completely antagonized the inhibitory effect of  <e2> loperamide </e2>  and partly antagonized the effect of morphine. 
mechanism	Additional  <e1> iron </e1>  significantly inhibited the absorption of cobalt in both dietary  <e2> cobalt </e2>  treatments. 
false	We examined the effect of exogenous estradiol on the changes in serum steroid hormone levels induced by a nonlethal dose of Escherichia coli  <e1> endotoxin </e1>  in male rats and the deaths due to nonlethal and lethal doses of  <e2> endotoxin </e2> . 
false	 <e1> Loperamide </e1>  and  <e2> morphine </e2>  (0.1 and 1.0 mg/kg, s.c.) 
false	 <e1> Loperamide </e1>  and  <e2> morphine </e2>  (0.1 and 1.0 mg/kg, s.c.) inhibited the dmPGE2 (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 
false	The serum androgen concentrations of  <e1> estradiol </e1>  +  <e2> endotoxin </e2> -treated rats did not change significantly, while those of endotoxin-treated rats dropped to 30-40%
mechanism	Due to its nephrotoxicity,  <e1> gentamicin </e1>  may cause abnormal renal uptake to be seen on  <e2> 99mTc-MDP </e2>  bone scintigraphy. 
false	Therapeutic drug monitoring (TDM) of  <e1> gentamicin </e1>  therapy, and bone scintigraphy employing 99mTc-MDP as the  <e2> radiopharmaceutical </e2>  was carried out in 22 patients. 
effect	Therapeutic drug monitoring can avoid iatrogenic alterations caused by  <e1> 99mTc-methylene diphosphonate </e1>  (MDP)- <e2> gentamicin </e2>  interaction.
false	The data presented here demonstrate that with serial pharmacokinetic dosing of  <e1> gentamicin </e1> , the iatrogenic alteration caused by  <e2> gentamicin </e2>  therapy can be avoided.
false	Therapeutic drug monitoring (TDM) of  <e1> gentamicin </e1>  therapy, and bone scintigraphy employing  <e2> 99mTc-MDP </e2>  as the radiopharmaceutical was carried out in 22 patients. 
false	N-methyllevallorphan (5 mg/kg, s.c.) completely antagonized the inhibitory effect of  <e1> loperamide </e1>  and partly antagonized the effect of  <e2> morphine </e2> . 
false	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids,  <e1> cyclosporin </e1> , azathioprine, methotrexate,  <e2> cyclophosphamide </e2> ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin,  <e1> azathioprine </e1> ,  <e2> methotrexate </e2> , cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
effect	 <e1> Loperamide </e1>  and morphine (0.1 and 1.0 mg/kg, s.c.) inhibited the  <e2> dmPGE2 </e2>  (0.3 mg/kg, p.o.)-induced diarrhea in cecectomized rats. 
false	This article looks at five commonly used  <e1> immunosuppressive drugs </e1>  in turn (corticosteroids, cyclosporin, azathioprine, methotrexate,  <e2> cyclophosphamide </e2> ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	This article looks at five commonly used immunosuppressive drugs in turn ( <e1> corticosteroids </e1> ,  <e2> cyclosporin </e2> , azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	This article looks at five commonly used  <e1> immunosuppressive drugs </e1>  in turn (corticosteroids, cyclosporin, azathioprine,  <e2> methotrexate </e2> , cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids,  <e1> cyclosporin </e1> ,  <e2> azathioprine </e2> , methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	This article looks at five commonly used  <e1> immunosuppressive drugs </e1>  in turn ( <e2> corticosteroids </e2> , cyclosporin, azathioprine, methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	This article looks at five commonly used  <e1> immunosuppressive drugs </e1>  in turn (corticosteroids, cyclosporin,  <e2> azathioprine </e2> , methotrexate, cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids,  <e1> cyclosporin </e1> , azathioprine,  <e2> methotrexate </e2> , cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	 <e1> Gentamicin </e1>  is an  <e2> aminoglycoside antibiotic </e2>  used to treat a wide variety of infections caused by gram-negative organisms, but it is potentially toxic to the kidneys. 
false	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol,  <e1> methanol </e1> , higher  <e2> alcohols </e2>  and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 
false	This article looks at five commonly used immunosuppressive drugs in turn (corticosteroids, cyclosporin,  <e1> azathioprine </e1> , methotrexate,  <e2> cyclophosphamide </e2> ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing  <e1> ethanol </e1> ,  <e2> methanol </e2> , higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages; 
false	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher  <e1> alcohols </e1>  and  <e2> acetaldehyde </e2>  in the same proportions as those found in most common distilled and fermented alcoholic beverages; 
effect	These results suggest that the hepatoxicity of  <e1> ethanol </e1>  in alcoholic beverages is enhanced by interaction with its congeners and  <e2> acetaldehyde </e2> ; 
false	This article looks at five commonly used immunosuppressive drugs in turn ( <e1> corticosteroids </e1> , cyclosporin, azathioprine,  <e2> methotrexate </e2> , cyclophosphamide), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing  <e1> ethanol </e1> , methanol, higher alcohols and  <e2> acetaldehyde </e2>  in the same proportions as those found in most common distilled and fermented alcoholic beverages; 
effect	Combined treatment with  <e1> 1,25(OH)2D3 </e1>  and  <e2> TAM </e2>  enhances the degree of apoptosis assessed using morphological markers that identify chromatin and nuclear matrix protein condensation. 
false	1, <e1> 25-Dihydroxycholecalciferol D3 </e1>  ( <e2> 1,25(OH)2D3 </e2> ), the active metabolite of vitamin D, is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 
false	These data emphasize that apoptosis can be induced in MCF-7 cells either by activation of  <e1> vitamin-D </e1> -mediated signalling or disruption of  <e2> estrogen </e2> -dependent signalling.
false	This article looks at five commonly used immunosuppressive drugs in turn ( <e1> corticosteroids </e1> , cyclosporin, azathioprine, methotrexate,  <e2> cyclophosphamide </e2> ), discussing the main, non-infection, unwanted effects, ways to avoid them and what to do if problems arise. 
false	In the experiments reported here, we examined the interactions between  <e1> 1,25(OH)2D3 </e1>  and the  <e2> antiestrogen </e2>  4-hydroxytamoxifen (TAM), which also induces apoptosis in MCF-7 cells. 
false	1, <e1> 25-Dihydroxycholecalciferol D3 </e1>  (1,25(OH)2D3), the active metabolite of  <e2> vitamin D </e2> , is a potent inhibitor of breast cancer cell growth both in vivo and in vitro. 
false	Little has been studied of the adverse effects of the exposure of the liver to the interaction of  <e1> ethanol </e1>  with its congeners and  <e2> acetaldehyde </e2> , coexisting in the contents of alcoholic beverages. 
false	In the experiments reported here, we examined the interactions between 1,25(OH)2D3 and the  <e1> antiestrogen </e1>   <e2> 4-hydroxytamoxifen </e2>  (TAM), which also induces apoptosis in MCF-7 cells. 
false	In the experiments reported here, we examined the interactions between  <e1> 1,25(OH)2D3 </e1>  and the antiestrogen  <e2> 4-hydroxytamoxifen </e2>  (TAM), which also induces apoptosis in MCF-7 cells. 
effect	Our data suggest that  <e1> TAM </e1>  significantly potentiates the reduction in cell number induced by  <e2> 1,25(OH)2D3 </e2>  alone. 
false	Induction of apoptosis in breast cancer cells in response to  <e1> vitamin D </e1>  and  <e2> antiestrogens </e2> .
false	We investigated the effects of adenosine receptor antagonists, caffeine, theophylline,  <e1> 8-phenyltheophylline </e1> , and 8-cyclopentyl-1,3-dipropylxanthine ( <e2> DPCPX </e2> ), in a light/dark test in mice. 
false	The anxiogenic effects of theophylline were reduced by pretreatment with  <e1> CGS 21680 </e1> , an A2-selective agonist, but not by  <e2> N6-cyclopentyladenosine </e2>  (CPA), an A1-selective agonist. 
false	However, the antagonism of the theophylline-induced anxiogenic effects by  <e1> CGS21680 </e1>  was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by  <e2> CPA </e2> . 
false	We investigated the effects of adenosine receptor antagonists, caffeine,  <e1> theophylline </e1> ,  <e2> 8-phenyltheophylline </e2> , and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 
false	However, the antagonism of the theophylline-induced anxiogenic effects by  <e1> CGS21680 </e1>  was only observed in the time spent in the light zone, and  <e2> DPCPX </e2> -induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 
false	We investigated the effects of adenosine receptor antagonists, caffeine, theophylline,  <e1> 8-phenyltheophylline </e1> , and  <e2> 8-cyclopentyl-1,3-dipropylxanthine </e2>  (DPCPX), in a light/dark test in mice. 
false	The anxiogenic effects of  <e1> theophylline </e1>  were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by  <e2> N6-cyclopentyladenosine </e2>  (CPA), an A1-selective agonist. 
false	However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and  <e1> DPCPX </e1> -induced anxiogenic effects were neither reversed by CGS 21680 nor by  <e2> CPA </e2> . 
false	However, the antagonism of the  <e1> theophylline </e1> -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by  <e2> CPA </e2> . 
effect	The anxiogenic effects of  <e1> theophylline </e1>  were reduced by pretreatment with  <e2> CGS 21680 </e2> , an A2-selective agonist, but not by N6-cyclopentyladenosine (CPA), an A1-selective agonist. 
false	We investigated the effects of adenosine receptor antagonists,  <e1> caffeine </e1> ,  <e2> theophylline </e2> , 8-phenyltheophylline, and 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), in a light/dark test in mice. 
false	However, the antagonism of the  <e1> theophylline </e1> -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and  <e2> DPCPX </e2> -induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 
false	However, the antagonism of the  <e1> theophylline </e1> -induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by  <e2> CGS 21680 </e2>  nor by CPA. 
false	However, the antagonism of the theophylline-induced anxiogenic effects by CGS21680 was only observed in the time spent in the light zone, and  <e1> DPCPX </e1> -induced anxiogenic effects were neither reversed by  <e2> CGS 21680 </e2>  nor by CPA. 
false	We investigated the effects of adenosine receptor antagonists, caffeine,  <e1> theophylline </e1> , 8-phenyltheophylline, and  <e2> 8-cyclopentyl-1,3-dipropylxanthine </e2>  (DPCPX), in a light/dark test in mice. 
false	However, the antagonism of the theophylline-induced anxiogenic effects by  <e1> CGS21680 </e1>  was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by  <e2> CGS 21680 </e2>  nor by CPA. 
false	[The effect of  <e1> sandimmune </e1>  on the activity of mixed-function mono-oxidases in the liver microsomes];The effects of the i <e2> mmunodepressant- </e2> -the drug sandimmune--on hepatic microsomal monooxygenase activities were studied. 
effect	However, the antagonism of the  <e1> theophylline </e1> -induced anxiogenic effects by  <e2> CGS21680 </e2>  was only observed in the time spent in the light zone, and DPCPX-induced anxiogenic effects were neither reversed by CGS 21680 nor by CPA. 
false	[The effect of  <e1> sandimmune </e1>  on the activity of mixed-function mono-oxidases in the liver microsomes];The effects of the immunodepressant--the drug s <e2> andimmune- </e2> -on hepatic microsomal monooxygenase activities were studied. 
false	[The effect of sandimmune on the activity of mixed-function mono-oxidases in the liver microsomes];The effects of the i <e1> mmunodepressant- </e1> -the drug s <e2> andimmune- </e2> -on hepatic microsomal monooxygenase activities were studied. 
false	The anxiogenic effects of  <e1> theophylline </e1>  were reduced by pretreatment with CGS 21680, an A2-selective agonist, but not by N6-cyclopentyladenosine ( <e2> CPA </e2> ), an A1-selective agonist. 
false	We investigated the effects of adenosine receptor antagonists, caffeine, theophylline, 8-phenyltheophylline, and  <e1> 8-cyclopentyl-1,3-dipropylxanthine </e1>  ( <e2> DPCPX </e2> ), in a light/dark test in mice. 
false	[The effect of  <e1> cimetidine </e1>  on the renal excretion of verografin and  <e2> iodamide </e2>  in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 
false	[The effect of cimetidine on the renal excretion of  <e1> verografin </e1>  and  <e2> iodamide </e2>  in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 
false	[The effect of cimetidine on the renal excretion of verografin and  <e1> iodamide </e1>  in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and i <e2> odamide  </e2> excretion in chronic canine experiments. 
false	[The effect of  <e1> cimetidine </e1>  on the renal excretion of verografin and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and i <e2> odamide  </e2> excretion in chronic canine experiments. 
false	[The effect of cimetidine on the renal excretion of verografin and  <e1> iodamide </e1>  in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v <e2> erografine  </e2> and iodamide excretion in chronic canine experiments. 
false	Possible extrarenal mechanisms of action of  <e1> cimetidine </e1>  on verografine and  <e2> iodamide </e2>  transport were also examined.
false	[The effect of  <e1> cimetidine </e1>  on the renal excretion of verografin and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced v <e2> erografine  </e2> and iodamide excretion in chronic canine experiments. 
false	We investigated the effects of adenosine receptor antagonists,  <e1> caffeine </e1> , theophylline, 8-phenyltheophylline, and  <e2> 8-cyclopentyl-1,3-dipropylxanthine </e2>  (DPCPX), in a light/dark test in mice. 
false	Possible extrarenal mechanisms of action of  <e1> cimetidine </e1>  on  <e2> verografine </e2>  and iodamide transport were also examined.
false	Possible extrarenal mechanisms of action of cimetidine on  <e1> verografine </e1>  and  <e2> iodamide </e2>  transport were also examined.
mechanism	[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs];The intravenous injection of c <e1> imetidine  </e1> in a dose of 20 mg/kg enhanced v <e2> erografine  </e2> and iodamide excretion in chronic canine experiments. 
false	[The effect of cimetidine on the renal excretion of verografin and  <e1> iodamide </e1>  in dogs];The intravenous injection of c <e2> imetidine  </e2> in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 
mechanism	[The effect of cimetidine on the renal excretion of verografin and iodamide in dogs];The intravenous injection of c <e1> imetidine  </e1> in a dose of 20 mg/kg enhanced verografine and i <e2> odamide  </e2> excretion in chronic canine experiments. 
false	[The effect of cimetidine on the renal excretion of  <e1> verografin </e1>  and iodamide in dogs];The intravenous injection of c <e2> imetidine  </e2> in a dose of 20 mg/kg enhanced verografine and iodamide excretion in chronic canine experiments. 
false	[The effect of cimetidine on the renal excretion of  <e1> verografin </e1>  and iodamide in dogs];The intravenous injection of cimetidine in a dose of 20 mg/kg enhanced verografine and i <e2> odamide  </e2> excretion in chronic canine experiments. 
false	Physiological oral  <e1> magnesium </e1>  supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with  <e2> magnesium salt </e2> s, with practically only one contra-indication: overt renal failure. 
false	Two different types of therapy with  <e1> magnesium </e1>  are used: physiological oral  <e2> magnesium </e2>  supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 
false	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between  <e1> magnesium </e1>  deficiency due to an insufficient  <e2> magnesium </e2>  intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 
false	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between  <e1> magnesium </e1>  deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of  <e2> magnesium </e2>  status which requires more or less specific regulation of its causal dysregulation. 
false	Specific and aspecific treatments of magnesium depletion are tricky using for example  <e1> magnesium sparing diuretics </e1> , pharmacological doses of  <e2> vitamin B6 </e2> , physiological doses of vitamin D and of selenium. 
false	Two different types of therapy with  <e1> magnesium </e1>  are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic  <e2> magnesium </e2>  overload. 
false	Two different types of therapy with  <e1> magnesium </e1>  are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological  <e2> magnesium </e2>  therapy which may induce toxicity since it creates iatrogenic magnesium overload. 
false	Two different types of therapy with  <e1> magnesium </e1>  are used: physiological oral magnesium supplementation which is totally atoxic since it palliates  <e2> magnesium </e2>  deficiencies by simply normalizing the magnesium intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 
false	Specific and aspecific treatments of magnesium depletion are tricky using for example  <e1> magnesium sparing diuretics </e1> , pharmacological doses of vitamin B6, physiological doses of  <e2> vitamin D </e2>  and of selenium. 
false	Specific and aspecific treatments of  <e1> magnesium </e1>  depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of  <e2> vitamin D </e2>  and of selenium. 
false	The higher  <e1> verografine </e1>  and  <e2> iodamide </e2>  excretion was due to their increased renal tubular secretion. 
false	Lastly local use of the mucocutaneous and cytoprotective properties of  <e1> magnesium </e1>  is still valid, in  <e2> cardioplegic solutions </e2>  and for preservation of transplants particularly.
false	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the  <e1> magnesium </e1>  intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic  <e2> magnesium </e2>  overload. 
false	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient  <e1> magnesium </e1>  intake which only requires oral physiological supplementation and  <e2> magnesium </e2>  depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 
false	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological  <e1> magnesium </e1>  therapy which may induce toxicity since it creates iatrogenic  <e2> magnesium </e2>  overload. 
false	Specific and aspecific treatments of  <e1> magnesium </e1>  depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of vitamin D and of  <e2> selenium </e2> . 
false	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between  <e1> magnesium </e1>  deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and  <e2> magnesium </e2>  depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 
false	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the  <e1> magnesium </e1>  intake and pharmacological  <e2> magnesium </e2>  therapy which may induce toxicity since it creates iatrogenic magnesium overload. 
false	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  <e1> magnesium </e1>  deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and  <e2> magnesium </e2>  depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 
false	Specific and aspecific treatments of  <e1> magnesium </e1>  depletion are tricky using for example  <e2> magnesium sparing diuretics </e2> , pharmacological doses of vitamin B6, physiological doses of vitamin D and of selenium. 
false	There are 3 types of indications: specific (for the treatment of some forms of  <e1> magnesium </e1>  deficit i.e. acute), pharmacological (i.e. without alterations of  <e2> magnesium </e2>  status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism). 
false	Specific and aspecific treatments of magnesium depletion are tricky using for example  <e1> magnesium sparing diuretics </e1> , pharmacological doses of vitamin B6, physiological doses of vitamin D and of  <e2> selenium </e2> . 
false	Two different types of therapy with magnesium are used: physiological oral magnesium supplementation which is totally atoxic since it palliates  <e1> magnesium </e1>  deficiencies by simply normalizing the magnesium intake and pharmacological  <e2> magnesium </e2>  therapy which may induce toxicity since it creates iatrogenic magnesium overload. 
false	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  <e1> magnesium </e1>  deficit and to discriminate between magnesium deficiency due to an insufficient  <e2> magnesium </e2>  intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 
false	Specific and aspecific treatments of magnesium depletion are tricky using for example magnesium sparing diuretics, pharmacological doses of vitamin B6, physiological doses of  <e1> vitamin D </e1>  and of  <e2> selenium </e2> . 
false	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of  <e1> magnesium </e1>  deficit and to discriminate between  <e2> magnesium </e2>  deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation. 
effect	The successive application of  <e1> glycine </e1>  (5 or 10 mg/kg egg weight (e.w.) and  <e2> glutamate </e2>  (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone. 
false	Two different types of therapy with  <e1> magnesium </e1>  are used: physiological oral magnesium supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the  <e2> magnesium </e2>  intake and pharmacological magnesium therapy which may induce toxicity since it creates iatrogenic magnesium overload. 
false	Two different types of therapy with magnesium are used: physiological oral  <e1> magnesium </e1>  supplementation which is totally atoxic since it palliates magnesium deficiencies by simply normalizing the magnesium intake and pharmacological  <e2> magnesium </e2>  therapy which may induce toxicity since it creates iatrogenic magnesium overload. 
false	Primary and secondary  <e1> magnesium </e1>  deficiencies constitute the sole indication of physiological oral  <e2> magnesium </e2>  therapy. 
false	Physiological oral  <e1> magnesium </e1>  load constitutes the best tool for diagnosis of  <e2> magnesium </e2>  deficiency and the first step of its treatment. 
false	It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient  <e1> magnesium </e1>  intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of  <e2> magnesium </e2>  status which requires more or less specific regulation of its causal dysregulation. 
false	This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as  <e1> cocaine </e1>  and  <e2> desipramine </e2> , in the nonfailing heart only. 
false	Compromised  <e1> norepinephrine </e1>  uptake-1 in functional class IV cannot be further increased by  <e2> cocaine </e2>  and desipramine. 
effect	The uptake inhibitors cocaine and  <e1> desipramine </e1>  (3 mumol/liter) potentiated the positive inotropic effects of  <e2> norepinephrine </e2>  in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 
false	The successive application of  <e1> glycine </e1>  (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of  <e2> glutamate </e2>  alone. 
effect	The uptake inhibitors  <e1> cocaine </e1>  and desipramine (3 mumol/liter) potentiated the positive inotropic effects of  <e2> norepinephrine </e2>  in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 
false	Radioligand binding experiments using the uptake inhibitor hydrogen-3  <e1> mazindol </e1>  revealed a significant decrease by approximately 30% in  <e2> norepinephrine </e2>  uptake-1 carrier density in functional classes II to III and IV myocardium versus nonfailing myocardium (p < 0.05). 
false	Compromised norepinephrine uptake-1 in functional class IV cannot be further increased by  <e1> cocaine </e1>  and  <e2> desipramine </e2> . 
false	[A pharmacological analysis of the effect of  <e1> angiotensin </e1>  on stimulated gastric secretion];Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on p <e2> entagastrin- </e2>  and histamine-induced gastric acid secretion. 
false	The uptake inhibitors  <e1> cocaine </e1>  and  <e2> desipramine </e2>  (3 mumol/liter) potentiated the positive inotropic effects of norepinephrine in nonfailing myocardium (p < 0.05) but not in functional class IV myocardium. 
false	[A pharmacological analysis of the effect of  <e1> angiotensin </e1>  on stimulated gastric secretion];Chronic experiments on dogs with gastric fistulas were carried out to study the influence of a <e2> ngiotensin 1  </e2> and angiotensin 2 on pentagastrin- and histamine-induced gastric acid secretion. 
false	[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion];Chronic experiments on dogs with gastric fistulas were carried out to study the influence of a <e1> ngiotensin 1  </e1> and a <e2> ngiotensin 2  </e2> on pentagastrin- and histamine-induced gastric acid secretion. 
false	[A pharmacological analysis of the effect of  <e1> angiotensin </e1>  on stimulated gastric secretion];Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on pentagastrin- and h <e2> istamine- </e2> induced gastric acid secretion. 
false	[A pharmacological analysis of the effect of  <e1> angiotensin </e1>  on stimulated gastric secretion];Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and a <e2> ngiotensin 2  </e2> on pentagastrin- and histamine-induced gastric acid secretion. 
false	[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion];Chronic experiments on dogs with gastric fistulas were carried out to study the influence of angiotensin 1 and angiotensin 2 on p <e1> entagastrin- </e1>  and h <e2> istamine- </e2> induced gastric acid secretion. 
false	[A pharmacological analysis of the effect of angiotensin on stimulated gastric secretion];Chronic experiments on dogs with gastric fistulas were carried out to study the influence of a <e1> ngiotensin 1  </e1> and angiotensin 2 on pentagastrin- and h <e2> istamine- </e2> induced gastric acid secretion. 
effect	It was concluded that, although  <e1> gentamycin </e1>  did augment the neuromuscular blockade of  <e2> atracurium </e2> , the effect was minimal.
false	 <e1> Atracurium </e1>  was again given by infusion to maintain 40% twitch for a second hour, then 2 mg  <e2> gentamycin </e2> /kg bwt were given i.v. 
int	Interaction of  <e1> gentamycin </e1>  and  <e2> atracurium </e2>  in anaesthetised horses.
false	At 75% recovery of fade, hoof twitch was 87 +/- 3% for  <e1> atracurium </e1>  alone and 82 +/- 4% for atracurium plus  <e2> gentamycin </e2> . 
false	Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for  <e1> atracurium </e1>  alone and 11.5 +/- 2.7 min for  <e2> atracurium </e2>  plus gentamycin (P = 0.03). 
false	The EC50 values for  <e1> isoproterenol </e1> , which is not a substrate for  <e2> norepinephrine </e2>  uptake-1, were reduced in myocardium in functional classes II to III and IV compared with those in nonfailing myocardium. 
false	Comparative analysis of the effects of stimulation and inhibition of cholino- and adrenoreceptors on this inhibitory action of  <e1> angiotensins </e1>  suggested the mediation of  <e2> angiotensin </e2>  influence through the modulation of cholinergic reactions of parietal cells in the stomach.
false	Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for  <e1> atracurium </e1>  alone and 13.7 +/- 1.2 min for  <e2> atracurium </e2>  plus gentamycin. 
false	Evoked hind limb digital extensor tension (hoof twitch) was maintained at 40% of baseline for 1 h by  <e1> atracurium </e1>  infusion in 7 horses anaesthetised with  <e2> halothane </e2> . 
effect	Recovery of hoof twitch from 50% to 75% took 7.7 +/- 0.7 min for atracurium alone and 11.5 +/- 2.7 min for  <e1> atracurium </e1>  plus  <e2> gentamycin </e2>  (P = 0.03). 
effect	At 75% recovery of fade, hoof twitch was 87 +/- 3% for atracurium alone and 82 +/- 4% for  <e1> atracurium </e1>  plus  <e2> gentamycin </e2> . 
false	Recovery from 50% twitch to 75% fade recovery took 13.8 +/- 0.8 min for  <e1> atracurium </e1>  alone and 13.7 +/- 1.2 min for atracurium plus  <e2> gentamycin </e2> . 
false	At 75% recovery of fade, hoof twitch was 87 +/- 3% for  <e1> atracurium </e1>  alone and 82 +/- 4% for  <e2> atracurium </e2>  plus gentamycin. 
false	The benzodiazepines are a family of  <e1> anxiolytic </e1>  and  <e2> hypnotic drugs </e2> . 
false	In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a  <e1> benzodiazepine </e1> ) and  <e2> ethanol </e2>  under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 
mechanism	Acid-catalyzed ethanolysis of  <e1> temazepam </e1>  in anhydrous and aqueous  <e2> ethanol </e2>  solutions.
false	The  <e1> benzodiazepines </e1>  are a family of  <e2> anxiolytic </e2>  and hypnotic drugs. 
mechanism	In addition to this pharmacological interaction, this report describes a novel chemical reaction between  <e1> temazepam </e1>  (a benzodiazepine) and  <e2> ethanol </e2>  under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 
false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1>  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2>  versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 
false	Weekly intramuscular  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1>  injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2>  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 
false	In  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> /vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys. 
false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1>  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 
effect	In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals, almost 40% loss of tyrosine hydroxylase-positive norepinephrine neurons was found in locus coeruleus/A5/A7 noradrenaline cell groups, whereas the extent of neuronal loss was lower than 15% of control values in  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> / <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated monkeys. 
false	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated monkeys were significantly affected. 
false	After 21 weeks of  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1>  treatment, all 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated animals displayed parkinsonian symptoms, whereas none of the  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 
effect	The  <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1>  treatment also had a significant effect on the  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> -induced loss of norepinephrine neurons in the locus coeruleus and adjoining A5 and A7 noradrenaline cell groups. 
false	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> /3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated animals than in  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /vehicle-treated monkeys. 
false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> /3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /vehicle). 
false	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1> -treated animals than in  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /vehicle-treated monkeys. 
false	After 21 weeks of  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1>  treatment, all  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 
false	In addition to this pharmacological interaction, this report describes a novel chemical reaction between  <e1> temazepam </e1>  (a  <e2> benzodiazepine </e2> ) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product. 
false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/ <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1>  versus  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /vehicle). 
effect	These behavioural observations were consistent with in vivo positron emission tomography dopamine transporter imaging data, and with post-mortem stereological counts of midbrain dopaminergic neurons, as well as striatal intensity measurements of dopamine transporter and tyrosine hydroxylase immunoreactivity, which were all significantly higher in  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> / <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2> -treated animals than in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle-treated monkeys. 
false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups ( <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> / <e2> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e2>  versus 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/vehicle). 
false	Co-administration of  <e1> panobinostat </e1>  with CYP3A inhibitors is feasible as the observed increase in  <e2> panobinostat </e2>  PK parameters was not considered clinically relevant. 
effect	Our data demonstrate that chronic treatment with the metabotropic glutamate receptor 5 antagonist,  <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1> , significantly reduces  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2>  toxicity towards dopaminergic and noradrenergic cell groups in non-human primates. 
mechanism	In the presence of  <e1> ketoconazole </e1> , there was 1.6- and 1.8-fold increase in C (max) and AUC of  <e2> panobinostat </e2> , respectively. 
false	On day 8, a single  <e1> panobinostat </e1>  dose was co-administered with  <e2> ketoconazole </e2> . 
false	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of  <e1> panobinostat </e1>  ( <e2> LBH589 </e2> ), an orally active histone deacetylase inhibitor.
false	After 21 weeks of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment, all  <e1> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e1> /vehicle-treated animals displayed parkinsonian symptoms, whereas none of the  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine-treated monkeys were significantly affected. 
false	Effect of  <e1> ketoconazole </e1> -mediated CYP3A4 inhibition on clinical pharmacokinetics of  <e2> panobinostat </e2>  (LBH589), an orally active histone deacetylase inhibitor.
false	Effect of  <e1> ketoconazole </e1> -mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active  <e2> histone deacetylase inhibitor </e2> .
false	Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat ( <e1> LBH589 </e1> ), an orally active  <e2> histone deacetylase inhibitor </e2> .
false	Weekly intramuscular 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine injections (0.2-0.5 mg/kg body weight), in combination with daily administration of  <e1> 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine </e1>  or vehicle, were performed until the development of parkinsonian motor symptoms in either of the two experimental groups (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/3-[(2-methyl-1,3-thiazol-4-yl) ethynyl] pyridine versus  <e2> 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine </e2> /vehicle). 
false	 <e1> Moxifloxacin </e1>  and  <e2> Lomefloxacin </e2>  reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 
false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate,  <e1> gelusil </e1> , erythromycin and  <e2> multi minerals </e2> . 
false	Moxifloxacin and Lomefloxacin reacts faster with  <e1> sucralfate </e1>  and  <e2> gelusil </e2>  in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 
mechanism	 <e1> Moxifloxacin </e1>  and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and  <e2> multi-minerals </e2>  in neutral media. 
mechanism	 <e1> Moxifloxacin </e1>  and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with  <e2> erythromycin </e2>  in basic media and multi-minerals in neutral media. 
false	Moxifloxacin and Lomefloxacin reacts faster with  <e1> sucralfate </e1>  and gelusil in acidic media whereas with  <e2> erythromycin </e2>  in basic media and multi-minerals in neutral media. 
mechanism	 <e1> Moxifloxacin </e1>  and Lomefloxacin reacts faster with  <e2> sucralfate </e2>  and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 
false	Being moxifloxacin and lomefloxacin  <e1> fluoroquinolones </e1>  the interaction study of was carried out with sucralfate, gelusil,  <e2> erythromycin </e2>  and multi minerals. 
false	Being  <e1> moxifloxacin </e1>  and lomefloxacin  <e2> fluoroquinolones </e2>  the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. 
false	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and  <e1> gelusil </e1>  in acidic media whereas with erythromycin in basic media and  <e2> multi-minerals </e2>  in neutral media. 
false	Being moxifloxacin and lomefloxacin  <e1> fluoroquinolones </e1>  the interaction study of was carried out with sucralfate,  <e2> gelusil </e2> , erythromycin and multi minerals. 
false	Being  <e1> moxifloxacin </e1>  and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and  <e2> multi minerals </e2> . 
mechanism	Moxifloxacin and  <e1> Lomefloxacin </e1>  reacts faster with  <e2> sucralfate </e2>  and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 
false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with  <e1> sucralfate </e1> , gelusil, erythromycin and  <e2> multi minerals </e2> . 
false	Being  <e1> moxifloxacin </e1>  and lomefloxacin fluoroquinolones the interaction study of was carried out with  <e2> sucralfate </e2> , gelusil, erythromycin and multi minerals. 
false	 <e1> Moxifloxacin </e1>  and  <e2> lomefloxacin </e2>  are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. 
false	 <e1> Moxifloxacin </e1>  and lomefloxacin are  <e2> fluoroquinolone antibiotics </e2>  used in treating urinary and respiratory tract infections. 
false	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with  <e1> erythromycin </e1>  in basic media and  <e2> multi-minerals </e2>  in neutral media. 
false	Effect of  <e1> ketoconazole </e1> -mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat ( <e2> LBH589 </e2> ), an orally active histone deacetylase inhibitor.
false	Considering the variability in exposure following enzyme inhibition and the fact that chronic dosing of  <e1> panobinostat </e1>  was not studied with CYP3A inhibitors, close monitoring of  <e2> panobinostat </e2> -related adverse events is necessary.
false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with  <e1> sucralfate </e1> , gelusil,  <e2> erythromycin </e2>  and multi minerals. 
mechanism	 <e1> Moxifloxacin </e1>  and Lomefloxacin reacts faster with sucralfate and  <e2> gelusil </e2>  in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 
false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with  <e1> sucralfate </e1> ,  <e2> gelusil </e2> , erythromycin and multi minerals. 
false	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral  <e1> ketamine </e1>  by 2.4-fold, whereas itraconazole treatment did not increase the exposure to  <e2> S-ketamine </e2> . 
advise	The findings suggest that the dosage of  <e1> S-ketamine </e1>  should be reduced in patients receiving  <e2> ticlopidine </e2> .
false	Being  <e1> moxifloxacin </e1>  and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil,  <e2> erythromycin </e2>  and multi minerals. 
false	 <e1> Ticlopidine </e1>  treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas  <e2> itraconazole </e2>  treatment did not increase the exposure to S-ketamine. 
false	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas  <e1> itraconazole </e1>  treatment did not increase the exposure to  <e2> S-ketamine </e2> . 
false	Moxifloxacin and Lomefloxacin reacts faster with  <e1> sucralfate </e1>  and gelusil in acidic media whereas with erythromycin in basic media and  <e2> multi-minerals </e2>  in neutral media. 
mechanism	 <e1> Ticlopidine </e1>  treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral  <e2> ketamine </e2>  by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. 
false	Being  <e1> moxifloxacin </e1>  and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate,  <e2> gelusil </e2> , erythromycin and multi minerals. 
false	In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg  <e1> S-ketamine </e1>  after pretreatments with oral  <e2> ticlopidine </e2>  (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 
false	This study examined drug-drug interactions of oral  <e1> S-ketamine </e1>  with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor  <e2> itraconazole </e2> . 
false	Moxifloxacin and Lomefloxacin reacts faster with sucralfate and  <e1> gelusil </e1>  in acidic media whereas with  <e2> erythromycin </e2>  in basic media and multi-minerals in neutral media. 
effect	Exposure to oral  <e1> S-ketamine </e1>  is unaffected by itraconazole but greatly increased by  <e2> ticlopidine </e2> .
false	Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral  <e1> ketamine </e1>  by 2.4-fold, whereas  <e2> itraconazole </e2>  treatment did not increase the exposure to S-ketamine. 
false	The ratio of norketamine AUC(0-   ) to  <e1> ketamine </e1>  AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and  <e2> itraconazole </e2>  phases (P = 0.006) as compared to placebo. 
false	The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the  <e1> ticlopidine </e1>  (P &lt; 0.001) and  <e2> itraconazole </e2>  phases (P = 0.006) as compared to placebo. 
false	The ratio of norketamine AUC(0-   ) to  <e1> ketamine </e1>  AUC(0-   ) was significantly decreased in the  <e2> ticlopidine </e2>  (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 
false	In the  <e1> ticlopidine </e1>  and  <e2> itraconazole </e2>  phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). 
false	In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg  <e1> S-ketamine </e1>  after pretreatments with oral ticlopidine (250 mg twice daily),  <e2> itraconazole </e2>  (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. 
false	Exposure to oral  <e1> S-ketamine </e1>  is unaffected by  <e2> itraconazole </e2>  but greatly increased by ticlopidine.
effect	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with  <e1> DZNep </e1>  and  <e2> ABT-737 </e2> , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 
mechanism	Moxifloxacin and  <e1> Lomefloxacin </e1>  reacts faster with sucralfate and  <e2> gelusil </e2>  in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. 
false	Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate,  <e1> gelusil </e1> ,  <e2> erythromycin </e2>  and multi minerals. 
false	The ratio of  <e1> norketamine </e1>  AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the  <e2> ticlopidine </e2>  (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. 
false	We also found that Bcl-2 was overexpressed in  <e1> DZNep </e1>  insensitive cells, and cotreatment with DZNep and  <e2> ABT-737 </e2> , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 
false	This study examined drug-drug interactions of oral  <e1> S-ketamine </e1>  with the cytochrome P450 (CYP) 2B6 inhibitor  <e2> ticlopidine </e2>  and the CYP3A inhibitor itraconazole. 
false	In addition,  <e1> DZNep </e1>  insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and  <e2> DZNep </e2>  could synergistically induced apoptosis. 
false	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with  <e1> DZNep </e1>  and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of  <e2> DZNep </e2>  insensitive MM cells. 
false	We also found that Bcl-2 was overexpressed in  <e1> DZNep </e1>  insensitive cells, and cotreatment with  <e2> DZNep </e2>  and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. 
false	The ratio of  <e1> norketamine </e1>  AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and  <e2> itraconazole </e2>  phases (P = 0.006) as compared to placebo. 
false	In addition,  <e1> DZNep </e1>  insensitivity might be associated with overexpression of Bcl-2, and the combination of  <e2> ABT-737 </e2>  and DZNep could synergistically induced apoptosis. 
effect	We present an interesting case of an HIV-positive woman on  <e1> antiretroviral </e1>  therapy having tubal pregnancies on two separate occasions with  <e2> Implanon </e2>  in place.
effect	In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of  <e1> ABT-737 </e1>  and  <e2> DZNep </e2>  could synergistically induced apoptosis. 
false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of  <e1> citalopram </e1>  (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]),  <e2> paroxetine </e2>  (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 
false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of  <e1> citalopram </e1>  (OR   =   1.73 [95% CI, 1.25-2.38]),  <e2> fluoxetine </e2>  (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 
false	Warfarin users who initiated  <e1> citalopram </e1> , fluoxetine,  <e2> paroxetine </e2> , amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 
false	Warfarin users who initiated citalopram, fluoxetine,  <e1> paroxetine </e1> ,  <e2> amitriptyline </e2> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 
false	Warfarin users who initiated  <e1> citalopram </e1> ,  <e2> fluoxetine </e2> , paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 
false	 <e1> Antidepressant </e1> - <e2> warfarin </e2>  interaction and associated gastrointestinal bleeding risk in a case-control study.
effect	 <e1> Warfarin </e1>  users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]),  <e2> amitriptyline </e2>  (OR   =   1.47 [95% CI, 1.02-2.11]). 
effect	 <e1> Warfarin </e1>  users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]),  <e2> fluoxetine </e2>  (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 
false	We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and  <e1> ABT-737 </e1> , a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of  <e2> DZNep </e2>  insensitive MM cells. 
effect	 <e1> Warfarin </e1>  users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]),  <e2> paroxetine </e2>  (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 
effect	 <e1> Warfarin </e1>  users who initiated citalopram, fluoxetine,  <e2> paroxetine </e2> , amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 
effect	 <e1> Warfarin </e1>  users who initiated citalopram, fluoxetine, paroxetine,  <e2> amitriptyline </e2> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 
false	Warfarin users who initiated citalopram,  <e1> fluoxetine </e1> , paroxetine,  <e2> amitriptyline </e2> , or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 
false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]),  <e1> paroxetine </e1>  (OR   =   1.64 [95% CI, 1.27-2.12]),  <e2> amitriptyline </e2>  (OR   =   1.47 [95% CI, 1.02-2.11]). 
effect	 <e1> Warfarin </e1>  users who initiated  <e2> citalopram </e2> , fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 
false	Warfarin users who initiated citalopram, fluoxetine,  <e1> paroxetine </e1> , amitriptyline, or  <e2> mirtazapine </e2>  had an increased risk of hospitalization for gastrointestinal bleeding. 
false	Warfarin users who initiated  <e1> citalopram </e1> , fluoxetine, paroxetine, amitriptyline, or  <e2> mirtazapine </e2>  had an increased risk of hospitalization for gastrointestinal bleeding. 
false	We sought to evaluate whether initiation of an  <e1> antidepressant </e1>  increases the risk of hospitalization for gastrointestinal bleeding in  <e2> warfarin </e2>  users.
false	With respect to toxicity, the order of CYP inhibitor effectiveness was  <e1> ABT </e1> > <e2> diethyldithiocarbamate </e2> ~tranylcypromine>ketoconazole. 
false	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~ <e1> tranylcypromine </e1> > <e2> ketoconazole </e2> . 
false	Warfarin users who initiated citalopram,  <e1> fluoxetine </e1> ,  <e2> paroxetine </e2> , amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 
false	These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of  <e1> precocene I </e1>  and therefore may not be an appropriate model for  <e2> precocene I </e2>  metabolism. 
false	With respect to toxicity, the order of CYP inhibitor effectiveness was  <e1> ABT </e1> >diethyldithiocarbamate~ <e2> tranylcypromine </e2> >ketoconazole. 
false	With respect to toxicity, the order of CYP inhibitor effectiveness was ABT> <e1> diethyldithiocarbamate </e1> ~ <e2> tranylcypromine </e2> >ketoconazole. 
effect	 <e1> Warfarin </e1>  users had an increased odds ratio of gastrointestinal bleeding upon initiation of  <e2> citalopram </e2>  (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 
false	Furafylline and  <e1> sulfaphenazole </e1>  had no effect, while  <e2> quinidine </e2>  appeared to augment precocene I toxicity. 
false	Of the isoform-specific CYP inhibitors tested for an effect on the  <e1> precocene I </e1>  metabolite profile, only  <e2> tranylcypromine </e2>  was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. 
effect	 <e1> Warfarin </e1>  users who initiated citalopram,  <e2> fluoxetine </e2> , paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. 
false	 <e1> Furafylline </e1>  and sulfaphenazole had no effect, while  <e2> quinidine </e2>  appeared to augment precocene I toxicity. 
false	 <e1> Furafylline </e1>  and  <e2> sulfaphenazole </e2>  had no effect, while quinidine appeared to augment precocene I toxicity. 
false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]),  <e1> fluoxetine </e1>  (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]),  <e2> amitriptyline </e2>  (OR   =   1.47 [95% CI, 1.02-2.11]). 
effect	 <e1> AAV2 </e1> -mediated retinal transduction is improved by co-injection of  <e2> heparinase III </e2>  or chondroitin ABC lyase. 
false	 <e1> AAV2 </e1>  containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase,  <e2> heparinase III </e2> , or chondroitin ABC lyase. 
false	AAV2-mediated retinal transduction is improved by co-injection of  <e1> heparinase III </e1>  or  <e2> chondroitin ABC lyase </e2> . 
effect	 <e1> AAV2 </e1> -mediated retinal transduction is improved by co-injection of heparinase III or  <e2> chondroitin ABC lyase </e2> . 
false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  <e1> collagenase </e1> , hyaluronan lyase, heparinase III, or  <e2> chondroitin ABC lyase </e2> . 
false	The addition of  <e1> heparinase III </e1>  or  <e2> chondroitin ABC lyase </e2>  greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. 
false	Electroretinograms survived with higher concentrations of  <e1> heparinase III </e1>  and  <e2> chondroitin ABC lyase </e2>  than were required for optimal retinal transduction. 
false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase,  <e1> hyaluronan lyase </e1> , heparinase III, or  <e2> chondroitin ABC lyase </e2> . 
false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  <e1> collagenase </e1> , hyaluronan lyase,  <e2> heparinase III </e2> , or chondroitin ABC lyase. 
false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including  <e1> collagenase </e1> ,  <e2> hyaluronan lyase </e2> , heparinase III, or chondroitin ABC lyase. 
false	Warfarin users who initiated citalopram, fluoxetine, paroxetine,  <e1> amitriptyline </e1> , or  <e2> mirtazapine </e2>  had an increased risk of hospitalization for gastrointestinal bleeding. 
false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase,  <e1> heparinase III </e1> , or  <e2> chondroitin ABC lyase </e2> . 
false	Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]),  <e1> fluoxetine </e1>  (OR   =   1.63 [95% CI, 1.11-2.38]),  <e2> paroxetine </e2>  (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). 
false	We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose  <e1> ketamine </e1>  in conjunction with  <e2> propofol </e2>  for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. 
false	EA signs were observed in all 7 patients in association with  <e1> propofol </e1>  TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to  <e2> propofol </e2> . 
false	Based on this experience, we suggest that low-dose  <e1> ketamine </e1>  added to propofol may be associated with prevention of EA in children with a history of EA with  <e2> propofol </e2>  TIVA.
false	AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase,  <e1> hyaluronan lyase </e1> ,  <e2> heparinase III </e2> , or chondroitin ABC lyase. 
effect	Based on this experience, we suggest that low-dose  <e1> ketamine </e1>  added to  <e2> propofol </e2>  may be associated with prevention of EA in children with a history of EA with propofol TIVA.
false	Prevention of emergence agitation in seven children receiving low-dose  <e1> ketamine </e1>  and  <e2> propofol </e2>  total intravenous anesthesia.
false	Based on this experience, we suggest that low-dose ketamine added to  <e1> propofol </e1>  may be associated with prevention of EA in children with a history of EA with  <e2> propofol </e2>  TIVA.
false	 <e1> Paroxetine </e1>  and  <e2> fluoxetine </e2>  reduce the plasma concentration of endoxifen by about 50%. 
mechanism	Paroxetine and  <e1> fluoxetine </e1>  reduce the plasma concentration of  <e2> endoxifen </e2>  by about 50%. 
false	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially  <e1> SSRI antidepressants </e1>  such as  <e2> paroxetine </e2>  and fluoxetine. 
false	If in certain cases, an antidepressant is considered necessary, it may be advisable to replace  <e1> tamoxifen </e1>  with  <e2> anastrozole </e2> .
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with  <e1> tamoxifen </e1>  for breast cancer, especially SSRI antidepressants such as  <e2> paroxetine </e2>  and fluoxetine. 
false	EA signs were observed in all 7 patients in association with  <e1> propofol </e1>  TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose  <e2> ketamine </e2>  was added to propofol. 
false	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially  <e1> SSRI antidepressants </e1>  such as paroxetine and  <e2> fluoxetine </e2> . 
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with  <e1> tamoxifen </e1>  for breast cancer, especially  <e2> SSRI antidepressants </e2>  such as paroxetine and fluoxetine. 
false	If in certain cases, an  <e1> antidepressant </e1>  is considered necessary, it may be advisable to replace tamoxifen with  <e2> anastrozole </e2> .
false	In female rats, neonatal  <e1> quinpirole </e1>  treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to  <e2> amphetamine </e2> . 
false	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with  <e1> quinpirole </e1> -free controls conditioned with amphetamine, but only female controls conditioned with  <e2> amphetamine </e2>  spent more time in the drug-paired context compared with saline-treated controls. 
false	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with  <e1> quinpirole </e1> -free controls conditioned with  <e2> amphetamine </e2> , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 
false	 <e1> Tamoxifen </e1> , an  <e2> estrogen antagonist </e2> , is the standard hormone treatment for breast cancer. 
false	Rats treated with neonatal  <e1> quinpirole </e1>  enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with  <e2> amphetamine </e2>  spent more time in the drug-paired context compared with saline-treated controls. 
false	Rats treated with neonatal  <e1> quinpirole </e1>  enhanced time spent in the amphetamine-paired context compared with  <e2> quinpirole </e2> -free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 
false	In female rats, neonatal quinpirole treatment enhanced  <e1> amphetamine </e1>  locomotor sensitization compared with quinpirole-free controls sensitized to  <e2> amphetamine </e2> . 
false	Rats treated with neonatal quinpirole enhanced time spent in the  <e1> amphetamine </e1> -paired context compared with  <e2> quinpirole </e2> -free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 
false	In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with  <e1> quinpirole </e1> -free controls sensitized to  <e2> amphetamine </e2> . 
false	Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with  <e1> amphetamine </e1> , but only female controls conditioned with  <e2> amphetamine </e2>  spent more time in the drug-paired context compared with saline-treated controls. 
advise	It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with  <e1> tamoxifen </e1>  for breast cancer, especially SSRI antidepressants such as paroxetine and  <e2> fluoxetine </e2> . 
mechanism	 <e1> Paroxetine </e1>  and fluoxetine reduce the plasma concentration of  <e2> endoxifen </e2>  by about 50%. 
false	 <e1> Amphetamine </e1>  locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with  <e2> quinpirole </e2> .
effect	In female rats, neonatal  <e1> quinpirole </e1>  treatment enhanced  <e2> amphetamine </e2>  locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. 
false	Male rats demonstrated sensitization to  <e1> amphetamine </e1> , although this was muted compared with female rats, and were unaffected by neonatal  <e2> quinpirole </e2> . 
false	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving  <e1> cyclosporine </e1>  than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice,  <e2> cyclosporine </e2>  is the stronger of the two with respect to CYP3A inhibition. 
false	Rats treated with neonatal  <e1> quinpirole </e1>  enhanced time spent in the  <e2> amphetamine </e2> -paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 
false	Rats treated with neonatal  <e1> quinpirole </e1>  enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with  <e2> amphetamine </e2> , but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. 
false	The latter displayed  <e1> midazolam </e1>  clearances similar to those in two larger cohorts of nonmatched  <e2> tacrolimus </e2> -treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). 
false	This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving  <e1> tacrolimus </e1> , indicating that, at the doses generally used in clinical practice,  <e2> cyclosporine </e2>  is the stronger of the two with respect to CYP3A inhibition. 
false	Rats treated with neonatal quinpirole enhanced time spent in the  <e1> amphetamine </e1> -paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with  <e2> amphetamine </e2>  spent more time in the drug-paired context compared with saline-treated controls. 
false	The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched  <e1> tacrolimus </e1> -treated patients (n = 58 and n = 80) and to those receiving a  <e2> calcineurin inhibitor </e2> -free regimen (n = 6). 
mechanism	Systemic and apparent oral  <e1> midazolam </e1>  clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in  <e2> cyclosporine </e2> -treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). 
false	In female rats, neonatal  <e1> quinpirole </e1>  treatment enhanced amphetamine locomotor sensitization compared with  <e2> quinpirole </e2> -free controls sensitized to amphetamine. 
false	In vivo CYP3A activity is significantly lower in  <e1> cyclosporine </e1> -treated as compared with  <e2> tacrolimus </e2> -treated renal allograft recipients.
false	The primary objective of the study was to ascertain the difference in  <e1> darbepoetin </e1>  responsiveness before and after 12 months of  <e2> cinacalcet </e2>  therapy. 
false	Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in  <e1> cyclosporine </e1> -treated patients (n = 20) than in matched  <e2> tacrolimus </e2> -treated patients (n = 20). 
false	Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to  <e1> erythropoietin </e1>  ( <e2> EPO </e2> ) resistance. 
effect	Reduction of PTH by  <e1> cinacalcet </e1>  is associated with a decrease in  <e2> darbepoetin </e2>  requirement. 
false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU,  <e1> cisplatin </e1> , doxorubicin and etoposide    <e2> celecoxib </e2>  following different incubation schedules were analyzed.
false	This study investigates the ability of  <e1> cyclooxygenase-2 inhibitors </e1>  to sensitize cells from different origins to several  <e2> chemotherapeutic agents </e2> . 
false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and  <e1> etoposide </e1>     <e2> celecoxib </e2>  following different incubation schedules were analyzed.
false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin,  <e1> doxorubicin </e1>  and  <e2> etoposide </e2>    celecoxib following different incubation schedules were analyzed.
false	Improved parathyroid hormone control by  <e1> cinacalcet </e1>  is associated with reduction in  <e2> darbepoetin </e2>  requirement in patients with end-stage renal disease.
false	We found antagonism between  <e1> celecoxib </e1>  and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and  <e2> doxorubicin </e2>  in all cell lines except for two combinations in HCT116 cells. 
false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  <e1> 5-FU </e1> ,  <e2> cisplatin </e2> , doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.
false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU,  <e1> cisplatin </e1> ,  <e2> doxorubicin </e2>  and etoposide   celecoxib following different incubation schedules were analyzed.
false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  <e1> 5-FU </e1> , cisplatin, doxorubicin and etoposide    <e2> celecoxib </e2>  following different incubation schedules were analyzed.
false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin,  <e1> doxorubicin </e1>  and etoposide    <e2> celecoxib </e2>  following different incubation schedules were analyzed.
effect	Interaction of  <e1> celecoxib </e1>  with different  <e2> anti-cancer drugs </e2>  is antagonistic in breast but not in other cancer cells.
false	To date, there is no conclusive evidence of a clinically-relevant interaction between any of the  <e1> proton pump inhibitors </e1>  and  <e2> clopidogrel </e2> .
false	[Interaction between  <e1> clopidogrel </e1>  and  <e2> proton pump inhibitors </e2> ].
effect	We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between  <e1> celecoxib </e1>  and  <e2> doxorubicin </e2>  in all cell lines except for two combinations in HCT116 cells. 
mechanism	Concomitant use of  <e1> omeprazole </e1>  and  <e2> clopidogrel </e2>  was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. 
false	Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors  <e1> omeprazole </e1>  and  <e2> esomeprazole </e2>  should be avoided. 
false	The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to  <e1> 5-FU </e1> , cisplatin,  <e2> doxorubicin </e2>  and etoposide   celecoxib following different incubation schedules were analyzed.
false	The influence of the other  <e1> proton pump inhibitors </e1>  when used simultaneously with  <e2> clopidogrel </e2>  has not yet been investigated in adequately randomized studies. 
advise	Regulatory agencies state that the combination of  <e1> clopidogrel </e1>  and the CYP2C19 inhibitors omeprazole and  <e2> esomeprazole </e2>  should be avoided. 
false	Medical treatment with  <e1> cinacalcet </e1>  is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on  <e2> darbepoetin </e2>  dosing is unknown. 
false	Concomitant use of  <e1> omeprazole </e1>  and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by  <e2> omeprazole </e2>  of CYP2C19, a cytochrome P450 (CYP) enzyme. 
false	This study aimed to evaluate the in vitro activity of  <e1> minocycline </e1>  combined with fosfomycin against isolates of  <e2> methicillin </e2> -resistant Staphylococcus aureus (MRSA). 
false	This study aimed to evaluate the in vitro activity of minocycline combined with  <e1> fosfomycin </e1>  against isolates of  <e2> methicillin </e2> -resistant Staphylococcus aureus (MRSA). 
effect	The combination of  <e1> minocycline </e1>  and  <e2> fosfomycin </e2>  can be synergistic against MRSA. 
false	Contradictory results regarding the effect of  <e1> proton pump inhibitors </e1>  on platelet reactivity and on clinical outcome in  <e2> clopidogrel </e2> -treated patients have been reported in literature. 
advise	Regulatory agencies state that the combination of  <e1> clopidogrel </e1>  and the CYP2C19 inhibitors  <e2> omeprazole </e2>  and esomeprazole should be avoided. 
false	In vitro activity of  <e1> minocycline </e1>  combined with fosfomycin against clinical isolates of  <e2> methicillin </e2> -resistant Staphylococcus aureus.
false	In vitro activity of minocycline combined with  <e1> fosfomycin </e1>  against clinical isolates of  <e2> methicillin </e2> -resistant Staphylococcus aureus.
mechanism	 <e1> Pantoprazole </e1>  has a much weaker effect on  <e2> clopidogrel </e2> 's pharmacokinetics and on platelet reactivity during concomitant use. 
false	Drug interaction of  <e1> thyroxine </e1>  with  <e2> simeticone </e2>  has not been reported previously and is not listed in the British National Formulary for Children. 
false	In vitro activity of  <e1> minocycline </e1>  combined with  <e2> fosfomycin </e2>  against clinical isolates of methicillin-resistant Staphylococcus aureus.
int	The authors report the case of an infant with confirmed congenital hypothyroidism on  <e1> levothyroxine </e1>  who experienced a possible drug interaction with  <e2> simeticone </e2> . 
mechanism	In conclusion, we demonstrated an isolated effect of  <e1> calcium </e1>  (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC)  <e2> iron </e2> . 
false	Calcium does not inhibit the absorption of 5 milligrams of nonheme or  <e1> heme i <e2> ron </e1>  </e2>  at doses less than 800 milligrams in nonpregnant women.
mechanism	In conclusion, we demonstrated an isolated effect of  <e1> calcium </e1>  (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC)  <e2> iron </e2> . 
false	 <e1> Calcium </e1>  does not inhibit the absorption of 5 milligrams of nonheme or heme  <e2> iron </e2>  at doses less than 800 milligrams in nonpregnant women.
mechanism	However, the evidence for a  <e1> calcium </e1>  effect on  <e2> iron </e2>  absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. 
false	Our objective was to establish potential effects of calcium on absorption of nonheme and  <e1> heme i <e2> ron </e1>  </e2>  and the dose response for this effect in the absence of a meal. 
false	Our objective was to establish potential effects of  <e1> calcium </e1>  on absorption of nonheme and heme  <e2> iron </e2>  and the dose response for this effect in the absence of a meal. 
false	Our objective was to establish potential effects of  <e1> calcium </e1>  on absorption of nonheme and  <e2> heme iron </e2>  and the dose response for this effect in the absence of a meal. 
false	We evaluated the effects of  <e1> calcium </e1>  doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as  <e2> ferrous sulfate </e2> ). 
false	 <e1> Calcium </e1>  does not inhibit the absorption of 5 milligrams of nonheme or  <e2> heme iron </e2>  at doses less than 800 milligrams in nonpregnant women.
false	 <e1> Calcium </e1>  was administered as  <e2> calcium chloride </e2>  in all studies and minerals were ingested on an empty stomach. 
false	We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg  <e1> nonheme iron </e1>  (as  <e2> ferrous sulfate </e2> ). 
mechanism	A  <e1> calcium </e1>  dose of 800 mg diminished absorption of 5 mg  <e2> heme iron </e2>  by 37.7%. 
false	This study aimed to evaluate the in vitro activity of  <e1> minocycline </e1>  combined with  <e2> fosfomycin </e2>  against isolates of methicillin-resistant Staphylococcus aureus (MRSA). 
false	However, the evidence for a calcium effect on  <e1> iron </e1>  absorption mainly comes from studies that did not isolate the effect of  <e2> calcium </e2>  from that of other dietary components, because it was detected in single-meal studies. 
effect	When cells were exposed to  <e1> docetaxel </e1>  followed by  <e2> sunitinib </e2> , synergism was observed. 
false	 <e1> Sunitinib </e1>  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  <e2> docetaxel </e2>  followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.
mechanism	 <e1> Calcium </e1>  is the only known component in the diet that may affect absorption of both nonheme and  <e2> heme iron </e2> . 
false	This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of  <e1> sunitinib </e1>  and  <e2> docetaxel </e2>  in NSCLC cell lines that are resistant to EGFR TKIs.
int	Synergistic interaction between  <e1> sunitinib </e1>  and  <e2> docetaxel </e2>  is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.
false	This study was aimed to investigate the efficacy of single use of  <e1> sunitinib </e1>  and that of concurrent or sequential administration of sunitinib and  <e2> docetaxel </e2>  in NSCLC cell lines that are resistant to EGFR TKIs.
effect	Although single or concurrent use of  <e1> sunitinib </e1>  and  <e2> docetaxel </e2>  has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. 
false	In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC)  <e1> i <e2> ron </e1>  </e2> . 
false	 <e1> Sunitinib </e1>  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by  <e2> docetaxel </e2>  and concurrent administration.
false	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  <e1> docetaxel </e1>  followed by sunitinib is superior to  <e2> sunitinib </e2>  followed by docetaxel and concurrent administration.
false	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by  <e1> sunitinib </e1>  is superior to sunitinib followed by  <e2> docetaxel </e2>  and concurrent administration.
false	 <e1> Sunitinib </e1>  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by  <e2> sunitinib </e2>  is superior to sunitinib followed by docetaxel and concurrent administration.
false	 <e1> Sunitinib </e1>  as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to  <e2> sunitinib </e2>  followed by docetaxel and concurrent administration.
false	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by  <e1> sunitinib </e1>  is superior to  <e2> sunitinib </e2>  followed by docetaxel and concurrent administration.
false	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to  <e1> sunitinib </e1>  followed by  <e2> docetaxel </e2>  and concurrent administration.
false	We also evaluated the effects of  <e1> calcium </e1>  doses between 200 and 800 mg on absorption of 5 mg  <e2> heme iron </e2>  [as concentrated RBC (CRBC)]. 
false	Results revealed that the strains were resistant to many drugs at high levels, only piperacillin,  <e1> carbenicillin </e1> ,  <e2> amikacin </e2>  and ciprofloxacin showed resistances at comparatively lower levels. 
effect	Distinct and statistically significant synergism was observed between  <e1> methylglyoxal </e1>  and  <e2> piperacillin </e2>  by disc diffusion tests when compared with their individual effects. 
effect	Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of  <e1> docetaxel </e1>  followed by  <e2> sunitinib </e2>  is superior to sunitinib followed by docetaxel and concurrent administration.
false	Results revealed that the strains were resistant to many drugs at high levels, only  <e1> piperacillin </e1> , carbenicillin,  <e2> amikacin </e2>  and ciprofloxacin showed resistances at comparatively lower levels. 
mechanism	 <e1> Calcium </e1>  is the only known component in the diet that may affect absorption of both nonheme and heme  <e2> iron </e2> . 
false	Results revealed that the strains were resistant to many drugs at high levels, only piperacillin,  <e1> carbenicillin </e1> , amikacin and  <e2> ciprofloxacin </e2>  showed resistances at comparatively lower levels. 
false	Results revealed that the strains were resistant to many drugs at high levels, only  <e1> piperacillin </e1> ,  <e2> carbenicillin </e2> , amikacin and ciprofloxacin showed resistances at comparatively lower levels. 
false	Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin,  <e1> amikacin </e1>  and  <e2> ciprofloxacin </e2>  showed resistances at comparatively lower levels. 
effect	Synergism was also noted when  <e1> methylglyoxal </e1>  was combined with  <e2> carbenicillin </e2>  and amikacin.
false	Results revealed that the strains were resistant to many drugs at high levels, only  <e1> piperacillin </e1> , carbenicillin, amikacin and  <e2> ciprofloxacin </e2>  showed resistances at comparatively lower levels. 
false	Distinct synergistic action of  <e1> piperacillin </e1>  and  <e2> methylglyoxal </e2>  against Pseudomonas aeruginosa.
false	The effects of anti-parkinsonian drug  <e1> hemantane </e1>  [ <e2> (2-adamantyl)hexamethylenimine </e2> ] (10 mg/kg, p. o.) 
false	and/or  <e1> antibiotic drug </e1>  doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( <e2> MPTP </e2> ) (4 x 20 mg/kg, i. p.) 
false	and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin  <e1> 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine </e1>  ( <e2> MPTP </e2> ) (4 x 20 mg/kg, i. p.) 
false	and/or  <e1> antibiotic drug </e1>   <e2> doxycycline </e2>  (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) 
false	and/or antibiotic drug  <e1> doxycycline </e1>  (100 mg/kg, p. o.), as well as that of neurotoxin  <e2> 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine </e2>  (MPTP) (4 x 20 mg/kg, i. p.) 
false	The effects of  <e1> anti-parkinsonian drug </e1>  hemantane [ <e2> (2-adamantyl)hexamethylenimine </e2> ] (10 mg/kg, p. o.) 
false	and/or antibiotic drug  <e1> doxycycline </e1>  (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine ( <e2> MPTP </e2> ) (4 x 20 mg/kg, i. p.) 
effect	(ii)  <e1> acetyl-l-carnitine </e1>  elicits a significant protective effect on DEB induced toxicity, which was potentiated by   <e2> alpha-lipoic acid </e2> .
false	The siRNA knockdown of p27(Kip1) decreased  <e1> dasatinib </e1> - and  <e2> paclitaxel </e2> -induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). 
false	The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by  <e1> dasatinib </e1>  and  <e2> paclitaxel </e2>  were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. 
effect	Treatment of HEY xenograft-bearing mice with  <e1> dasatinib </e1>  plus  <e2> paclitaxel </e2>  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 
false	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  <e1> dasatinib </e1>  +  <e2> paclitaxel </e2>  vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 
false	Treatment of HEY xenograft-bearing mice with  <e1> dasatinib </e1>  plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs  <e2> paclitaxel </e2> : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 
false	Treatment of HEY xenograft-bearing mice with dasatinib plus  <e1> paclitaxel </e1>  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  <e2> dasatinib </e2>  + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 
false	Protective effect of  <e1> acetyl-l-carnitine </e1>  and   <e2> alpha lipoic acid </e2>  against the acute toxicity of diepoxybutane to human lymphocytes.
false	The effects of  <e1> anti-parkinsonian drug </e1>   <e2> hemantane </e2>  [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) 
false	Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse,  <e1> dasatinib </e1>  + paclitaxel vs  <e2> paclitaxel </e2> : 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 
effect	Acute administration of  <e1> hemantane </e1>  or  <e2> doxycycline </e2>  failed to influence locomotion in mice, while their combination normalized motor activity. 
effect	Inhibition of Src family and Abl kinases with either siRNAs or  <e1> dasatinib </e1>  enhances  <e2> paclitaxel </e2>  sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.
false	The effect of  <e1> dasatinib </e1> , an inhibitor of Src and Abl kinases, on  <e2> paclitaxel </e2>  sensitivity was measured in ovarian cancer cells and HEY xenografts. 
effect	Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that  <e1> dasatinib </e1> -mediated induction of p27(Kip1) enhanced  <e2> paclitaxel </e2> -induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. 
false	Phase I trial of  <e1> lenalidomide </e1>  and CCI-779 in patients with relapsed multiple myeloma: evidence for  <e2> lenalidomide </e2> -CCI-779 interaction via P-glycoprotein.
false	Treatment of HEY xenograft-bearing mice with dasatinib plus  <e1> paclitaxel </e1>  inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib +  <e2> paclitaxel </e2>  vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 
false	Treatment of HEY xenograft-bearing mice with  <e1> dasatinib </e1>  plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib +  <e2> paclitaxel </e2>  vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); 
effect	The preclinical combination of  <e1> lenalidomide </e1>  with the mTOR inhibitor  <e2> CCI-779 </e2>  has displayed synergy in vitro and represents a novel combination in MM.
false	Phase I trial of lenalidomide and  <e1> CCI-779 </e1>  in patients with relapsed multiple myeloma: evidence for  <e2> lenalidomide </e2> -CCI-779 interaction via P-glycoprotein.
false	Phase I trial of  <e1> lenalidomide </e1>  and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide- <e2> CCI-779 </e2>  interaction via P-glycoprotein.
false	The objective of this study was to evaluate the effect of oral administration of  <e1> ginseng stem-and-leaf saponins </e1>  ( <e2> GSLS </e2> ) on the humoral immune responses of chickens to inactivated ND and AI vaccines. 
false	Considering the safety of  <e1> GSLS </e1> , because no adverse effect was found throughout the experiments,  <e2> GSLS </e2>  may be a promising oral adjuvant to improve immunization in poultry.
effect	In experiment 2, the same regimen of  <e1> GSLS </e1>  was administered to chickens inoculated with  <e2> inactivated AI vaccines </e2> , and an enhanced serum antibody response to AI vaccination was also observed. 
false	The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins ( <e1> GSLS </e1> ) on the humoral immune responses of chickens to inactivated ND and AI  <e2> vaccines </e2> . 
false	Phase I trial of  <e1> lenalidomide </e1>  and  <e2> CCI-779 </e2>  in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
false	Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for  <e1> lenalidomide </e1> - <e2> CCI-779 </e2>  interaction via P-glycoprotein.
false	In experiment 1, oral administration of  <e1> GSLS </e1>  at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with  <e2> inactivated ND vaccine </e2>  was evaluated. 
false	The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and  <e1> AI </e1>   <e2> vaccines </e2> . 
false	The effect of  <e1> DTIC </e1>  and  <e2> imexon </e2> , alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). 
effect	The role of p27(Kip1) in  <e1> dasatinib </e1> -enhanced  <e2> paclitaxel </e2>  cytotoxicity in human ovarian cancer cells.
false	We evaluated mechanisms of interaction between the alkyating agent  <e1> dacarbazine </e1>  ( <e2> DTIC </e2> ) and the pro-oxidant, imexon, in the human A375 melanoma cell line.
false	Enhancement of humoral immune responses to inactivated Newcastle disease and  <e1> avian influenza vaccines </e1>  by oral administration of  <e2> ginseng stem-and-leaf saponins </e2>  in chickens.
false	We evaluated mechanisms of interaction between the alkyating agent  <e1> dacarbazine </e1>  (DTIC) and the pro-oxidant,  <e2> imexon </e2> , in the human A375 melanoma cell line.
false	There was a >75% reduction in cellular glutathione and cysteine with  <e1> imexon </e1>  but not  <e2> DTIC </e2> . 
effect	Furthermore, we present a case report in which a second  <e1> Herceptin </e1>  treatment following  <e2> lapatinib </e2>  resulted in the marked shrinkage of multiple metastatic tumors in HER2-positive breast cancer. 
effect	In an in vitro assay,  <e1> lapatinib </e1>  induced HER2 expression at the cell surface of HER2-positive breast cancer cell lines, leading to the enhancement of  <e2> Herceptin </e2> -mediated ADCC. 
false	We evaluated how  <e1> lapatinib </e1>  interacts with  <e2> Herceptin </e2>  in HER2-positive breast cancer, with a particular focus on Herceptin-mediated antibody-dependent cellular cytotoxicity (ADCC). 
false	We evaluated how  <e1> lapatinib </e1>  interacts with Herceptin in HER2-positive breast cancer, with a particular focus on  <e2> Herceptin </e2> -mediated antibody-dependent cellular cytotoxicity (ADCC). 
false	 <e1> Lapatinib </e1>  may have the potential to convert  <e2> Herceptin </e2> -refractory to Herceptin-sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
false	Although it was previously reported that  <e1> lapatinib </e1>  combined with Herceptin improved the progression-free survival rate compared with  <e2> lapatinib </e2>  alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
effect	 <e1> Lapatinib </e1>  enhances  <e2> herceptin </e2> -mediated antibody-dependent cellular cytotoxicity by up-regulation of cell surface HER2 expression.
false	Although it was previously reported that lapatinib combined with  <e1> Herceptin </e1>  improved the progression-free survival rate compared with lapatinib alone for patients with  <e2> Herceptin </e2> -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
false	Interaction of  <e1> dacarbazine </e1>  and  <e2> imexon </e2> , in vitro and in vivo, in human A375 melanoma cells.
false	Although it was previously reported that lapatinib combined with Herceptin improved the progression-free survival rate compared with  <e1> lapatinib </e1>  alone for patients with  <e2> Herceptin </e2> -refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
false	Lapatinib may have the potential to convert  <e1> Herceptin </e1> -refractory to  <e2> Herceptin </e2> -sensitive tumors in HER2-positive breast cancer by up-regulation of the cell surface expression of HER2.
false	We evaluated how lapatinib interacts with  <e1> Herceptin </e1>  in HER2-positive breast cancer, with a particular focus on  <e2> Herceptin </e2> -mediated antibody-dependent cellular cytotoxicity (ADCC). 
false	 <e1> CRM197 </e1>  induced apoptosis, and furthermore, the combination of CRM197 plus  <e2> doxorubicin </e2>  enhanced cytotoxicity in a T-ALL cell line. 
effect	Although it was previously reported that  <e1> lapatinib </e1>  combined with  <e2> Herceptin </e2>  improved the progression-free survival rate compared with lapatinib alone for patients with Herceptin-refractory HER2-positive metastatic breast cancer, the mechanism is purported to be an antiproliferative effect relating to the synergism of these two agents.
false	 <e1> CRM197 </e1>  induced apoptosis, and furthermore, the combination of  <e2> CRM197 </e2>  plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. 
false	saline + saline,  <e1> ephedrine </e1>  (10   mg/kg) + saline, saline +  <e2> dexmedetomidine </e2>  (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 
false	The purpose of this study was to evaluate whether the psychostimulant drug  <e1> ephedrine </e1>  has any effect on  <e2> dexmedetomidine </e2> -induced antinociception and locomotor inhibitor activity in mice in acute application.
false	We concluded that the combined administration of dexmedetomidine with  <e1> ephedrine </e1>  may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an  <e2> analgesic </e2>  in humans.
false	In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg  <e1> ephedrine </e1>  intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by  <e2> dexmedetomidine </e2> . 
false	saline + saline,  <e1> ephedrine </e1>  (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and  <e2> ephedrine </e2>  (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 
effect	In the hot plate test in mice, co-administration of 15     g/kg  <e1> dexmedetomidine </e1>  with 10   mg/kg  <e2> ephedrine </e2>  intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. 
effect	 <e1> Ephedrine </e1>  enhances the antinociceptive effect of  <e2> dexmedetomidine </e2>  in mice.
false	We concluded that the combined administration of  <e1> dexmedetomidine </e1>  with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an  <e2> analgesic </e2>  in humans.
false	saline + saline, ephedrine (10   mg/kg) + saline, saline +  <e1> dexmedetomidine </e1>  (15     g/kg) and ephedrine (10   mg/kg) +  <e2> dexmedetomidine </e2>  (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 
false	We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of  <e1> dexmedetomidine </e1>  as an  <e2> analgesic </e2>  in humans.
effect	At the same time, the locomotor inhibitory effect of  <e1> dexmedetomidine </e1>  was counteracted by  <e2> ephedrine </e2> . 
false	The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF,  <e1> cross-reacting material 197 </e1>  ( <e2> CRM197 </e2> ). 
false	saline + saline, ephedrine (10   mg/kg) + saline, saline +  <e1> dexmedetomidine </e1>  (15     g/kg) and  <e2> ephedrine </e2>  (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 
false	saline + saline,  <e1> ephedrine </e1>  (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) +  <e2> dexmedetomidine </e2>  (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. 
effect	We have demonstrated appropriateness of inhospital administration of fixed  <e1> amlodipine </e1> / <e2> valsartan </e2>  combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.
effect	We concluded that the combined administration of  <e1> dexmedetomidine </e1>  with  <e2> ephedrine </e2>  may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.
false	We concluded that the combined administration of  <e1> dexmedetomidine </e1>  with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of  <e2> dexmedetomidine </e2>  as an analgesic in humans.
false	All patients had indications for antihypertensive therapy and were randomized either to fixed combination  <e1> amlodipine </e1> / <e2> valsartan </e2>  (n=43) or to therapy which corresponded to the hospital formulary (n=43). 
false	In the hot plate test in mice, co-administration of 15     g/kg  <e1> dexmedetomidine </e1>  with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by  <e2> dexmedetomidine </e2> . 
false	[Efficacy of fixed combination  <e1> amlodipine </e1> / <e2> valsartan </e2>  in hospitalized patients with hypertensive disease]
false	We have demonstrated appropriateness of inhospital administration of fixed amlodipine/ <e1> valsartan </e1>  combination as an approach allowing to achieve target BP in shorter time, with the use of fewer  <e2> antihypertensive drugs </e2> , and diminishing concealed inefficacy of treatment.
false	But the use of fixed combination  <e1> amlodipine </e1> /valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of  <e2> antihypertensive drugs </e2>  (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). 
false	The FDA has approved  <e1> ticagrelor </e1>  ( <e2> Brilinta </e2> -AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 
false	 <e1> Ticagrelor </e1>  (Brilinta)--better than clopidogrel ( <e2> Plavix </e2> )
false	The FDA has approved  <e1> ticagrelor </e1>  (Brilinta-AstraZeneca), an oral  <e2> antiplatelet drug </e2> , for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 
false	It will compete with  <e1> clopidogrel </e1>  ( <e2> Plavix </e2> ) and prasugrel (Effient) for such use. 
false	The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral  <e1> antiplatelet drug </e1> , for use with low-dose  <e2> aspirin </e2>  to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 
false	Ticagrelor (Brilinta)--better than  <e1> clopidogrel </e1>  ( <e2> Plavix </e2> )
false	Rate of achievement of target BP with fixed combination  <e1> amlodipine </e1> / <e2> valsartan </e2>  (93%) was comparable with that on traditional therapy (90%). 
false	We have demonstrated appropriateness of inhospital administration of fixed  <e1> amlodipine </e1> /valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer  <e2> antihypertensive drugs </e2> , and diminishing concealed inefficacy of treatment.
false	 <e1> Ticagrelor </e1>  ( <e2> Brilinta </e2> )--better than clopidogrel (Plavix)
false	Ticagrelor ( <e1> Brilinta </e1> )--better than clopidogrel ( <e2> Plavix </e2> )
effect	The FDA has approved  <e1> ticagrelor </e1>  (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose  <e2> aspirin </e2>  to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 
false	It will compete with clopidogrel ( <e1> Plavix </e1> ) and prasugrel ( <e2> Effient </e2> ) for such use. 
mechanism	 <e1> Ibuprofen </e1>  plasma concentration was also increased when it was administered with  <e2> piperine </e2> . 
false	The synergistic antinociception activity of  <e1> ibuprofen </e1>  when administered with piperine can be attributed to increased plasma concentration of  <e2> ibuprofen </e2> . 
false	Influence of  <e1> piperine </e1>  on  <e2> ibuprofen </e2>  induced antinociception and its pharmacokinetics.
false	In the present study  <e1> piperine </e1>  (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of ibuprofen evaluated by both  <e2> acetic acid </e2>  writhing and formalin test, when it was administered with ibuprofen. 
false	It will compete with  <e1> clopidogrel </e1>  (Plavix) and  <e2> prasugrel </e2>  (Effient) for such use. 
effect	From this study it can be concluded that  <e1> piperine </e1>  can be used as a bioenhancer along with  <e2> ibuprofen </e2> .
effect	The FDA has approved ticagrelor ( <e1> Brilinta </e1> -AstraZeneca), an oral antiplatelet drug, for use with low-dose  <e2> aspirin </e2>  to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). 
false	It will compete with  <e1> clopidogrel </e1>  (Plavix) and prasugrel ( <e2> Effient </e2> ) for such use. 
false	In the present study piperine (10 mg/kg) significantly increased the dose-dependent antinociceptive activity of  <e1> ibuprofen </e1>  evaluated by both acetic acid writhing and formalin test, when it was administered with  <e2> ibuprofen </e2> . 
false	Ticagrelor ( <e1> Brilinta </e1> )--better than  <e2> clopidogrel </e2>  (Plavix)
